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Spasticity is a major symptom of the upper 
motor neuron (UMN) syndrome. This syn-
drome results from damage of the descending 
cortical-reticulospinal motor pathways at the 
cortical, brainstem, or spinal cord level. Caus-
es include a lack of oxygen flow to the brain 
before, during, or after birth (cerebral palsy), 
an acquired brain lesion or spinal cord lesion, 
ischemic or hemorrhagic stroke, and multiple 
sclerosis. 
Although the incidence of spasticity is not 
known with certainty, it likely affects over 12 
million people worldwide.1 Of people with 
multiple sclerosis, more than 85% have at 
least mild spasticity, and 35% have moderate 
to severe spasticity that frequently modifies 
their activities.2 In the post-stroke population, 
38% to 60% of individuals encounter spas-
ticity one year after a stroke.3-6 Furthermore, 
approximately 75% of patients who survive a 
traumatic brain lesion,7 up to 78% of patients 
with a traumatic spinal cord lesion,8,9 and 77 
to 89% of individuals with cerebral palsy10-12 
eventually experience spasticity.
After the onset of UMN syndrome, spastici-
ty does not develop immediately but evolves 
over the course of days, weeks, or even 
months.13 The syndrome is then characterized 
by paresis, increased muscle tone, spasticity 
(Fig.1,2) and in patients with a spinal cord le-
sion on T6 or higher levels (Fig. 1)14-18 or an 
acquired brain lesion19-21 by episodic attacks 
of sympathetic hyperactivity (“sympathetic 
storm”).
Clinical spasticity symptoms include clonus, 
the clasp-knife phenomenon, hyperreflexia, 
muscle spasms, and the Babinski sign. The 
symptoms may vary considerably from slight 
to severe hypertonia, which may lead to con-
tractures. Spasticity may be localized to cer-
tain regions of the body, or it may even be 
generalized. When it is generalized, daily care 
Figure 2. Severe hypertonia of upper and lower extremities and opisthotonos after near-drowning. Splints are 
applied to prevent contractures of the equinovarus position of the foot.
Figure 1. Severe hypertonia of upper extremities 
complicated by excessive perspiration as result 
of paroxysmal sympathetic hyperactivity after 
traumatic brain injury. Splints and dressing material 
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can be challenging, and discomfort becomes 
an essential part of daily life.22,23 
Spasticity may be painful, especially if it pulls 
joints into abnormal positions and prevents their 
normal movement. Moreover, spasticity may 
not be present all the time; it may be related to, 
or worsened by, physiological and psychological 
triggers.24 Pregnancy, posture, cold weather, cir-
cadian rhythm, and skin conditions have been 
identified as potential triggers. Patients’ self-re-
ports have suggested that bowel- and blad-
der-related issues, the menstrual cycle, mental 
stress, and tight clothing trigger also an increase 
in spasticity. Nonetheless, even without any 
trigger, the degree of spasticity can vary from 
day to day, and even throughout the day and 
night. Although spasticity can make daily care 
more difficult, some degree of spasticity of the 
lower extremities can be positive,7 since it can 
help with standing upright, performing pivot 
transfers, or even walking, using the Iimb as a 
cane.8,25,26
A variety of strategies is available for the 
management of spasticity. In cases of mild of 
spasticity a watch-and-wait strategy without 
treatment may be more appropiate.7 When 
spasticity causes pain, interferes with daily liv-
ing activities or nightly sleep, leads to increas-
ing levels of functional disability, or poses prob-
lems for care, treatment is indicated.7 Because 
spasticity is a multidimensional problem, its 
treatment is best provided by an experienced 
multidisciplinary team. All treatments start with 
daily range-of-motion exercises.27 The next 
step, in cases of insufficient response, is oral 
spasmolytic medication.7,22,28,29 Although oral 
medication may be effective, it can, at high-
er dosages, cause unwanted adverse effects, 
such as sedation or changes in mood or cog-
nition. For localized spasticity, botulinum toxin 
chemo-denervation is becoming increasingly 
the treatment of choice because of its effec-
tiveness, ease of use, and low rate of adverse 
effects.30,31 Generalized severe spasticity of 
both the upper and lower extremities can be 
effectively treated using intrathecal baclofen 
administration. 
Intrathecal baclofen drug delivery
Richard Penn was the first to describe intrathe-
cal baclofen administration (ITB) in 1984 using 
an implantable drug delivery system for intrac-
table spasticity in 1984.32 In the same year, 
the therapy was introduced and applied in the 
Netherlands. The first patient was a young 
woman with cervical spinal cord injury and se-
vere spasticity caused by complications in pain 
treatment. Her spasticity could be controlled 
with a lumbar intrathecal test bolus injection 
of 50 µg of baclofen. For continuous ITB, we 
implanted a pump connected to an intrathecal 
catheter. Up to now, the patient has been suc-
cessfully treated with ITB.
Principles of ITB
Gamma-aminobutyric acid (GABA) is the ma-
jor inhibitory neurotransmitter in the central 
nervous system. The chemical structure of 
baclofen matches the structure of this neu-
rotransmitter and is a vigorous and selective 
GABA-B receptor agonist.33,34 ITB causes re-
ceptor stimulation, leading to the presynap-
tic suppression of hyperreflexia, which is why 
it is used in spasticity treatment. Due to the 
blood–brain barrier,35 oral administration leads 
to relatively low cerebrospinal fluid (CSF) con-
centrations, which makes the treatment in-
sufficient for moderate to severe spasticity.36 
Unlike oral administration, ITB achieves high 
CSF levels,35,37-39 resulting in a high concentra-
tion of baclofen in the spinal cord. The high 
concentration results in improved reduction of 
spasticity with fewer side effects than can be 
achieved with oral administration. The side ef-
fects of ITB administration are similar to those 
of oral administration, but they occur much less 
frequently. ITB is therefore associated with a 
significantly lower dose (100 times or more), a 
12
predominantly spinal cord effect, and minimal 
systemic absorption.35
Clinical application
ITB is indicated for therapy-resistant, disabling, 
generalized spasticity of spinal or cerebral or-
igin. We perform screening for eligibility at a 
rehabilitation center which include the evalu-
ation of reduction of spasticity after test bo-
lus injection (Fig. 3). First the patients receive 
an intrathecal test bolus injection of 50 µg by 
lumbar puncture. The dosage can be increased 
by 25 µg each day, up to a maximum of 100 
µg in case of insufficient result of lower dos-
es. Patients with a residual standing or walking 
function are hospitalized for one day for ex-
ternal intrathecal catheter insertion. Thereaf-
ter, the next step of testing performed at the 
rehabilitation center with an external infusion 
pump for continuous baclofen infusion via the 
indwelling intrathecal catheter. With daily dose 
titration, functional improvement can be deter-
mined. A patient is a candidate for ITB when 
the screening reveals a two-point reduction in 
the total scores on spasticity scales. Hospital-
ization (or rehospitalization) is then scheduled 
for the implantation of the drug delivery sys-
tem, which consists of the inserted intrathecal 
catheter that is subcutaneously tunneled and 
connected to the implanted pump in a pre-
pared abdominal pocket.
Figure 3. Severe adductor/flexor hypertonia of the lower left extremity in multiple sclerosis. Status before (A) 
and after (B) lumbar puncture with injection of 50 µg baclofen.
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Implantable drug delivery system
In the early 1980s, a critical discussion began 
about the type of the implanted pump for 
ITB should be a constant flow pump40-42 or a 
programmable pump.37,43 Continuous drug 
administration with an implanted fixed-rate 
delivery device which does not need a battery 
is less expensive than a programmable system. 
Over time, it became apparent that optimal 
ITB treatment was hindered by a constant flow 
pump, which lacked the flexibility to alter the 
amount of baclofen. Programmable devices 
enable drug dosages to be modified without 
interventions such as aspiration of the pump 
reservoir content and refilling with a different 
drug concentration; such interventions are 
necessary with fixed-rate delivery systems. In 
contrast a programmable device can be con-
trolled or deactivated when necessary, such 
as in case of drug delivery failure. Today, the 
programmable SynchroMed II peristaltic roller 
pump (Medtronic Inc., Minneapolis, MN, USA) 
is commonly used for ITB.
Currently, about 30,000 devices are yearly im-
planted for the relief of pain and spasticity. The 
battery life of the pump was initially four years, 
which has been increased to seven years. We 
use the 20 ml variant of the pump for ITB. We 
have implemented a limited refill period of up 
to three months based on the unknown stabil-
ity of the pump’s medication solution at body 
temperature. Except for a corrosion problem 
that could lead to a pump stall, the delivery 
system has proven reliable and suitable for clin-
ical practice. The device is 3 Tesla MRI compat-
ible without the need for emptying the reser-
voir. However, interrogation of the pump must 
be performed to ensure the pump has correctly 
reactivated after an MRI procedure. Occasion-
ally, a restart is delayed for a couple of hours 
after exiting the MRI magnetic field. Com-
patibility with MRI does not mean that every 
ITB patient is suitable for a MRI examination. 
When the pump is implanted in the area under 
examination, substantial image distortion and 
artefacts make assessment of abnormalities dif-
ficult or even impossible.
Several intrathecal catheter types for the pump 
have been developed. Currently, two types, 
the 8731SC catheter and Ascenda catheter, 
are normally used. Since catheters remain in 
situ for many years, some older catheter types 
are currently still implanted. Problems in intra-
thecal drug delivery are mainly related to the 
catheter and include obstruction, kinking, frac-
ture, defective pump connectors, disconnec-
tion of both catheter parts, and dislocation.44,45 
Adaptation of the surgical technique46,47 and 
improved catheter materials have led to a de-
crease in the incidence of problems. Although 
the Ascenda catheter seems to have less cathe-
ter problems, its poor opacity is problematic, as 
this can hinder the identification of the poten-
tial cause of catheter failure.
Collaboration between a university 
medical center and a home-based 
Ambulant Care Clinic in ITB trouble-
shooting
ITB-treatment has a niche character and a frag-
mentation of the availability. We discussed with 
health insurance companies the possibility of 
concentrating care in a specific number of cen-
ters of expertise. Because we could offer a re-
gional solution to the fragmented nature of the 
care currently provided for ITB the companies 
agreed to cooperate in the establishment of an 
ITB hub at Erasmus University Medical Center 
in close cooperation with the Rijndam Volwas-
senen Revalidatie rehabilitation center and the 
home-based Ambulant Care Clinic Care4hom-
ecare. This approach represents a solution to 
the logistical requirements in patient selection, 
the implantation of a drug delivery system, and 
ITB aftercare. 
For adequate troubleshooting, around-the-
clock availability of expertise for patient relief, 
pump analysis and programming expertise, the 





































































































































































































































































































































































































Figure 4. Activities of the nurse practitioners. 
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ability to “double-check” highly concentrated 
medication and pump programming, advanced 
radiological diagnostics, and an operating 
room and intensive care are required. Howev-
er, in particular, achieving 24-hour availability 
for such a “double-check” service would not 
be straightforward. Therefore, in order to of-
fer around-the-clock care, we decided to col-
laborate with the home-based Ambulant Care 
Clinic (Fig. 4). This decision was based on the 
extensive experience of the Clinic’s nurse prac-
titioners of the handling of drug delivery de-
vices. Due to the aftercare activities that they 
provide for the more than 400 patients who 
have implanted pumps, the staff of the Ambu-
lant Care Clinic has unique experience in ITB 
pump handling. For this reason, we decided 
to arrange partial employment at the Eras-
mus University Medical Center for the Clinic’s 
nurse practitioners. These nurse practitioners 
can thus support the daily practice of patient 
treatment. In addition, they can contribute to 
satisfying the logistical need for the around-
the-clock availability of experienced trouble-
shooting physicians by providing the constant 
on-call support of skilled ITB nurse practitioners 
required for double-checking medication and 
pumps. The double-check is crucial not only for 
guaranteeing the standard “five rights”48 (the 
right person, right drug, right dose, right route 
of administration, and right time) but also for 
managing the complex pump programming.
Previous studies 
In 1984 a longitudinal clinical ITB program was 
started to implement ITB as an optimal treat-
ment that would be immediately accessible to 
all patients who needed it. The primary goal 
was to improve the quality of life of patients 
with spasticity. Before the start of this ITB pro-
gram, we were already focused on the intra-
thecal administration of opioids49-54 for chronic 
and tumor-related pain. Experience with differ-
ent pump devices for pain treatment gave us 
the opportunity to develop clinical experience 
with ITB quickly. 
The initiated ITB studies focused on clinical ef-
ficacy,44,55 measurement of the severity of spas-
ticity using surface electromyography,56 urolog-
ical aspects,57 dystonia,58 a Seldinger technique 
for subarachnoid catheterization,59 111Indi-
um-DTPA scintigraphy,60 side effects, and com-
plications.44,55 Furthermore, we explored ways 
to receive reimbursement, reduce barriers to 
patients obtaining the treatment, and motivate 
stakeholders to support the therapy. 
Since the first publication of Penn, many 
studies on ITB have reported striking results. 
22,44,55,61-70 Despite these reports, a high compli-
cation rate including drug delivery failure and 
an insufficient workup and infrastructure for 
problem solving remained.44,45,71-75 In addition, 
we still encounter a substantial undertreatment 
and a delayed initiation of ITB.2,36 Multiple 
factors play a role. Physicians are not aware 
about the beneficial effects of ITB treatment. 
ITB treatment has a limited availability due to 
the complexity of workup and treatment with 
complicated pump-related features (communi-
cation with the pump; controlling, refilling, and 
programming the dose; the infusion rate; and 
bridge bolus adjustments). ITB is a time-con-
suming treatment requiring long-term after-
care, which also includes burdensome wheel-
chair taxi or ambulance transportation to the 
hospital for pump refills and dose-adaptations. 
ITB treatment results in additional costs for pa-
tients and accompanying (in)formal caregivers. 
The treatment is also accompanied by device 
related problems, in particular the spinal cath-
eter, and 24-hour troubleshooting capacity is 
needed. 
The above mentioned issues are the main rea-
son for the studies in this thesis, aiming to im-
prove ITB aftercare, the diagnosis of ITB related 
complications and treatment of ITB treatment 
failure.
Introduction, aim of the study
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Current studies
Improvement of ITB aftercare
It is not easy to achieve the goal of providing 
ITB treatment to all patients with spasticity 
who could benefit from this invasive treatment. 
One of the barriers is the long-term follow-up 
of ITB which has only been provided by hos-
pitals or neuromodulation centers. However, 
aftercare including transport to the hospital 
or neuromodulation center is often a burden 
for severely handicapped patients which has 
been a reason for not seeking therapy. This 
problem could be substantially mitigated by 
performing aftercare with a dedicated team in 
the patients’ own setting by using telemedicine 
for real-time communication with the expert 
center for consultation and remote control on 
delivery of medication. Therefore, we initiated 
a program for the development and evaluation 
of a home-based Ambulant Care Clinic (Care-
4homecare). The aim was to provide high-level 
standard care in close cooperation with neuro-
modulation centers, whereby the treatment is 
performed by ITB-trained nurse practitioners, 
supervised by medical specialists who were 
on call around the clock. With this approach, 
ITB becomes more available and affordable for 
patients with severe spasticity. The first step in 
the development of the Ambulant Care Clinic 
was to acquire official recognition In the Neth-
erlands for the clinic by the Ministry of Health, 
Wellbeing, and Sport. After the obtained ap-
proval, the next step was to obtain financial 
support for the demonstration of quality and 
safety of the approach. 
Diagnosis and treatment of ITB failure
For adequate ITB troubleshooting, the follow-
ing requirements are needed: around-the-clock 
availability of professionals with expertise in 
pump analysis, and pump programming, ad-
vanced radiological diagnostics, an operating 
room and intensive care. The implementation 
of optimal troubleshooting is a complex issue.76 
I witnessed that for ITB troubleshooting the 
diagnostic procedures were too limited or per-
formed too late, and that surgical interventions 
were frequently conducted without, or with 
limited, diagnostic procedures.62,70,71 I was also 
concerned that the consequences of the sud-
den termination of ITB treatment, which can 
be life-threatening, sometimes seemed to be 
unrecognized or underestimated.72,73 For this 
reasons we organized a 24-hours optimized 
structure for ITB troubleshooting in the Eras-
mus MC, University Medical Center Rotter-
dam. In this thesis, I report on the studies on 
improvement of the diagnostic procedures and 
initiation of some specific treatments.
More precisely, the specific objectives of the 
thesis are:
•  to evaluate the safety and efficiency of a 
home-based ambulant clinic for aftercare 
(Chapter 2),
•  to describe the various causes of ITB failure 
(Chapter 3,6,7), 
•  to assess the role of radiological and nuclear 
imaging techniques in identifying the cause 
of ITB failure (Chapter 3,5,6),
•  to investigate the optimization of radiologi-
cal and nuclear imaging techniques (Chapter 
3-5),
•  to investigate the role of low-dose single-en-
ergy computed tomography (CT) as a re-
placement for plain radiography (Chapter 
4,5,7),
•  to evaluate the appropriateness of cerebro-
spinal fluid (CSF) flow restoration in case of 
spinal canal obstruction (Chapter 8), 
•  to report about emergency ITB treatment in 
severe, intractable autonomic dysreflexia as a 
result of an ITB withdrawal syndrome (Chap-
ter 9).
Outline of this thesis
This thesis is divided into 11 chapters. After the 
introduction and the aim of the study in Chap-
Chapter 1
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ter 1, Chapter 2 describes the development and 
evaluation of a home-based Ambulant Care 
Clinic for ITB aftercare on location. Chapter 3 is 
dealing with the analysis of plain radiography 
in intrathecal drug delivery failures. Chapter 4 
reports the result of a pilot study for a routine 
replacement of plain radiography by low-dose 
single-energy CT. Chapter 5 describes the re-
sults of  catheter access port (CT) myelography 
in intrathecal drug delivery failures in a large 
patient group. Chapter 6 describes the results 
of 111Indium diethylene-triamine-penta-acid- 
(DTPA) scintigraphy in a large patient group. 
Chapter 7 gives an overview of complications 
associated with intrathecal drug delivery sys-
tems. Chapter 8 reports a preliminary case se-
ries on the restoration of rostral cerebrospinal 
fluid flow to solve treatment failure caused 
by an obstruction in long-term ITB. Chapter 9 
outlines a case report of ITB as emergency treat-
ment in severe, intractable autonomic dysre-
flexia in cervical spinal cord injury. In Chapter 10 
the results of the previous studies are discussed.
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It has been shown that the administration of in-
trathecal baclofen (ITB) via an implantable drug 
delivery system provides a reduction of intrac-
table severe spasticity. Regarding long-term use 
only data from observational studies are avail-
able; these studies showed secondary benefits 
including fewer side-effects, improvement in 
activities of daily living, less sleep disturbance, 
and fewer care needs.1-9
Until now, long-term follow-up of ITB has only 
been performed in a hospital setting. However, 
this is often inconvenient for severely immobi-
lized patients and sometimes makes it impossi-
ble to provide therapy. Despite the advantag-
es of ITB therapy, this inconvenience may be 
one of the reasons for the substantial under-
treatment and/or an often ‘too late’ initiation 
of ITB.5 These problems might be reduced by 
performing ITB aftercare in the patient’s own 
surroundings (e.g. at home, in a nursing home 
or in disabled community). Therefore, we de-
veloped a home-based Ambulant Care Clinic 
to provide high-level standard care in a close 
cooperation with some of the neuromodulation 
centers.
We obtained recognition as a home-based Am-
bulant Care Clinic of the Ministry of Health, 
Wellbeing and Sport. For the provision of home 
based specialized medical care, no regular fi-
ABSTRACT
Objectives
Patients with intractable spasticity treated with intrathecal baclofen (ITB) need regular evaluation and aftercare 
in an outpatient clinic or pain clinic setting. Logistically, this can be challenging. A solution could be to perform 
treatment at the patient’s home setting. In the Netherlands, a project of the Dutch Healthcare Authority was 
initiated to deliver ambulatory ITB-related services via a home-based Ambulant Care Clinic. This aftercare is 
performed by nurse practitioners (NP) with support from a medical specialist. The scope of the study was to in-
vestigate the efficiency and safety of ITB-care for patients with severe disabling spasticity in their home setting. 
Materials and Methods
A retrospective analysis of prospectively collected data; Patients with congenital or acquired spasticity were 
treated with ITB (1st April 2011 to January 1st, 2016) using an implanted programmable pump system were 
referred to the home-based Ambulant Care Clinic by various neuromodulation centers in the Netherlands. All 
study parameters were part of the standard intake and follow-up documentation. 
Results
Of the 900 patients treated with ITB in the Netherlands, 239 were referred to the home-based Ambulant Care 
Clinic and included in this study. Mean age was 45.5 (range 7-82) years; 52% lived at home; the average 
satisfaction score was 9 (scale 0-10); and 0.29% had (serious) adverse events (60% of clinical manifestations 
were prevented by remote double-check control). Certifications for patient safety and quality standards were 
obtained.  
Conclusion
The concept of ITB aftercare on location demonstrated efficacy and safety in the described setting. For trouble-
shooting, close collaboration with a neuromodulation center is necessary and can be arranged in chain-based 
care.
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nancial reimbursement was available. However, 
since the Ministry offers financial support for 
new projects to stimulate innovations in health-
care, our ‘home-based Ambulatory Care Clinic 
Neuromodulation’ activity was accepted as an 
innovation project. One of the requirements for 
approval of this project was the demonstration 
of quality and safety.   
Materials and Methods
We performed a retrospective analysis of pro-
spectively collected data, investigating the effi-
cacy and safety of delivery of home based ITB 
aftercare in the period of 1st April 2011 to Jan-
uary1st, 2016. 
The study was approved by the local Medical Eth-
ical committee (2018-1221). After referral to the 
home-based Ambulant Care Clinic patients gave 
consent for the treatment at the initial visit. Due 
to the retrospective character of the study the lo-
cal Medical Ethical Committee waived away the 
requirement to obtain informed consent.  
Only patients with severe disabling spasticity 
were eligible, and these were treated with ITB 
using an implanted programmable pump sys-
tem (SynchroMed II, Medtronic Inc., Minneap-
olis, USA) and referred to the home-based Am-
bulant Care Clinic by neuromodulation centers. 
Patients had to have achieved a stabilized dose 
for at least three months before their referral. 
After referral for aftercare, there followed an 
initial visit from a specialized physician and 
nurse practitioner (NP).  During the visit the ITB 
aftercare on location concept was explained, 
and informed consent and medical history were 
obtained, followed by a physical examination 
and a read-out of the pump settings.
In addition to this, in the first three years for 
the initial visit we used a standard questionnaire 
where patients were asked about the burden of 
traveling to the center for their ITB aftercare. 
At the following visits we gathered informa-
tion and entered it in the electronic patient file 
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activity, printouts of the programming pump, 
any (serious) adverse events, complaints, annu-
al patient satisfaction scores, and travel time/
distance to the center. We recorded the num-
ber of pump refill visits during the study period, 
as well as the additional visits for dose adjust-
ments.
Via an annually applied anonymous question-
naire, patients provided their feedback on the 
ITB management service and their satisfaction 
level with the service. In case of official com-
plaints, we started a complaints procedure. 
In our setting we have chosen to work with 
NP’s (NP: Master’s Degree in Advanced Nurs-
ing Practice). In our country, NP’s are allowed to 
perform medical tasks independently. They are 
obliged to follow training every year. A re-reg-
istration will follow after 5 years only if all of 
the training requirements have been met. In the 
first 3 months working with ITB, the NP’s are 
trained on the job by a medical specialist and 
an experienced nurse practitioner and work 
on an observer basis. During the next year 
they receive intensive supervision. In addition, 
weekly multidisciplinary patient meetings and 
3 monthly intervision sessions are held. During 
their work, the NP’s are supervised by a medical 
specialist or a (colleague) NP. The team is avail-
able on call 24/7. For percutaneous pump refills, 
patients were visited at least every 90 days as 
well as, if necessary, for dose adjustments and/
or troubleshooting. We performed visits at the 
patient’s home, a nursing home, a community 
for disabled persons, or (in case of a temporary 
stay) in the rehabilitation center or hospital.
One week before the appointment, a NP pre-
pared the visit. The NP prescribed a baclofen 
solution and (after being checked by a second 
nurse practitioner or medical supervisor) and 
digitally sent the prescription to the pharmacy. 
After receiving the medication, the NP checked 
the prescription and medication label and stored 
the medication at room temperature. Two to 
three days before the visit, the NP telephoned 
the patient or caregiver to enquire about the 
clinical status of the patient; if this was not sta-
ble, the condition was discussed with the medi-
cal supervisor. On location, the NP made a brief 
note of medical history (focusing on spasticity 
treatment), performed a physical examination, 
and used telemedicine (encrypted bi-directional 
video connection via the 3G or 4G-broadband, 
Cisco Jabber Video Telepresence software ver-
sion 4.7, Visions Connected, Amsterdam, The 
Netherlands). The screen-to-screen connection 
gives the supervisor and another NP or medical 
specialist access to communicate with the pa-
tient and the NP on location, as well as remote 
visual control of the prescription and the syringe 
label. After this, the connection was terminat-
ed, and the NP performed the refill and/or dose 
adjustments and programming procedures. Af-
ter refilling the pump under aseptic conditions, 
the NP made another telemedicine application 
for remote visual control of the pump program-
ming printout. If the supervisor observed an 
error in programming an immediate correction 
was made. Occasionally we video-recorded the 
procedure either at the request of a physician or 
for training purposes. The NP documented the 
results in the electronic patient file. The patient 
received a printout of the pump programming 
session. Finally, the NP sent a consultation let-
ter to the patient’s physician(s). If requested, a 
brief consultation letter was left behind after 
the visit. 
The equipment included a synthetic, washable 
three-compartment trolley, separating sterile 
and non-sterile material, a box for medication 
storage during transport, a pump program-
mer (N’Vision, Medtronic, Minneapolis, USA), 
a mobile printer, a laptop and a mobile tele-
phone. The small laptop computer had an in-
tegrated camera and a built-in dongle device 
allowing wireless broadband access. Also, the 
supervisor (based at the headquarters of the 
ambulant clinic) was provided with a computer 




For safety management, we followed the 
Dutch Technical Agreement 8009 ‘Safety 
management system for hospitals and orga-
nizations which administer hospital care. This 
embeds patient safety in healthcare practices. 
It enables risk identification, the implemen-
tation of improvements and evaluations, and 
modification of policies. It also includes the 
‘5 rights’, i.e. the “right patient, right action, 
right time, right cues, right reason”.10 The 
team adhered to these rights: i.e. used the ap-
propriate concentration of medication and the 
appropriate pump programming. Throughout 
the study all (serious) adverse events (S)AE) 
were recorded at each visit and discussed at 
our 6-weekly multidisciplinary team progress 
meetings. A subheading was made of the (S)
AE that occurred due to surgery, as well as 
hospital-related and long-term related com-
plications.
All visits, telephone calls and patient consul-
tations were reported in an electronic patient 
dossier, including the referral letter, physical 
examination, treatment, medication and print-
outs of the pump programming. 
For prospective and retrospective risk man-
agement of near-incidents we applied the 
‘Healthcare Failure Mode and Effect Analy-
sis’ (HFMEA) of the ‘National Center for Pa-
tient Safety’ (NCPS).12 In case of a high risk 
of frequency and severity of consequences we 
made an extensive PRISMA Medical analysis 
(Prevention Recovery Information System for 
Monitoring and Analysis)11 to manage struc-
tural human errors in practice.
 
External audits
A quality and safety certification procedure 
were performed annually by an independent 
professional inspection institute (KIWA, Rijs- 
wijk, the Netherlands). The certificate demon-
strates that the home-based Ambulant Care 
Clinic met the necessary requirements for ef-
ficient and safe management and verifies that 
the related processes were correctly performed, 
and, in a way, which enables the clinic to be 
sustainable. For the audit, the home-based Am-
bulant Care Clinic had to describe all protocols 
and procedure descriptions together with de-
scriptive flow charts. The hygiene audit process 
included a ‘spot check’ whereby the NP (upon 
patient’s consent) was accompanied and ob-
served by a hygiene auditor. As part of the an-
nual audit, the supervising pharmacist carried 
out an assessment of medication delivery and 
transportation. 
From 1st April 2011 to 1st January 2016, 239 
patients of the current total population of 900 
patients were referred to the home-based Am-
bulant Care Clinic. Table I presents the demo-
graphic and baseline characteristics. Multiple 
sclerosis (MS), cerebral palsy (CP) and spinal 
cord injury (SCI) were the most frequently re-
ported etiologies of spasticity.
At the start of the homed-based Ambulatory 
Care Clinic, nine hospitals in the Netherlands 
were treating patients with ITB. In addition to 
the hospitals, there were also satellite centers, 
e.g. rehabilitation centers refilling and/or mak-
ing dose adjustments. The majority of patients 
live at home: 28% live in a nursing home and 
20.1% live in a community for disabled per-
sons.
Communications
At the start of the study, 3G broadband was 
used for online videoconferencing. From 2014 
onwards, 4G broadband was available and 
used. In the 3G broadband era, on 5 occasions 
the connection was insufficient to establish a 
video feed. Three patients allowed the use of 
their own WiFi; for two patients the only solu-
tion for control was a real-time telephone call. 
At the end of 2014, the telecommunication 
provider (KPN) delivered coverage to 98.4% 
of the inhabitants and 96% surface coverage 
Efficiency and safety of aftercare with intrathecal baclofen on location
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throughout the Netherlands. Since then, very 
few connection problems have been encoun-
tered. 
Feasibility
During the first three years, 143 patients re-
ferred to the home-based Ambulant Care Clinic 
were asked about the burden of travelling (Fig. 
I). Of these, 104 were able to answer the ques-
tionnaire themselves; their mean score was 5.7 
(out of 10, where a score of 10 indicates the 
highest burden); and 47 patients scored 7 or 
higher. Of the 39 patients who were unable to 
answer the questions themselves, their caregiv-
ers answered the question on burden of travel-
ing with a mean score of 6.4 (Fig. II). Data was 
missing for 8 patients.
Patients were also asked: ‘If traveling is a bur-
den, what kind of negative effect does it have: 
lack of energy, fatigue, increase of spasticity, 
increase of pain, or something else, please de-
scribe’ (Fig. III). 
Although 11 patients scored 1 for burden of 
traveling, all patients experienced one or more 
negative consequences. Most patients expe-
rienced a lack of energy: 67% of the patients 
who answered themselves, and 64% of those 
whose caregivers gave the answers on their be-
half (Fig. IV).
Satisfaction
Patients and caregivers were positive about/
satisfied with the ITB on location. All patients 
reported increased convenience from home-
based Ambulant Care Clinic when compared to 
standard aftercare by visiting a medical center.
Safety evaluation 
From a total of 6,807 procedures, 11 AE’s and 9 
SAE’s were registered. In one patient, a low res-
ervoir alarm created discomfort, but no harm. 
The wound management was adjusted because 
of postoperative deviant wound edges. After 
replacement of the pump, hematoma was re-
ported post-operatively. One patient called in 
during duty hours with increased spasticity; 
earlier that day the patient had undergone an 
access-port procedure in the hospital. Inves-
tigation showed that, prior to discharge, the 
priming bolus had been omitted. We discussed 
the AE with the staff of the hospital and an ad-
aptation was made in the work process to pre-
vent this in future.
On two occasions, patients developed signs of 
underdosage (a mild increase of spasticity and 
Results





Male 26 31 7 44 0 8 18 134
Female 49 7 8 26 7 1 7 105
 75 38 15 70 7 9 25 239
Age 
(years)
        
Mean 54.1 55.7 55,. 29.6 55.3 61.5 34.4 45.58
Range (29-82) (22-81) (36-75) (8-70) (35-66) (42-82) (7-74) (7-82)
Table I. Demographic and baseline characteristics of the aftercare population (n=239).
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some sweating) between the refill intervals. 
Our protocol for this situation involves aspira-
tion of the reservoir content. In both instances 
an empty reservoir was found, probably due to 
an inadvertent pocket injection. The pump was 
refilled, and a reduced dose adjustment was 
made. Another patient was again initiated with 
oral baclofen, this happened after patient was 
relocated to another nursing home. The local 
geriatrician telephoned our team reporting that 
the patient was somnolent. Careful case histo-
ry revealed double treatment and the oral ba-
clofen was immediately discontinued.
Serious adverse events
In three other refills in obese patients the pump 
was emptied normally and indicated a correct 
needle position; however, later on it appeared 
that the volume was injected outside the pump. 
Over time dyspnea occurred (in 2 patients); in 
one case this was diagnosed as pneumonia and 
was not recognized by the patient’s own ger-
iatrician as a moderate withdrawal syndrome. 
Both patients were hospitalized, and both re-
covered fully after refilling the pump and dose 
adjustment. In one patient there was an in-
creased discrepancy between the calculated 
and the actual volume of the pump reservoir; 
this patient was referred to hospital and the 
pump was replaced. The older pump was re-
turned to Medtronic for further investigation.
The remaining SAE’s occurred during the post-
operative stage of treatment, or after analysis 
of the patient’s ITB system. Due to established 
collaboration with the neuromodulation cen-
ters, when the SAE occurred the first contact 
with the patients was via the ambulatory care 
clinic. The SAE’s included: meningitis, with-
drawal after incorrect pump programming, 
withdrawal after incorrect pump refilling with 
medication outside the pump, wound care, and 
liquor leakage. In one SAE, a patient received 
Figure III. Consequences of traveling, patients. 
N=104.
Figure I. Burden of traveling, patient. N=104. Figure II. Answer on burden of traveling for patients. 
N=39.
Figure IV. Caregivers’ answer consequences on 
burden of traveling for patients. N=39.
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the incorrect dosage of oral medication from 
a caregiver in the nursing home which led to 
hospitalization and temporary cessation of ITB.
In total, 81 mistakes were reported. In the first 
year, two incidents were related to availability 
during duty hours; for this, an immediate ad-
aptation was made to the method of working. 
Seven incidents of pump programming errors 
were reported; in all cases the double-check 
procedures prevented clinical manifestations. In 
two cases no order was made to prepare the 
syringe before the pump was refilled, which 
necessitated a rush order. The highest number 
of incidents (21) was related to appointments, 
in particular when dose adaptations had to be 
made between the normal scheduled proce-
dures. On six occasions, erroneous archiving of 
patients’ information in the electronic patient 
dossier had to be corrected. On nine occasions, 
incidences were reported due to delivery of the 
medication via the cooperative pharmacist, and 
five incorrect preparations were found. 
HFMEA and PRISMA Medical analyses
The retrospective HFMEA analyses included im-
provements in; appointments, reporting delay, 
mistakes with patient data, and the labeling of 
medication syringes. As prospective subjects we 
performed: triage telephone call by the secretar-
ies, transport, storage medication, on-line con-
nections, pump refill procedure, and evaluation 
of the collaboration between Erasmus Univer-
sity Medical Center and Rehabilitation Center 
Rijndam adult rehabilitation population. For the 
PRISMA Medical analyses we included; med-
ication preparation and transport, motor stall 
pump device, and refilling outside the pump.
External audits
The annual quality and safety certification pro-
cedure performed by KIWA showed no non 
conformances. The degree of involvement of 
the entire team was acknowledged. All 240 
protocols and procedure descriptions (with re-
lated descriptive flow charts) were described. 
The audit of the hygienist and the supervising 
pharmacist also showed no deviations. The 
healthcare insurance company ‘Achmea’ grant-
ed a quality and safety award (Page 240). 
Discussion
This study has shown the feasibility and safety 
of a home-based Ambulatory Care Clinic for 
ITB management in a domestic setting using 
telemedicine for real-time remote communi-
cation. Applying the concept prevents burden-
some traveling to a medical center for severely 
handicapped patients. The importance of this 
was shown by the satisfaction scores. An im-
portant finding was that 51.9% of the patients 
were living at home, which has a considerable 
beneficial impact on the family’s daily life. The 
majority of these patients received professional 
help for basic care. Routine aftercare in a home 
setting is very important, particularly since this 
avoids travel to an ITB center.
Telemedicine includes a growing variety of ap-
plications and services to provide equal access 
to medical support, irrespective of geographic 
circumstances.12 This term covers our activities, 
and implies a more specific application using 
interactive video communication13. The present 
study was performed in a small country with 
relatively short travel distances. In less densely 
populated countries with greater travel distanc-
es the related problems might be more exten-
sive.
In our study a lower incidence of complications 
was observed than in the subject literature. 
Whether there is a specific relationship between 
the treatment in the hospital or at home was 
not part of the scope of our study, so that we 
can not comment on the matter. 
Our concept could help to optimize the quality 
of life of patients who suffer severely. This was 
demonstrated by the extended growth of the 
test population; we performed aftercare in ≥ 
25% of the entire ITB population in the Neth-
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erlands. The prevention of substantial adverse 
events demonstrated the value of the dou-
ble-check procedures. We agree with Bradford 
et al.14 that providing care at home should not 
involve a reduction of standards, implying that 
the double check should be included. The feasi-
bility of the use of a laptop computer or tablet14 
to conduct double-checks using an e-health 
technique has been demonstrated without con-
travention of  the existing standards. We found 
that obesity played an important role in the 
three adverse events during pump refill.15 Find-
ing the small refill membrane and the risk of 
needle dislocation during syringe changes are 
important parts of the process. Particularly in a 
40-ml pump, a change of syringe could result in 
an (unrecognized) injection outside the pump. 
Good collaboration in case of troubleshooting 
with a medical center is indispensable. Direct 
referral of patients in case of problems is also 
very important. On the other hand, it is import-
ant that the patient stays as briefly as possible 
in a medical center; aftercare in their own sur-
roundings is guaranteed by a home-based Am-
bulatory Care Clinic. Although time consuming, 
during a process of continuous improvement of 
treatment, the Ambulatory Care Clinic recog-
nized that the HFMEA and the extended PRIS-
MA Medical analyses should be conducted in 
routine practice.
A limitation of our study is that due to its ret-
rospective character, we were not able to make 
a comparison of the adverse event data of 
the home-based ambulatory clinic with hos-
pital-based data. This might have created a 
stronger argument that the home-based am-
bulatory group can be treated as safely as the 
hospital-based group. The problem is that the 
hospital-based patients are treated in different 
hospitals, and unfortunately, we do not possess 
the relevant data. Further research into this is 
therefore recommended.
Conclusions
The concept of home-based Ambulatory Care 
Clinic has clearly shown its feasibility and safety 
and can prevent a patient’s burdensome travel-
ing to a medical center for pump refills and dose 
adjustments. The encrypted bi-directional vid-
eoconferencing with 4G connection has proven 
its reliability and enabled communication with 
patients, and the performance of double checks 
on medication and procedures. Close coopera-
tion with a neuromodulation center in case of 
problems is indispensable and can be arranged 
in chain-based care. In this way clinical stan-
dards can be preserved for complex treatment. 
The method can be valuable for application 
elsewhere, particularly in countries with long 
traveling distances between care centers. The 
Dutch Healthcare Authorities are convinced 
about the research results and have included 
ITB-aftercare, performed by a home-based 
Ambulatory Care Clinic, as a fixed component 
in healthcare with associated reimbursement 
structure.
Comments
The authors describe an interesting model for 
ITB follow-up care in a home-based setting, 
decreasing the burden for disabled patients 
who would otherwise have to travel long dis-
tances to a center. The program, implemented 
by medically-supervised nurse practitioners, 
demonstrated good outcomes and high patient 
satisfaction. It is a model that could be replicat-
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This is a very exciting study proving the safe-
ty and efficiency of utilizing NPs in the role of 
routine pump management in the outpatient/
home setting.
Kristin Buxton, MS, RN, CPNP
Boston, MA, USA
*****
The manuscript in the discussion and conclu-
sion should reinforce that ITB is a safe therapy 
- the incidence of issues for all of the patient 
contacts are quite low – this would be helpful 
in debunking the “danger” of ITB and further 
addressing barriers to care and implementation 
(at home, can’t travel, too many complications 
of ITB, if can’t travel to office then more likely 
to have complications regarding management) 
– so many issues can be added in discussion to 
highlight safety, ability to refill or manage not 
in office but remotely.... access and awareness 
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Introduction
For over 30 years intrathecal drug delivery 
systems have been successfully applied in 
thousands of patients for the management of 
spasticity1,2 and dystonia (both intrathecal ba-
clofen)3, and for chronic pain (intrathecal an-
algesic drugs)4,5. Compared with oral adminis-
tration, infusion directly into the cerebrospinal 
fluid (CSF) has an extended treatment effect 
and with fewer unwanted side-effects1, 6. There 
is general consensus that intrathecal thera-
py should be reserved for patients who have 
an insufficient response to more conservative 
therapies and/or for patients who experience 
serious side-effects7. 
Despite generally favorable and safe out-
comes8,9 and continuous advancements in 
manufacturing technology, pump and cath-
eter-related adverse events still occur10. Al-
though the benefits usually outweigh the 
risks11, even limited exposure to adverse events 
remains a problem. Early recognition of com-
Plain radiography in patients treated with intrathecal drug delivery using an implantable pump device
ABSTRACT
Objectives
Intrathecal drug administration using an implanted pump system is well established in intractable spasticity 
and pain. However, despite continuous advancements in manufacturing technology, adverse events related to 
the pump and catheter still occur. Most of them, such as migration, damage, disconnection and occlusion, are 
related to the spinal catheter. The aim of this overview is to update radiologists on how plain radiography of the 
implanted delivery system for intrathecal drug administration should be interpreted and to increase awareness 
for the need of urgent and timely multidisciplinary troubleshooting. 
Methods
Plain radiographic images of patients treated with intrathecal drug administration using an implantable drug 
delivery system were analyzed in a multidisciplinary setting at our (university) referral center for complications 
in intrathecal drug administration. 
Results
Examples of catheter-related adverse events are described and a proposal is made for stepwise interpretation 
of standard plain radiographic images.
Conclusion
Plain radiological images are the mainstay for the diagnosis of catheter-related adverse events in intrathecal 
drug delivery. Radiologists play an important role in an early diagnosis. An awareness of abnormal radiological 
findings seems important to avoid a life-threatening withdrawal syndrome.
Keywords
Radiography, diagnostic imaging, spinal infusions, implantable infusion pumps, adverse events.
Teaching points 
•  Untimely cessation of intrathecal drug delivery can lead to a life-threating withdrawal syndrome.
•  Initially mild symptoms can lead to an exacerbation of a withdrawal syndrome. 
•  Most intrathecal catheter-related problems are visible on plain radiography. 
•  Common causes of catheter problems are migration, lacerations, occlusion and disconnection.
•  Knowledge on implanted intrathecal catheters is crucial for interpretation of plain radiography.
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plications and their prompt management is 
needed.
Most of the drug delivery device-related ad-
verse events are caused by intrathecal catheter 
failure12-14. Approximately 15-40% of patients 
experienced catheter complications2,15-18. With 
the new developed Ascenda catheter instead 
of the older silicone catheters, a tremendous 
reduction from 18% to 1.1% was reported by 
Motta19. The main reasons for this are migra-
tion, lacerations, occlusion, and disconnection 
of the catheter, which cause a sudden cessation 
of intrathecal drug administration. Abrupt in-
terruption of intrathecal baclofen delivery can 
present within several to 48 h with a spectrum 
of signs and symptoms. Then, the initially mild 
symptoms of exacerbation of spasticity, fever, 
excessive sweating, and pruritus can escalate 
to a life-threatening multi-organ failure. During 
time hyperthermia develops with values up to 
42˚ Celsius20, accompanied by nausea, respira-
tory distress, hypotension, tachycardia, hallu-
cinations, delirium, disorientation, psychosis, 
sometimes with seizures, rhabdomyolysis with 
increased creatinine kinase levels resulting in 
disseminated intravascular coagulation and a 
multi organ failure21-30. In rare cases, intrathecal 
baclofen withdrawal can even be fatal31,32. The 
symptoms are probably related to the release of 
excitatory neurotransmitters that occurs when 
baclofen-mediated inhibition GABA-B effect is 
abruptly interrupted33-36. The heterogeneous 
symptoms occurring during withdrawal of in-
trathecal baclofen and of intrathecal opioid 
treatment, may result in misdiagnosis, wrong 
referrals and (eventually) in a disastrous treat-
Figure 1. Implanted, programmable pump system. External view and drawing of implanted pump and 
intrathecal catheter 8731 ceter access port.  Pump with the catheter access port (black arrow head), pump 
catheter connection (thick black arrow), refill membrane (thick white arrow) and suture loops for fixation 
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Figure 2. Anterior-posterior (a) and lateral (b) plain radiography of the lumbar spine, in vivo image (d) and 
artist rendering (c) of the typical folded fixation anchor (with anchor symbol), large diameter catheter pump 
segment (black arrow), small diameter outside spinal canal (thick white arrow), and intrathecal (small white 
arrow, catheter end symbol) segment of the 8731SC catheter. 
Table 1. Explanation of the 
symbols.
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Figure 3. Anterior-posterior (a) and lateral (b) plain radiography of the lumbar spine, in vivo image (d) and 
artist rendering (c) of the typical unfolded fixation anchor of the Ascenda catheter. The small diameter 
catheter pump is hardly visible. The only reference points (3a, b) are the needle connector (needle symbol), 
the unfolded anchor (anchor symbol), and the titanium catheter tip (catheter end symbol).
Figure 4. Reel syndrome with signs of withdrawal syndrome in a 52-year-old woman with dystonia in CRPS. The 
apex of the pump is turned from the 11:00 to the 02:00 o’clock position (white arrow). Because of the visible 
traction on the catheter (black arrow), the pump must be rotated several times about the horizontal axis.
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ment delay. An additional problem is the re-
ferral of the patient in good time to a special-
ized center, which is a requisite for successful 
treatment37. Different imaging techniques, 
including plain radiography, fluoroscopy with 
contrast material injection via the access port 
of the pump, CT myelography, MRI and 111In-
dium-DTPA scintigraphy, are used to diagnose 
malfunction of the drug delivery system14, 38-43. 
Of all these imaging modalities, plain radiog-
raphy is the most important, especially in an 
acute situation. Furthermore, a rigorous and 
adequate interpretation of the images by the 
radiologist is crucial to make a correct diagnosis 
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Figure 5. Disconnection at the pump-catheter site (white arrow) with signs of withdrawal syndrome in a 52-year-
old woman with dystonia in complex regional pain syndrome.
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Figure 6. Reel syndrome with signs of withdrawal syndrome in a 45-year-old extremely obese woman with 
spasticity in multiple sclerosis. Baseline plain radiography (a, c, e) with follow-up images after 4 weeks (b, d, 
f). The apex of the pump is turned from the 11:00 (a) to the 02:00 (b) o’clock position (black-white arrow). 
The Ascenda needle connector is moved from the original position (a) to a more lateral position (b) (gray-white 
arrow) with disconnection of catheter pump segment (black arrow). The Ascenda catheter is hardly visible (white 
arrows). The tip of the catheter is unchanged (c-f) at level T8 (gray-black arrow).
and, if necessary, implement (urgent) interven-
tions.
This overview aims to offer the radiologist 
a systematic approach for the evaluation of 
all parts of the intrathecal delivery system on 
plain radiography. This may help radiologists 
to identify causes of drug delivery failures in 
emergency and in chronic situations. 
Materials and methods
Below we describe the most commonly used: i) 
intrathecal drug delivery system, ii) intrathecal 
catheter, and iii) surgical implantation technique.
Intrathecal drug delivery system
Although several pump systems are avail-
able, the implantable Synchromed II pump 
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(Medtronic, Minneapolis, USA) is by far the 
most rigorously tested and most applied im-
planted programmable device, worldwide. 
Here, we focus on this pump only. 
The implantable Synchromed II pump and the 
related intrathecal catheters have received 
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Figure 7. A magnification view of the black circle (a) shows the radiopaque pump identifier consisting of the 
logo of the manufacturer and three alphabetic letters (white arrow) with visible electronics (b) into the left-hand 
side (black arrow). For (some) odd rotations of the pump to the vertical axis (Twiddler’s syndrome), the pump is 
located on the head, which can be recognized by the logo in mirror image, and the electronics to the right-hand 
side (c).
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the ‘Conformité Européenne’ (CE) mark and 
are approved by the U.S. Food and Drug Ad-
ministration (FDA) for treatment of pain and 
spasticity. During continuous intrathecal drug 
delivery, the prescribed medication is admin-
istered through an intrathecal catheter, con-
nected with an implantable programmable 
pump system. The pump provides precise in-
trathecal drug delivery to patients with spas-
ticity or chronic intractable pain. Via the refill 
septum, which is in the center of the device 
(Fig. 1a), the reservoir is filled percutaneous-
ly. The gas below the reservoir exerts pressure 
which advances the drug into the inner tubing 
of the pump. The accompanying programmer 
device enables the delivery rate and mode to 
be programmed. A rotor system pushes the 
programmed dose with precision through the 
catheter access port via the catheter into the 
intrathecal space. 
Intrathecal catheter 
Over time, several catheter types for the im-
plantable Synchromed II pump have been 
developed and are commercially available. 
Although two types of intrathecal catheters 
(the 8731SC, and the Ascenda) are currently 
available, older types are still in use. Determin-
ing the type of implanted catheter via plain 
radiography is important for correct interpre-
tation.
The 8731SC catheter is normally visible on 
plain radiography (Fig. 2). The pump-catheter 
connection is sutureless and the two segments 
of the catheter have a different diameter, i.e. 
the pump segment of the catheter has a larger 
outer diameter than the spinal segment. Fur-
thermore, the 8731SC catheter is provided 
with a two-pin catheter-catheter connector, a 
folded V-wing anchor which is fixed on the fas-
cia, and has a catheter-end with six side holes 
and a round titanium tip. The folded V-wing in 
the 8731SC catheter locks the catheter in place 
(Fig. 2cd) and is, therefore, important for the 
diagnosis of catheter disorders. A partially or 
completely unfolded anchor (see Fig. 9) creates 
a major risk for dislodgement, potentially lead-
ing to a complete migration.
Figure 8. Twiddler’s syndrome with signs of withdrawal syndrome in a 51-year-old woman with dystonia in 
complex regional pain syndrome. A repeatedly twisted old type catheter is visible on lateral plain radiography 
behind the implanted pump (white arrow) (a), magnification of the pump with artist rendering (b) and an in-
vivo image (c). The catheter is fixed to the pump with an old sutured connector (gray arrow).
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The Ascenda catheter (Fig. 3) has a poor opac-
ity and the pump-catheter connection is also 
sutureless. Both catheter segments have the 
same diameter and are connected to each 
other with a needle connector. The fixation on 
the fascia is conducted by an unfolded V-wing 
anchor (Fig. 3cd). This catheter also has a cath-
eter-end with six side holes and a round titani-
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Figure 9. 8731SC catheter migration (gray arrow) caused by an open V-wing anchor (anchor symbol) in an 
80-year-old woman with intractable pain and spasticity caused by failed back surgery syndrome, with a spinal 
cord lesion (SCL) T12 treated with intrathecal baclofen.
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um tip. In contrast to the 8731SC catheter, the 
unfolded V-wing in the Ascenda catheter locks 
the catheter in place.
Older catheters have a sutured pump-cateter 
connection and distinct differences in anchor-
ing (this could even be absent), different cath-
eter-catheter connection, different catheter 
ends, and the presence or absence of a mush-
room-shaped titanium tip. Either a so-called 
‘one’ piece catheter type with only a connec-
tion at the pump, or a two-segment catheter 
are used. 
Surgical implantation technique drug delivery 
system 
Implantation is performed under local anes-
thesia with intravenous sedation or general 
anesthesia, With the patient in lateral decubi-
tus position, a 3-4 cm dorsal midline incision is 
made at the planned implantation level up to 
the muscular fascia. On level L2-L3 or L1-L2 a 
silicone catheter is obliquely inserted into the 
intrathecal space, using a 15 (8731SC catheter) 
or 16 Gauge (Ascenda catheter) introduction 
(Tuohy) needle. The introduction needle is in-
serted 1-2 cm using a paramedian approach44 
to prevent catheter shearing and crushing by 
the frequent movements of the vertebral spinal 
process when a midline approach is applied. 
Under fluoroscopy the catheter is advanced 
to the mid-thoracic level45-47. Some physicians 
claim that positioning of the tip at the high tho-
racic, or even cervical position, gives a better 
result on the upper extremities, however, this 
Figure 10. Sheared catheter 8731SC (gray arrow) with retracted segment partially outside the spinal canal, 
with no cerebrospinal leakage and no clinical signs of postural spinal headache or an intracranial hypotension 
syndrome, in a 48-year-old woman with cerebral palsy treated with intrathecal baclofen. 
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Radiologic examination after implan-
tation of an intrathecal drug delivery 
system
Since the quality of the perioperative fluo-
roscopic images is insufficient for detailed 
information, routine postoperative plain radi-
ography is performed after all of the surgical 
procedures and manipulations. For adequate 
interpretation, plain radiography of the pump 
and the entire implanted catheter in two direc-
tions is required38. 
Development of a stepwise interpretation 
schedule
A stepwise interpretation of the standard 
plain radiographic images has been developed 
(Appendix) to offer the radiologist a systematic 
approach for the evaluation of all parts of the 
intrathecal delivery system on plain radiogra-
phy. This stepwise interpretation is based on 
expert opinion.
Results
The normal and abnormal plain radiographic 
findings are described in a 14-step approach, a 
pump roller examination is also described.
 
Fourteen-step interpretation of standard plain 
radiographic images (Page 42)
Step 1 Previous radiographs available?
Comparison with previous radiological exam-
inations is required to detect subtle or overt 
changes in the location and position of the 
pump and catheter.
Step 2 Type of catheter used
Primarily the use of a 8731SC catheter (Fig. 
1a, 2, 5, 9, 10, 11), an Ascenda catheter (Fig. 
3,6) or an older one (Fig. 4, 8) should be de-
termined.
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Figure 11. A 62-year-old man with treatment-resistant 
spasticity was successfully treated for many years 
with intrathecal baclofen. During exacerbation of the 
clinical symptomatology, the catheter 8731SC was 
found to be torn off and left behind in the spinal canal 
(white arrow). For further treatment, a new catheter, 
of the same type was inserted (gray arrow).
has not yet been proven48,49. At the abdominal 
site a subcutaneous pocket is made in which 
the pump is placed and sutured using the 
outside suture loops of the pump. The pump 
catheter segment is sutureless connected to 
the pump and tunneled from the pump pock-
et to the dorsal incision where it is connected 
to the spinal catheter part. The excess catheter 
length should be placed dorsal to the pump in 
the pocket. 
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Step 3 Pump position 
The position of the pump is described by re-
porting the pump apex (Fig. 1a, 3-7, 9, 10, 12) 
the location in clock position, and the abdom-
inal quadrant in which the pump is placed. To 
exclude pump rotations, it is important to com-
pare the current pump position with previous 
radiological images. Rotations about the hori-
zontal axis are known as the Reel syndrome50, 
51 (Fig. 4, 6), resulting in traction on the cath-
eter and risk of disconnection at the level of 
the pump-catheter (Fig. 5) or catheter-catheter 
connection (Fig. 6b).
Step 4 Pump-catheter connection
On plain radiography, the pump-catheter con-
nection is clearly visible (Fig. 2-5, 9). 
Step 5 Excess pump catheter segment behind 
the pump
In common practice, the excess catheter length 
is positioned behind the pump. In case the 
catheter surplus is located above the pump 
reservoir, refilling with medication or injecting 
contrast material in the catheter access port 
might result in catheter puncturing. Cathe-
ter perforation can result in dose adjustment 
problems, or even in a severe withdrawal syn-
drome40. 
Step 6 Control identifier
With the magnification view the radiopaque 
identifier with the company logo and three al-
phabetic letters can be recognized opposite the 
pump apex (Fig. 7). When the pump is rotated 
around its longitudinal axis an odd number of 
times, the identifier is visible as a mirror image. 
This rotation was originally described in cardiac 
pacemakers52 and is known as the Twiddler’s 
syndrome. The rotation can occur either spon-
taneously or as result of repeated twiddling 
with the device by the patient. The syndrome 
has also been described in an implanted pump 
for intrathecal drug administration53. After sev-
eral rotations (Fig. 8), the catheter will occlude, 
rupture or dislodge resulting in termination of 
the drug delivery. 
Step 7 Catheter pump segment 
The 8731SC thick-walled pump catheter seg-
Figure 12. In this pump rotor examination, a normal rotation was found (change position 3 points wing, black 
arrow). The white arrow shows the pump position identifier (Fig. 7). 
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ment is clearly visible (Fig. 1a, 2, 5, 10) and 
in most cases the spinal segment is also visible 
(Fig.2, 9, 10, 11). The lack of opacity of the As-
cenda catheter creates problems with visualiza-
tion of the pump segment (Fig. 5, 6). Normally, 
this segment is clearly visible in older catheters.
Step 8 Catheter-catheter connector
The standard position of the clearly visible 
catheter-catheter connector is near the spine 
(Fig. 3, 4, 6a, 10). However, if the connection is 
placed in the pump pocket, recognition can be 
difficult. In the 8731SC catheter the connector 
is visible as a two-pin connector (Fig. 10), in 
the Ascenda catheter as a needle (Fig. 3, 6abe), 
and in older catheters often as a sharp small 
two-pin connector. 
Step 9 Spinal segment of the catheter outside 
the spinal canal 
The spinal segment of the 8731SC catheter has 
a smaller diameter than the pump segment and 
seems to be vulnerable to twisting, migration 
(Fig. 9) and shearing (Fig. 10). The pump seg-
ment and the spinal segment of the Ascenda 
catheter have the same small diameter. The 
improved mechanical properties make it less 
vulnerable. Kinking cannot be demonstrated 
on plain radiography in all implanted catheters. 
For a definite conclusion, additional investiga-
tions, such as injection of contrast material or 
scintigraphy, are needed. 
Step 10 Different anchors
A folded anchor in the 8731SC catheter (Fig. 2) 
and an unfolded anchor in the Ascenda cathe-
ter (Fig. 3) are present. In older catheters both 
folded and unfolded anchors can be found. At 
the anterior-posterior view anchors are often 
poorly visible (Fig. 3a), while on the lateral im-
age they are adequately visible (Fig. 3b).
Step 11 Catheter insertion, midline or 
paramedian?
Inserting an intrathecal catheter using the mid-
line approach raises the risk of catheter crush-
ing due to spinal column movements (Fig. 10). 
Therefore, a paramedian approach is the stan-
dard implantation technique.
Step 12/13 Spinal intrathecal catheter 
segment
Due to the poor visibility of the Ascenda cath-
eter, the thoracic or the cervical vertebral col-
umn catheter segment is inadequately imaged. 
This leads to lack of information on the position 
of the catheter.
Due to the titanium end, the radiopaque tip 
can be recognized (Fig. 3 ,6). Attention must 
be paid to retained catheter fragments (Fig. 
11). This can occur at the time of catheter in-
sertion, removal, or as a late complication54,55. 
There is no consensus about the treatment of 
retained fragments. Both conservative54,55 (Fig. 
11) and surgical treatment54,56 are performed. 
Nevertheless, serious complications like sub-
arachnoid hemorrhage41,57,58 and migration into 
the ventricle58 are reported. Special attention 
must be paid if an intrathecal fragment also 
remains partially outside the spinal canal. Leak-
age of CSF with the development of postural 
headache, a pseudomeningocele58 or even an 
intracranial hypotension syndrome could occur. 
However, sometimes no CSF leakage is present 
(Fig. 10). In a conservative approach the posi-
tion of the retained catheter fragment should 
be followed-up over time.
Step 14 Radio-opaque catheter tip
In the latest catheters, a titanium tip has been 
built into the end of the catheter, in these intra-
thecal catheters, on plain radiography this tip is 
recognized as a ball at the end of the catheter 
(Fig. 2, 3, 6). 
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Special pump roller examination 
If the rotor of the pump stalls, a two-tone emer-
gency alarm will sound. After interrogation 
with the device programmer the device display 
indicates a ‘Motor Stall’. When no motor stall is 
indicated and this is not derived from the pump 
logs, a roller study should be performed in case 
failure is suspected (Fig. 12). In this procedure, 
the pump is programmed in the continuous in-
fusion mode, using a preset, without activation 
and with a priming bolus of 10 microliters with 
a duration of 1 min. With fluoroscopy, the rotor 
is visualized, thereby reducing the aperture. A 
plain radiographic image is made and the pre-
set bolus delivery is activated. After 2 min, a 
new plain radiographic image is made and the 
two images are compared. In a normal pump 
function, the rollers have moved approximately 
60º from their original position. The extra radi-
opaque dot on one of the roller arms helps to 
visualize the roller movement (Fig. 12). 
Discussion
Although intrathecal drug administration using 
an implanted pump system has been employed 
for many years in therapy-resistant spasticity 
and intractable pain, knowledge on diagnostic 
imaging during adverse events remains limited. 
The main reasons for this limited knowledge 
include i) the diminished frequency of cathe-
ter-related treatment failures due to advance-
ments in manufacturing and ii) the limited ap-
plication of the treatment in different clinics. 
While plain radiography is the mainstay for 
the diagnosis of drug delivery device-related 
adverse events, radiologists play an important 
role in early diagnosis. An awareness of typical 
radiographic images in relation to intrathecal 
catheter failure is important to avoid a (some-
times life-threating) withdrawal syndrome. The 
most frequent causes of drug delivery failure 
are migration, damage, disconnection, and oc-
clusion of the spinal catheter. In our opinion, 
applying the presented 14-step analysis and 
increasing the awareness of abnormal radio-
logical findings will help physicians to avoid a 
life-threatening withdrawal syndrome.
A limitation of this proposal is that our ap-
proach has not yet been validated but is based 
on our expert opinion. Due to the present lack 
of high-quality evidence, we strongly believe 
that, as a first step in quality improvement, the 
current variation in radiological practice should 
be avoided. The stepwise approach, as pro-
posed by our group, might be an effective first 
step towards raising the quality of care related 
to troubleshooting for intrathecal drug delivery 
with implanted systems.
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tomography with two- 
and three-dimensional 
postprocessing as an 
alternative to plain 
radiography for intrathecal 
catheter visualization: 
A phantom pilot study
Elmar M. Delhaas






In intrathecal drug delivery, visualization of the device has been performed with plain radiography. However, 
the visibility of the related structures can be problematic. In troubleshooting, after the contrast material injec-
tion via the catheter access port, a CT scan has been used. In troubleshooting, we also used a non-contrast CT 
scan with 2D and 3D reconstructions. With the current phantom study, we aimed to obtain high-resolution 
imaging of a poor opaque catheter with the use of a low-dose single-energy 2D and 3D CT scan with limited 
radiation exposure as a substitute for plain radiography. 
Materials and Methods
The catheter was placed into a fatty substance and mounted on an anthropomorphic abdomen phantom 
followed by CT with varying kVp settings and with added tin beam filtering. Dose levels corrected based on 
the spinal catheter tip on T8 would result in a calculated effective dose in the range of the mSv’s calculated for 
the plain X-ray examination. 
Results
Ultimately, Sn100 kVp has the best trade-off between visibility, artifacts, and noise for a fixed dose. Although 
3D VRT imaging was challenging at this low dose level, we could make a full evaluation possible with com-
plementary 2D projections.
Conclusion
We could correctly identify the catheter and related structures, which supports the investigation of this in vivo 
and side-by-side evaluation with plain radiography. If found superior, then this technique may be able to re-
place plain radiography while providing better visualization and acceptable radiation exposure.
Keywords
Catheter opacity, CT 2D/3D reconstructions, intrathecal drug delivery, phantom study
Running Title 
Intrathecal catheter opacity 2D/3D low-dose CT
Introduction
Intrathecal drug administration using the 
implantable SynchroMed II delivery device 
(Medtronic Inc., Minneapolis, United States) 
is well established in treating intractable pain, 
spasticity, and dystonia. Despite generally fa-
vorable and safe outcomes and continuous 
advancements in manufacturing technology, 
adverse events related to the pump and cath-
eter still occur. 
Visualization of the pump and catheter is per-
formed after device implantation and in trou-
bleshooting to confirm the correct pump and 
catheter positioning. Historically, the corner-
stone for the diagnosis of a catheter-related 
problem was plain radiography, which was in 
most cases, but not in all, acceptable in the old-
er catheter types.1 However, the opacity of the 
latest developed clinically used Ascenda cathe-
ter is more problematic (Fig. 1A, 5C).1
In troubleshooting, we, therefore, extend-
ed the plain radiography with catheter access 
port (CAP) CT myelography with high-resolu-
tion two- (2D) (Fig. 1B) and three-dimensional 
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Figure 1. Visibility of spinal catheter with CT in troubleshooting Plain radiography: invisible Ascenda catheter 
and visible type 8731SC catheter segment (A, red arrow), and dorsal to the spine, several hardly recognized 
structures of both catheters on (A, green arrow). Zoomed two-dimensional maximum intensity projection (B) 
and three-dimensional volume rendered images (C, D) revealed visible Ascenda structures: catheter (blue 
arrow), catheter–catheter connector (yellow arrow), and fixation anchor (orange arrow), as well as retained 
8731SC catheter parts (red arrow). 
Intrathecal catheter opacity 2D/3D low-dose CT
(3D) (Fig. 1C, 1D),2-8  reconstructions based on 
maximum intensity projection (MIP),9 multi-
planar reformation (MPR),9 and volume ren-
dering techniques (VRTs).9 With this approach, 
we could provide optimal visualization of the 
entire catheter pathway (Fig. 1B−1D)7 and re-
duce beam-hardening artifacts around the im-
planted titanium pump. Normally, compared to 
plain radiography, CT has the disadvantage of 
an increased radiation dose. With the current 
phantom study, we aimed to obtain high-res-
olution imaging of the Ascenda catheter with 
the use of a low-dose single-energy 2D and 3D 
CT scan with limited radiation exposure as a 
substitute for plain radiography. Based on this 
experience we now intend to replace plain ra-
diography by CT in all cases where imaging of 
the pump and catheter is needed.
Materials and Methods
We tested the visualization of the Ascenda 
catheter placed into a fatty substance and 
mounted on an Anthropomorphic Abdomen 
Phantom (QRM GmbH, Moehrendorf, Ger-
58
many) with a 2.5 cm fat equivalent exten-
sion ring (Fig. 3). We performed a low-dose 
single-energy spiral CT scan (SECT) using a 
multi-slice CT scanner (SOMATOM Drive 
VA62A, Siemens Healthcare GmbH, Erlan-
gen, Germany). Scans were performed with 
varying kVp settings (80, 100, 140) and with 
added tin (Sn) beam filtering (Sn100, Sn140) 
to evaluate a trade-off between the catheter 
visibility, the pump beam-hardening artifacts, 
and the X-ray energy level. Because an Sn fil-
ter at 80 kVp and 120 kVp is not available, 
this setting was not used. By adapting the 
tube load (in mAs), three scans per kVp set-
ting were performed with three fixed values 
of the dose length product (DLP) for a 20 cm 
scan range on the phantom: 15, 30, and 60 
mGy*cm. These dose levels, corrected for an 
average 50 cm scan range based on the spinal 
catheter tip on T8, would result in a calculated 
effective dose of, respectively, 0.6, 1.1, and 
2.3 mSv. These values are approximately less 
than, virtually equal to, and more than the 
dose level of 0.7 mSv previously used in plain 






Target CTDIvol standard patient: 1,5 mGy
Collimation: narrow n*0,6 millimeter




Smooth & medium algorithm
Strong iterative reconstruction (4-5)
Coronal/sagittal MPR & MIP
Oblique VRT 
Additional iMAR images if needed
The protocol with a DLP of 30 mGy*cm has an 
optimum radiation dose level for all kVp set-
tings because the lowest dose resulted in poor 
visualization and the highest dose resulted in 
better visualization than needed. A low energy 
level of 80 kVp had the highest contrast be-
tween the catheter and the surrounding tissue, 
benefiting catheter visualization, but also had 
the highest level of beam-hardening artifacts 
around the pump. The highest energy level of 
140 kVp with added Sn filtering had minimal 
artifacts, but the reduced contrast caused the 
catheter visibility to become insufficient. Sn 
filtering resulted in increased dose efficiency 
with an improved signal-to-noise ratio for the 
same dose in this phantom study (Fig. 3, 100 
kVp versus Sn100 kVp). Ultimately, Sn100 kVp 
has the best trade-off between visibility, arti-
facts, and noise for a fixed dose (Fig. 3). The 
clinical CT settings are summarized in Figure 
2. Although 3D VRT imaging was challenging 
at this low dose level, we could make a full 
evaluation possible with complementary 2D 
MIP and MPR projections (Fig. 4,5). However, 
with Sn filter, not all metal-related artifacts that 
obscure adjacent tissues could be suppressed. 
Additional improvement in visualization of 
the pump, proximal catheter and surrounding 
soft-tissue structures10 could be achieved with 
the use of metal artifact reduction (MAR) al-
gorithm (iMAR [Siemens], Smart-MAR [GE 
Healthcare], O-MAR [Philips], SEMAR [Can-
on])11 which suppresses the scattering in the 
images caused by the metal pump (Fig. 5). 
Discussion
A low-dose CT scan for visualization of the 
pump and catheter with an equivalent radia-
tion dose to conventional plain radiography is 
feasible. To extend CT with 2D and 3D recon-
structions will be of value for the postoperative 
evaluation of a normal drug delivery system 
and for the proper diagnosis in troubleshoot-
ing. The optimal DLP was 30 mGy*cm with 


































































































































































































































































































































































































































































































































































Figure 5. Surplus catheter behind the pump 3D VRT reconstruction (A) with iterative metal 
artifact reduction reconstruction algorithm (B) showing a normal course of surplus catheter 
length behind the pump, which is invisible on plain radiography (C, white arrow) and CT (B). 
The Ascenda catheter cannot be followed along its track on plain radiography (C); The only 
structures visible are the catheter–catheter connector (green arrow) and the fixation anchor 
(orange arrow).
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radiation exposure of 1.1 mSv for a scan range 
of 50 cm, which is close to the dose of plain 
radiography images. The dose of plain radi-
ography in our center was approximately 0.7 
mSv, although a value of 3.6 mSv for at least 
six needed plain radiography images has been 
reported.12 We prefer the use of 100 kVp with 
the Sn filter. The benefit of the filter use is the 
reduction of beam-hardening artifacts originat-
ing from the metal pump, but not all metal-re-
lated artifacts that obscure adjacent tissues can 
be suppressed. Application of a metal artefact 
reduction algorithm can thereby be of help. 
When Sn filter is used the obtained narrowed, 
and increased mean energy level of the X-ray 
tube spectrum will create an improvement in 
the overall image quality.13 The choice for an 
increase in kVp resulted in a decrease in the 
contrast between the catheter and the sur-
rounding tissue, which is accompanied by a 
reduction in artifacts. 
Furthermore, the choice for Sn filtering result-
ed in an additional decrease in the contrast be-
tween the catheter and the surrounding tissue, 
which is accompanied by an increased signal-
to-noise ratio. Another disadvantage is the 
need for higher mAs settings, which may limit 
the increase of scan speed if the patient is mov-
ing, and which is not uncommon in our spastic 
patient group. In the relatively small phantom, 
we could omit the beam hardening with Sn100 
kVp (Fig. 2). In obese patients or with the hin-
drance of upper extremity contractures, high-
er radiation dose values may be needed. This 
objective could be automatically realized with 
the automatic mA exposure modulation setup 
of a CT scanner. For a definite conclusion and 
the application of CT in vivo using CT scanners 
from different vendors, imaging protocols per 
scanner should be developed.
Conclusion
The positive findings of our phantom study in 
correctly identifying the catheter components 
supports the in vivo evaluation and a side-
by-side comparison with plain radiography. 
If found superior, then this technique may be 
able to replace plain radiography while provid-
ing better visualization and acceptable radia-
tion exposure. 
Comments
Whilst it is easy to diagnose there is a problem 
with an intrathecal pump/catheter unit (in-
creased pain, increased spasticity) it can some- 
times be far from easy to separate underdosing 
from treatment more reliably and reduce com-





Short article but very clear in defining the prob-
lem of not being to visualize catheter continu-
ity without additional expense and has- sle of 




1  Delhaas EM, Harhangi BS, Frankema SPG, Huygen 
FJPM, van der Lugt A. Plain radiography in pa-
tients treated with intrathecal drug delivery using 
an implantable pump device. Insights Imaging. Oct 
2017;8(5):499-511.
2  Abousamra O, Rogers KJ, McManus M, Miller F, 
Sees JP. Evaluation of intrathecal baclofen deliv-
ery system malfunction by computed tomography 




3  Schapiro A, Racadio J, Kinnett D, Maugans T. Com-
bined C-arm fluoroscopy and C-arm cone beam 
computed tomography for the evaluation of pa-
tients with possible intrathecal baclofen delivery 
system malfunctions. Neurosurgery. Sep 2011;69(1 
Suppl Operative):ons27-33; discussion ons33.
4  Miracle AC, Fox MA, Ayyangar RN, Vyas A, 
Mukherji SK, Quint DJ. Imaging evaluation of in-
trathecal baclofen pump-catheter systems. Am J 
Neuroradiol. 2011;32(7):1158-1164.
5  Dvorak EM, McGuire JR, Nelson MES. Incidence 
and identification of intrathecal baclofen catheter 
malfunction. PM R. 2010;2(8):751-756.
6  Ellis JA, Leung R, Winfree CJ. Spinal infusion 
pump-catheter leak detected by high-resolution 
3D computed tomography. J Neurosurg Spine. Nov 
2011;15(5):555-557.
7  Morgalla M, Fortunato M, Azam A, Tatagiba M, 
Lepski G. High-resolution three-dimensional com-
puted tomography for assessing complications re-
lated to intrathecal drug delivery. Pain Physician. 
Jul 2016;19(5):E775-780.
8  Dupoiron D, Carvajal G. High-resolution three- 
dimensional computed tomography reconstruction 
as first-line imaging modality to detect intrathe-
cal catheter malfunction. Neuromodulation. Oct 
2018;21(7):717-720.
9  Dalrymple NC, Prasad SR, Freckleton MW, Chin-
tapalli KN. Informatics in radiology (infoRAD): in-
troduction to the language of three-dimensional 
imaging with multidetector CT. Radiographics. Sep-
Oct 2005;25(5):1409-1428.
10  Kotsenas AL, Michalak GJ, DeLone DR, et al. 
CT metal artifact reduction in the spine: can 
an iterative reconstruction technique improve 
visualization? AJNR Am J Neuroradiol. Nov 
2015;36(11):2184-2190.
11  Greffier J, Larbi A, Frandon J, Daviau PA, Beregi JP, 
Pereira F. Influence of iterative reconstruction and 
dose levels on metallic artifact reduction: A phan-
tom study within four CT systems. Diagn Interv 
Imaging. Jan 29 2019;100:269-277.
12  Vilar-Palop J, Vilar J, Hernandez-Aguado I, 
Gonzalez-Alvarez I, Lumbreras B. Updated ef-
fective doses in radiology. J Radiol Prot. Dec 
2016;36(4):975-990.
13  Gordic S, Morsbach F, Schmidt B, et al. Ul-
tralow-dose chest computed tomography for 
pulmonary nodule detection: first performance 
evaluation of single energy scanning with spectral 
shaping. Invest Radiol. Jul 2014;49(7):465-473.
Intrathecal catheter opacity 2D/3D low-dose CT
64
eFigure 1 Phantom study. Thoracic  phantom (A,B),  Coverage with saline sacs (C),  Thoracic schematic view  (D), 
Abdominal phantom (E), Coverage with intrathecal catheters (8731 and Ascenda), Abdominal schematic view (H), 
Pump connected with catheter and coverage with fatty substance (I), low-dose single-energy CT scan images (J-L). 
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Intrathecal drug delivery is used for the treatment of intractable spasticity, dystonia, and pain. When the 
symptomatology is not responding to the therapy, the cause could be a failure of the medication infusion. 
The purpose of this study was to assess the value of the pump catheter access port (CAP)-myelography and 
CAP-CT-myelography as an advanced imaging method in treatment failure. 
Materials and Methods
We analyzed observational routinely collected data of 70 CAP procedures with 2D and 3D reconstructions 
in 53 adult patients between November 2013 and November 2018 in whom the cause of failure was un-
clear. CAP-myelography and CAP-CT-myelography were performed with 2D/3D image reconstructions. When 
 myelography could not be performed or when the study did not reveal the cause, addition procedures such 
as non-contrast CT, MRI, lumbar puncture CT myelography, and 111Indium-DTPA SPECT CT were performed. 
Results
CAP fluid aspiration contrast medium injection was not possible (n=17). In one case contrast was injected in de 
the pump pocket unintentionally.  The remaining examinations CAP myelography (n=52) had limited value for 
the diagnosis. CAP-CT myelography (n-50) was normal (n=31). The abnormal results were: dorsal dural leak 
(n=5), subdural catheter position (n=2), limited rostral flow of contrast material (n=4), limited and abnormal 
contrast distribution (n=3), obstruction of rostral flow (n=2), a leak at the pump-catheter connection (n=1), 
and a sheared catheter localized in the pump pocket (n=2). A limited contrast distribution turned out to be 
false positive findings (n=2). CAP-CT myelography was normal in 31 procedures. Four normal CT-CAP myelo-
graphic procedures were false negative as the reference tests revealed a cause of ITDD failure. The CAP-CT 
procedures resulted in a sensitivity of 81% (17/21) and in a specificity of 93% (27/29). 
Conclusion
CAP-CT myelography with 2D/3D reconstructions is an essential step in the diagnostic algorithm for patients 
with ITDD failure.
Keywords
intrathecal treatment failure, pump, catheter access port, computed tomography, myelography
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Introduction
Several observational studies demonstrate 
the value of intrathecal drug delivery (ITDD) 
for therapy-resistant spasticity, dystonia, and 
pain.1-3 Older data show a high complication 
rate, mainly related to the intrathecal catheter, 
which varied widely among the treating spe-
cialists.4-7 Current complications are related to 
the handling of the delivery system itself, as 
well as to its implantation or to the underlying 
condition of the patient. As result of catheter 
improvements, the complication rate seems to 
be considerably reduced.8, 9 
 Algorithms for troubleshooting and the in-
volved diagnostic procedures are under debate. 
One topic in the discussion is the role of cath-
eter access port (CAP) computed tomography 
(CT) myelography as an advanced diagnostic 
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procedure. Saulino et al.10 stated that the CAP-
CT procedure should be part of the standard 
approach. However, it was recently suggested 
that the use of this procedure should be limited 
to emergencies and should not be considered as 
a routine examination.11 The aspiration failure 
rate of the CAP puncture, the non-physiolog-
ical flow of contrast material in the intrathecal 
space, the probable lower costs, and the low-
er radiation dose of 111Indium-diethylene-tri-
amine-penta-acetic acid scintigraphy (111In-DT-
PA) single-photon emission CT (SPECT-CT) 
were presented as arguments.11 
 The CAP procedure is not always easy to 
perform, which could be one of the reasons 
for its omission from the standard diagnostic 
approach. In ITDD failures, advanced imag-
ing procedures are frequently not performed 
or performed inadequately, which can lead to 
undertreatment, unnecessary surgery, or even 
unjustified termination of the therapy. Over 
the last few years, we routinely used CAP my-
elography and fluoroscopy in troubleshooting, 
combined with CT and two-dimensional (2D) 
multiplanar reformation (MPR),12 2D maxi-
mum intensity projection (MIP),12 and three-di-
mensional (3D) volume-rendering technique 
(VRT)12 reconstructions. The intended use of 
the CAP-CT procedure was to diagnose cath-
eter leaks or obstruction or abnormal rostral 
distribution of the injected contrast material. 
With this retrospective observational study fo-
cused on routinely collected data, we aimed to 
assess the value of CAP (CT) myelography as 




We included all routinely collected data from 70 
CAP (CT) myelography and additional related 
imaging procedures in 53 adult patients who 
were evaluated for ITDD failure between No-
vember 2013 and November 2018. Fifty-two 
of the patients were referred to our hospital 
for ITDD troubleshooting. A SynchroMed II 
pump model 8637 with the associated intra-
thecal catheters (Type 8731SC or Ascenda 
8780/8781) (Medtronic Inc., Minneapolis, 
MN, USA) was used for the drug delivery. The 
indication used was, depending on the partic-
ular patient’s underlying etiology, either mor-
phine-HCl, a morphine-HCl/baclofen mixture, 
or baclofen prepared by the hospital pharma-
cy according to the existing regulations. CAP-
(CT) myelography was considered when the 
ITTD failure could not be managed with dose 
adaptations in combination with conservative 
non-pharmaceutical treatment and the cause 
was not identified as being related to the pa-
tient’s history, a pump readout, the presence 
of medication fluid in the pump reservoir, or 
plain radiography. ITDD failure was defined as 
the presence of one or more of the following 
criteria: a decrease in effectiveness of the treat-
ment, a discrepancy between the volumes that 
the pump device calculated and the residual 
volumes obtained by the refill procedure, mani- 
fest- or occult-drug cerebrospinal fluid (CSF) 
leakage, repeated dosage increases without 
clinical improvement, and extremely high dos-
ages with an insufficient clinical result. The first 
and last author reexamined the images, taking 
all clinical features into consideration. Their as-
sessments were focused on the distribution of 
the contrast medium injected via the CAP, the 
pump shape, catheter-pump connections, the 
course of the catheter, catheter-catheter con-
nection, the dural insertion, and the intrathecal 
distribution. The study was approved by the 
medical ethics committee of our center (MEC-
2017-326), and the requirement to obtain in-
formed consent was waived. 
CAP myelography 
CAP insertion using a 24-G non-coring Huber 
needle was performed under fluoroscopy. We 
found that, with the template provided with 
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the CAP kit (Model 8540, Medtronic Inc., Min-
neapolis, MN, USA), the CAP funnel position 
could not be recognized in all cases. During flu-
oroscopy, we use a metal object (e.g., a surgical 
clamp or a pair of tweezers) to determine the 
CAP funnel’s location. We positioned the C-arm 
fluoroscopy device such that the beam was par-
allel to the CAP axis, which allowed perpendic-
ular needle insertion into the funnel. To prevent 
an injection overdose caused by the flushing of 
the highly concentrated catheter content into 
the intrathecal space, we first aspirated 2 ml of 
fluid.13 When we could not aspirate, we omitted 
the contrast material injection and terminated 
the procedure or performed, when not already 
present, a non-contrast CT (NCCT) scan. After 
successful fluid aspiration, we injected 10 ml of 
contrast material (iohexol, Omnipaque™ 300, 
GE Healthcare B.V., Eindhoven, Netherlands). 
Due to the high viscosity of the contrast ma-
terial and the small needle diameter, we had to 
apply significant force during the injection. To 
reduce the force required, the contrast material 
was injected at body temperature. To ensure an 
optimal distribution of the contrast material in 
the CSF, we turned the patient to the left and 
to the right and placed him or her in the Tren-
delenburg position. Under fluoroscopy, we con-
trolled the catheter pathway and the intrathecal 
distribution of the contrast material. Next, we 
flushed the catheter with 2 ml of NaCl 0.9% 
fluid to remove the contrast material from the 
catheter. To prevent a withdrawal syndrome, 
we programmed the pump for a catheter-prim-
ing bolus injection, which was calculated based 
on the catheter length. 
CAP-CT myelography 
Following CAP myelography, we performed a 
CT scan. The first, and largest, group of pa-
tients were evaluated with a single-energy CT 
(SECT) scanner. To optimize the CT results, 
we recently switched from SECT to dual-ener-
gy CT (DECT).14 Therefore, we used the twin 
beam dual-energy CT scan (Siemens Healthcare 
GmbH, Erlangen, Germany) with gold (Au) and 
tin (Sn) filters in combination in front of the 120 
kVp x-ray beam.15 The filters split the beam into 
a high- and low-energy X-ray spectrum before 
it reaches the patient. The different x-rays give 
DECT an additional advantage over SECT by 
obtaining better information when metal im-
plants (e.g., the pump or osteosynthesis materi-
al) are present in the scanned area. With a met-
al artifact reduction algorithm (iMAR), further 
image improvement could be obtained. Origi-
nally, we limited the reconstructed scan field of 
view (FOV) to the spine. To obtain information 
concerning the entire implanted drug delivery 
system, we extended the FOV to the extra-ver-
tebral abdominal region. For the imaging of the 
intrathecal catheter and the distribution of the 
contrast material above the catheter tip, we 
applied a lumbar–cervical spine scan range. A 
breath-holding command was given to avoid 
pump movement during breathing. The scan 
parameters for DECT included the following: 
collimation: 300 x 0.6 mm; rotation time: 0.5 s; 
and slice thickness: 0.8 mm.
On a workstation, we reconstructed 12 mm 
MIPs,12 which enables the imaging of highly in-
tensive structures with respect to the surround-
ing structures, and 1.5 mm MPRs,12 whereby 
thin-slice axial data were converted into coro-
nal, sagittal, oblique, or curved planes, which 
allow one to follow the course of the implanted 
catheter. Using VRT,12 we transformed the axial 
data into 3D images. 
Additional imaging procedures
When CAP(-CT) myelography was impossible 
or when additional confirmation of the result 
was needed, we performed supplementary im-
aging with NCCT, magnetic resonance imaging 
(MRI), lumbar puncture (LP) CT myelography, 
or optimized 111In-DTPA scintigraphy combined 
with SPECT-CT examination. To be certain of 
a normal rostral intrathecal activity distribu-
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tion over time, we optimized the scintigraphy 
by standardizing the pump flow rate, as result 
of which the tip of the intrathecal would be 
reached after 24 hours.
Statistical analysis
The sensitivity and specificity of the different 
procedures were calculated, comparing the im-
aging assessment outcome as the index test, 
while the gold standard reference test was 
based on all performed imaging procedures, 
and clinical and surgical information. A true 
positive result was thereby defined when an 
abnormality could be demonstrated with the 
index test and the reference revealed indeed 
a cause of ITDD failure, a true negative when 
no abnormality was found with the index test 
and the reference test, a false positive when an 
estimated abnormality could not be confirmed 
by the reference, and a false negative when 
the abnormality was missed. Due to the limited 
number of NCCT scan procedures, we omitted 
the calculations of accuracy. 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1 summarizes the patient characteristics. 
We performed 70 procedures in 53 patients. 
No adverse events were reported as a result 
of the procedures. In 13 patients, the method 
was conducted several times, which resulted in 
17 additional procedures, when the patient’s 
spasticity was insufficiently under control and 
another after two years for again an exacerba-
tion of her spasticity (n=2), for a persistent leak 
(n=2) for an unexplained reoccurrence of treat-
ment failure (n=2), for a persistent treatment 
failure (n=8), after the performed surgical in-
tervention was found to have had a limited ef-
fect (n=1), for control of a surgical intervention 
(n=1), and four years after the successful mi-
crosurgical removal of an intradural cyst, when 
a broken catheter was replaced which resulted 
in a persistent dorsal dural leak at the original 
catheter insertion site (n=1). 
CAP CSF aspiration
In 17 procedures, we could not aspirate the CSF, 
and therefore, contrast material was not inject-
ed via the CAP. In eight of them NCCT scans 
were performed, showing an epidural catheter 
position in four examinations (Fig. 1C), which 
was confirmed by LP-CT myelography in one 
case (Fig.1D), a downwards curved intrathe-
cal catheter in one examination, whereby with 
additional 111In-DTPA SPECT-CT, a normal ros-
Figure 1. CAP-CT MPR myelography revealed a normal intrathecal 8731SC catheter tip position (A, gray 
arrow) and a regular small-diameter Ascenda catheter tip position (B, gray arrow). The NCCT MPR image 
fostered suspicion of an epidural tip position of the 8731SC catheter (C, gray arrow). LP CT myelography 
confirmed the epidural position (D, gray arrow). CAP-CT MPR myelography showed extensive subdural 
(E, black arrow) and minimal intrathecal (E, white arrow) contrast material, which explained the irregular 
contrast material distribution found with CAP myelography (Fig.3C).
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tral CSF flow was identified, and normal find-
ings in three examinations in which 111In-DTPA 
SPECT-CT confirmed normal findings (n=2)  or 
detected catheter obstruction (n=1). In the oth-
er nine patients, we performed LP-CT myelog-
raphy (n=1) showing a granuloma, MRI (n=2) 
revealing normal findings, 111In-DTPA SPECT-
CT (n=3) demonstrating CSF flow obstruction 
(n=1), or normal results (n=2), and three pa-
tients refused further diagnostic procedures. In 
nine of the seventeen patients (53%) in which 
CSF aspiration was not possible scintigraphy re-
vealed normal tracer distribution (n=5) and MRI 
revealed no abnormalities (n=2), dose adaption 
was successful, indicating a functional catheter.
CAP myelography
In 53 procedures, we injected the contrast me-
dium via the needle in the CAP. Myelography 
could not be performed due to an unintended 
injection into the pump pocket (n=1, Fig. 2A). 
The reference standard (Table 1) was CAP my-
elography (n=2), MRI (n=1), CAP-CT myelog-
raphy (n=31), 111In-DTPA SPECT-CT (n=15), 
clinical outcome (n=2) and surgical findings 
(n=1). Sixteen of 52 CAP myelography’s re-
vealed a suspected pump-catheter related 
cause of ITDD failure including catheter leak 
(n=2, Fig. 3A), a downwards curved catheter 
with possible reduced flow (n=1), limited ab-
normal contrast distribution (n=6, Figs. 3B–C), 
an acute stop in the contrast distribution (n=2, 
Fig. 3D), a limited contrast distribution (n=5, 
Fig. 3E). In 12 of these 16 CAP myelographic 
procedures, the reference tests revealed a cause 
of ITDD failure, while in 4 procedures the limit-
ed contrast distribution (n=3) and a downwards 
curved catheter with possible reduced flow 
(n=1) turned out to be a false positive finding. 
Eleven normal CAP myelographic procedures 
were false negative as the reference tests re-
vealed a cause of ITDD failure. The calculat-
ed sensitivity of CAP myelography was 52% 
(12/23) with a specificity of 86% (25/29). 
Figure 2. Scattering on CAP-CT MPR (gray arrow) images caused by contrast material in the pump pocket. At 
the procedure, 7 ml of contrast material was unintentionally injected into the pump pocket (A). A sheared 
catheter located in the pump pocket caused contrast material accumulation (B). Severe CSF and contrast 
material appearance in the pump pocket (C) as a result of a dorsal dural leak at the previous catheter insertion, 
where CSF passed retrograde along the implanted catheter, and a normal pump appearance after aspiration of 
the fluid and dural leak treatment with an epidural blood patch (D).
CAP-CT myelography 
We carried out 50 CAP-CT myelography pro-
cedures in which images of the spinal column 
were reconstructed. In 24 of the procedures, the 
FOV of the image reconstruction was enlarged 
to the extra-vertebral region, including the ab-
dominal pump position and the extra-spinal 
catheter tract. The reference standard (Table 1) 
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Figure 3. CAP myelography revealed a pump-catheter connector leak (A, arrow), irregular distribution of 
the contrast material, caused by an intradural cyst (B), subdural catheter position (C), CSF flow obstruction 
(catheter tip position above the obstruction) (D), and an inadequate Trendelenburg maneuver (E).
was CAP myelography (n=1), CAP-CT myelog-
raphy (n=31), 111In-DTPA SPECT-CT (n=15), 
clinical outcome (n=2), and surgical findings 
(n=1). CAP-CT myelography revealed 16 sus-
pected causes of ITB failure including dorsal 
dural leak (n=5, Figs. 4F-G), subdural catheter 
position (n=2, Fig. 1E), limited rostral flow of 
contrast material (n=4), limited and abnormal 
contrast distribution (n=3), obstruction of ros-
tral flow (n=2). The extra-vertebral image re-
constructions revealed 3 causes of ITDD failure 
including contrast media around the pump ow-
ing to a leak at the pump-catheter connection 
(n=1), a sheared catheter in the pump pocket 
(n=1, Fig. 2B), contrast material in the abdom-
inal soft tissue due to a catheter leak (n=1, Fig. 
4B-C), which was not identified by CAP my-
elography (Fig. 4A). Dural leaks (n=5) were 
caused by a previous catheter insertion site 
(n=4, Figs. 2C, 4D-E), and after a reinsertion of 
a catheter (n=1, Figs. 4F–G). In two cases the 
dural leak which was visible on the spinal CAP-
CT myelography was accompanied by retro- 
grade flow to the pump pocket, visible on the 
extra-vertebral image reconstruction (Fig. 2C). 
In two procedures, a limited contrast distribu-
tion was found which turned out to be false 
positive findings. CAP-CT myelography was 
normal in 31 procedures. Four normal CT-CAP 
myelographic procedures were false negative 
as the reference tests revealed a cause of ITDD 
failure, including one examination in which only 
the spinal region was evaluated while a cathe-
ter leak was present in the extra-spinal region, 
one examination in which the follow-up scin-
tigraphy was normal, but an intrathecal cathe-
ter leak was found during surgical intervention, 
one examination in which scintigraphy revealed 
catheter obstruction and one examination in 
which scintigraphy revealed retrograde tracer 
distribution via a retained catheter. The CAP-
CT procedures resulted in a sensitivity of 81% 
(17/21) and in a specificity of 93% (27/29). 
Discussion
Based on the analysis of the observational col-
lected data of CAP and CAP-CT myelography 
during for troubleshooting, we confirmed the 
importance of CAP-CT myelography in diagno-
sis the causes of ITDD failure. The procedure 
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could be performed safely. CAP-CT myelogra-
phy exhibited better sensitivity and specificity 
than CAP myelography. Finally, NCCT could be 
helpful for the diagnosis of epidural catheter 
position when fluid cannot be aspirated via the 
CAP and CAP-CT myelography is therefore not 
possible.
CAP procedure 
When fluid cannot be aspirated from a pump, it 
does not always indicate a catheter obstruction 
or a disconnection16, as we confirmed in near-
ly half of the cases. We initially terminated the 
CAP procedure if the fluid could not be aspirat-
ed. To diagnose an epidural catheter position, 
an NCCT scan could be performed. This finding 
underscores the relevance of replacing standard 
plain radiography as a postoperative procedure 
with  low-dose CT,17 which could result in an 
earlier detection of ITDD failure.
Figure 4. A: The tiny catheter leak was not recognized with CAP fluoroscopic myelography (left, yellow 
arrow). CAP-CT MPR myelography revealed abnormal subcutaneous contrast material accumulation (middle, 
yellow arrow). The 3D VRT reconstructions demonstrated minor catheter leak (right, yellow arrow). B: CAP-
CT MPR myelography showed dural leak at the original insertion of a migrated catheter (green arrow), with 
at the opposite site the newly inserted catheter (orange arrow). C: CAP MIP myelography showed minor 




This study confirmed that an appropriate di-
agnosis, or identifying an abnormality, can 
often not be made with CAP fluoroscopy and 
myelography only, which limits their value 
when not followed routinely by CAP-CT my-
elography. Therefore, the use of only CAP-CT 
myelography has been suggested.18 However, 
fluoroscopy provides a screening overview that 
makes it possible to identify sufficient intra-
thecal distribution of contrast material, which 
is crucial for an optimal diagnostic CT myelog-
raphy examination. An optimal distribution of 
contrast material can be achieved through ro-
tation and turning of the patient in different di-
rections, including the Trendelenburg position. 
An inadequate distribution of contrast material 
could result in false-positive examinations, as 
the limited distribution may be interpreted as 
a CSF flow obstruction. Therefore, when flu-
oroscopy reveals insufficient contrast material 
distribution in the intrathecal space, the Tren-
delenburg maneuver should be performed or 
repeated. 
CAP-CT myelography
Through the use of CT myelography extend-
ed with 2D MPR/MIP and 3D VRT post-pro-
cessing reconstructions, we achieve substantial 
improvement in diagnostic accuracy. The found 
sensitivity and specificity of the spinal CT my-
elography examinations indicated the useful-
ness of the proposed procedure. However, the 
extra-vertebral parts of the ITDD system should 
be included in the reconstructed FOV to de-
tect rare catheter leaks or dural leaks that only 
become manifest as a result of accumulations 
of contrast material in the pump pocket. This 
unexpected finding was caused by retrograde 
flow of CSF and contrast material along the im-
planted catheter to the pump pocket in cathe-
ter and dural leaks. This means that, when fluid 
accumulation in the pump pocket is detected, a 
dural leak should be considered. 
The reduction of beam-hardening artifacts on 
DECT facilitated the identification of fluid in 
the pump pocket and leaks at the metal cathe-
ter–catheter connection. However, beam-hard-
ening reduction should be used carefully when 
one suspects a leak in the pump pocket, which 
can cause more irregular scattering that resem-
bles beam hardening. The diagnosis of a leak 
could be overlooked when a strong beam-hard-
ening reduction algorithm is applied. 
The observed accumulation of the contrast 
material in the subdural space, with a faint 
distribution in the intrathecal space, due to a 
subdural location of the catheter is rare. The 
subdural cavity between the meningeal layer 
of the dura mater and the inner arachnoid ma-
ter of the leptomeninges that are adherent to 
each other usually does not exist.19 One of the 
explanations is unintentional separation during 
puncture.20, 21 
In all of the patients with an unintended epi-
dural catheter, the cause was not a dural perfo-
ration at the tip of the catheter but an epidural 
position starting at the dural insertion. Despite 
the epidural location, aspiration of 2 ml via 
the CAP was possible. It seems that, despite 
low-volume infusion, epidural fluid accumula-
tion occurs when tissue absorption is insuffi-
cient, which is likely related to epidural fibrosis 
as a result of long-term infusion.22-24
After identifying normal rostral distribution 
with scintigraphy, we accepted the finding of 
the curved catheter in the intrathecal space 
as normal in the absence of further complica-
tions.25 Although an intracranial subarachnoid 
hemorrhage can occur as a result of the intra-
thecal catheter migration of a retained cathe-
ter,26 the standard approach in the absence of 
clinical symptomatology is not to remove it.25 
However, the situation is different when the re-
tained catheter creates a fistula in the surround-
ing tissue that leads to a CSF leak, which was 
fortunately not present in our series. 
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Additional imaging procedures
When we cannot assess the cause of ITDD fail-
ure with CAP-CT myelography, we normally 
proceed with other imaging modalities, such 
as MRI and/or lumbar puncture CT myelog-
raphy. In particular, when we needed dynam-
ic information concerning catheter flow or the 
distribution of intrathecal contrast material, 
we performed 111In-DTPA SPECT-CT scintigra-
phy. Owing to the high accuracy of 111In-DTPA 
SPECT-CT, it is open to discussion whether the 
primary choice for ITDD troubleshooting should 
be CAP-CT myelography or 111In-DTPA SPECT 
CT scintigraphy.11 We prefer our modified (DE)
CT-CT myelography, as it offers excellent possi-
bilities in terms of identifying flow obstruction, 
catheter kinking, and leak. Further advantages 
are that puncturing the CAP provides an oppor-
tunity to aspirate CSF for diagnostic microbio-
logical and pharmacological examinations. For 
therapeutic purposes, the intrathecal catheter 
content can be aspirated after an overdose or 
for complex dose concentration changes. More-
over, a bolus dose of the current medication, an 
additional drug, or contrast material for con-
trolling the ITDD can be injected via the CAP. 
CAP-CT myelography generally provides more 
local information, than low-dose 111In-DTPA 
SPECT-CT. In dural and catheter leaks, the more 
detailed images of CAP-CT myelography are 
essential in the treatment. However, 111In-DT-
PA SPECT-CT is of value when no fluid can be 
aspirated via the CAP. In addition, when a nor-
mal-shaped limited flow is identified and there 
is no certainty that the Trendelenburg position 
has been appropriately performed, scintigraphy 
can be used to visualize the physiologic fluid 
distribution. In both methods, however, identi-
fying fluid in the pump pocket can be an issue. 
In CAP-CT myelography, pump scattering can 
mask the presence of fluid, although the irreg-
ular scattering of fluid differs from that of beam 
hardening caused by the pump. The problem 
can be overcome by reducing the scattering via 
advanced CT techniques like DECT. We found 
that, in 111In-DTPA SPECT-CT, the intense tracer 
activity in the pump is not an obstacle to as-
sessing aberrant fluid in or nearby the implant-
ed pump with the use of image scaling and the 
progression of the fluid accumulation during 
multiple imaging sessions. Hence, we disagree 
with those who advocate reserving the CAP-
CT procedure only for emergencies and using 
111In-DTPA in all non-acute situations.11 As 
the first line of advanced imaging in trouble-
shooting, the advantages of scintigraphy do 
not outweigh the convenience and accuracy 
of a CAP(-CT) myelographic procedure, even 
when one not consider the burden placed on 
the patient, the costs, and the low likelihood of 
availability in every center. 
Study limitations
The analysis of the observational routinely col-
lected data was intended to evaluate the diag-
nostic role of CAP-CT myelography in ITDD 
failure and to improve the procedure and the 
evaluation of its results. A limitation is that the 
data analysis could not be addressed using ex-
isting reporting guidelines such as STrength-
ening the Reporting of OBservational studies 
in Epidemiology (STROBE).27 Nevertheless, 
routinely collected data are frequently used to 
improve patient care and health care efficiency. 
To our knowledge, our study is the most exten-
sive analysis; however, the sample size is small. 
In addition, the retrospective character of this 
research presents a chronology bias;28 how this 
might have influenced our conclusions must be 
considered. To reduce misclassification bias, all 
images were reassessed. The most important 
limitation is the unstructured approach to data 
collection, which resulted in the absence of a 
standardized reference test based on a second 
imaging modality or surgery to determine the 
real cause of ITB failure. Instead, we composed 
the reference based on all available data, in-
cluding the index test, additional imaging mo-
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dalities, surgery, and wait-and-see results. De-
spite the bias in the design of this study, the 
data suggest that CAP myelography followed 
by CAP-CT myelography are indispensable 
steps in determining the causes of ITDD treat-
ment failure.
Conclusions
In our view, the main contributions of this arti-
cle are as follows:
•  After plain radiography, CAP-(DE)CT my-
elography with image reconstructions of the 
spinal and extra-vertebral regions in combi-
nation with 2D MPR/MIP and 3D VRT re-
constructions is a first-line advanced imaging 
procedure for cases involving ITDD failure 
and can serve as the standard in the majority 
of the cases on which treatment decisions can 
be based. However, we experienced a sub-
stantial overlap with 111In-DTPA SPECT-CT in 
the final diagnosis. 
•  Failure to aspirate CSF via the CAP does not 
indicate a catheter failure in all cases. When 
aspiration is not possible, an NCCT-scan 
should be performed to exclude an epidural 
catheter position.
•  Solely conducting CAP myelography is insuffi-
cient for the diagnosis of ITDD but it has value 
in facilitating needle insertion of the CAP and 
as a screening method determining sufficient 
distribution of the contrast material, which is 
crucial for a diagnostic CAP-CT myelography.
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In 65 of the 70 procedures, we could retrieve 
data about the needle insertion in the CAP fun-
nel. In 40 cases, we had a regular needle inser-
tion, and in 19 and 6 cases the needle insertion 
was associated with mild and severe needle 
bending, respectively (eFig.1). 
Discussion
For puncturing the CAP, a nearly perpendicu-
lar approach to the funnel-shaped opening is 
required to recognize and pass the built-in sili- 
cone septum. We experienced a tendency of 
bending and distortion of the thin needle—in 
particular, in a more deeply positioned pump, 
or in the presence of rigid fibrotic scar tissue—
which causes the procedure not to be easy. 
When the extended fibrotic reaction is present 
around the pump, the recognition of the stiff 
fibrotic tissue or the CAP silicone membrane 
eFigure 1: Needle insertion of the catheter access port (CAP) funnel with mild (A) and severe needle bending 
(B–D).
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eFigure 2: Huber needle for pump reservoir refill (A). A conical-shaped Huber CAP needle with a proximal 
diameter of 22G, and a distal one of 24G, is suggested to prevent needle distortion (B). Current Huber needle 
for CAP insertion (C). Another improvement would be a template of the CAP kit with a partially open ring 
(D, gray arrow).
can be problematic. This occurrence plays a role 
when we cannot aspirate fluid. In our opinion, 
there is, therefore, an urgent need for improve-
ment of the insertion with the vulnerable 24G 
Huber needle. We are convinced that the com-
plexity of the CAP needle insertion plays an 
essential role in omitting the procedure men-
tioned in the literature.15
Proposal
A solution for the vulnerable 24G Huber nee-
dle could be the use of a conical 20G–24G one 
(eFig.2). We have (as of yet) been unable to 
find a manufacturer of such a needle. 
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To assess the feasibility and diagnostic accuracy of an optimized 111Indium-diethylenetriamine-penta-acetic- 
acid Single Photon Emission Computed Tomography (111In-DTPA SPECT-CT) examination in patients with 
 intrathecal drug delivery (ITDD) failure.  
Design
Retrospective analysis of observational, routinely collected data from a case series of patients.
Setting
University Center for Pain Medicine and Department of Radiology & Nuclear medicine.
Participants
Twenty-seven patients participated between January 2014 and January 2019. Thirty-six examinations were 
performed. 
Methods
Standardized pump flow rate with additional SPECT-CT imaging was performed. Ten ml mixture of the treat-
ment medication and 20 MBq 111In-DTPA was injected in the pump reservoir. Planar and SPECT-CT images 
were acquired at 24, 48, and 72 h after injection, and at 96 h and/or 7 days, if needed. Reassessment of all 
images by the first two authors according to a conventional analysis on planar imaging and to optimized 
analysis with evaluation of SPECT-CT images, taken into account a standardized pump flow rate and with a 
stepwise standardized interpretation.    
Results
Twenty-two abnormalities in twenty-one examinations were identified, consisting of: leakage (n=7), spinal 
catheter obstruction (n=7), and cerebrospinal fluid flow obstruction (n=8). Interventions (n=19) confirmed 
the cause of ITDD failure. CSF flow obstruction turned out to be false a positive finding at follow-up (n=1). 
In the 15 normal examinations one false negative finding was encountered. The sensitivity was 95% (20/21) 
and the specificity 93% (14/15). A a significant difference (p < 0.000) was found between the accuracy of the 
conventional analysis and optimized analysis. 
Conclusions
The optimized 111In-DTPA SPECT-CT examination is a powerful diagnostic to detect the cause of ITDD failure.
Keywords 




Intrathecal baclofen or analgesic drug deliv-
ery (ITDD) using an implanted pump system 
is a well-established treatment with approx-
imately 30,000 implants per year. Despite ad-
vancements in manufacturing technology and 
implantation techniques, a high incidence of 
adverse events and therapy failure is reported.1-4 
For many years, consensus guidelines for trou-
bleshooting in ITDD were lacking, which may 
increase the risk of underdiagnosis, undertreat-
ment, unneeded surgical interventions, or even 
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unjustified termination of therapy. ITDD failure 
has an enormous impact on the patients’ quality 
of life, because it is the last-resort therapy for 
many patients. Tolerance for treatment,5 exacer-
bation of the underlying disorder or comorbid-
ity as a cause of the failure should therefore be 
concluded after extensive diagnostic procedures 
only. Recently, an expert panel developed an al-
gorithm to reach consensus on the optimal diag-
nostic approach in ITDD failure,6 and a guideline 
for the interpretation of the plain radiography 
was published.7 The indications for more ad-
vanced diagnostic procedures are 1) a decrease 
in the effectiveness of ITDD; 2) a discrepancy 
between obtained residual volumes by the re-
fill procedure and those calculated by the pump 
device; 3) manifest or occult drug and cerebro-
spinal fluid (CSF) leakage, or 4) a repeated and 
sometimes extremely high dose increase with-
out a sufficient clinical response.6,8,9 In suspected 
ITDD failure, the initial steps in the diagnostic 
approach are clinical history taking9, a readout 
of the pump programming, a check for the pres-
ence of medication fluid in the pump reservoir, 
and plain radiography examinations.7 However, 
when this approach is inconclusive, there is no 
consensus on the further evaluation. The pos-
sible next steps could be the aspiration of CSF 
from the intrathecal space via the catheter ac-
cess port (CAP)6,9, contrast material injection via 
the CAP combined with computed tomography 
(CT) myelography,6,10,11 high-resolution CT with 
two-dimensional (2D) and three-dimensional 
(3D) reconstructions12, or a surgical catheter or 
pump revision (without diagnostic procedures 
before surgery). When the first three steps do 
not reveal the cause, 111Indium-diethylenetri-
amine-penta-acetic-acid (111In-DTPA) scintig-
raphy could be performed.5,8-10,13-18 Some clini-
cians even bypass the CAP procedure and use 
111In-DTPA imaging as the next step after plain 
radiography.19 With its long radioactive half-
life time of 2.8 days, 111In-DTPA offers unique 
possibilities for dynamic imaging studies. After 
injecting into the pump reservoir images can be 
acquired for several days following the radio-
tracer distribution in the spinal catheter system 
and the subarachnoid space, without interrupt-
ing drug treatment.13-15,17 99mTechnetium-DTPA 
has also been used for this purpose5,13, but due 
to 99mTechnetium’s limited half-life time of six 
hours, the pump must be reprogrammed for 
a high delivery rate, which will hamper track-
ing of tracer spread with a regular flow rate. 
 Furthermore, the pump reservoir, the inner 
pump tubing, and the spinal catheter must be 
emptied in advance to prevent a drug overdose 
due to the increased flow rate.5 
Although 111In-DTPA scintigraphy has been per-
formed for several decades, published data are 
limited. Moreover, different scanning methods 
have been used, and there is no consensus on 
image interpretation, normal flow patterns and 
diagnostic criteria for determining ITDD fail-
ure.15 In this retrospective study of observation-
al, routinely collected data, we intend to assess 
the feasibility and diagnostic accuracy of an 
optimized 111In-DTPA protocol. This optimized 
111In-DTPA protocol includes standardization 
of the pump flow rate, performing additional 
single-photon-emission low-dose computed 
tomography (SPECT-CT) imaging and the use 
of a standard evaluation format for image in-
terpretation. We hypothesize that an optimized 
111In-DTPA scanning protocol and analysis in-
cluding evaluation according to a standard for-
mat is needed and that SPECT-CT is a useful 
addition to planar imaging.
Materials and methods
We included all adult patients who underwent 
111In-DTPA scintigraphy for ITTD failure evalua-
tion between January 2014 and January 2019. 
All patients except one were referred from 
other centers for ITTD troubleshooting. In all 
patients, conventional diagnostic modalities in-
cluding clinical history, a readout of the pump 
programming, accurate aspiration volume ver-
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sus interrogated, or plain radiography did not 
reveal the diagnosis. In 2014, the optimized 
111In-DTPA protocol and analysis (OP, Table 1) 
was implemented in our center.  Standardiza-
tion of the pump flow rate allows the evalu-
ation of tracer transit time which is crucial for 
a correct interpretation of the images. From 
cerebral fluid flow studies20, 21, it is known that 
the upward flow from caudally up to the ce-
rebral cisterns takes 2 to 2.5 h, with a steady 
state reached after 8 h. With the infusion rate 
we used, in which the catheter tip is reached 
in 24 h, the cerebral cisterns should be visible 
at 48 h after the filling of the pump, due to 
both CSF flow as well as passive tracer diffusion 
in the CSF. The additional SPECT-CT is intend-
ed to obtain more detailed information about 
the location of a potential flow disorder. This 
retrospective study has been approved by the 
Medical Ethics Committee of the EMC, with a 
waiver of informed consent (MEC-2017-326). 
111In-DTPA scintigraphy
Approximately one week before the scheduled 
scintigraphy, a readout of the pump program-
ming features for information on the catheter 
properties and the medication concentration was 
performed. The expected transit time for reach-
ing the catheter tip was calculated. When the 
catheter end would not be achieved in 24 h, the 
pump was programmed for a bridge bolus. This 
includes a bolus delivery of the old drug concen-
tration at the rate necessary to empty the inner 
pump tubing and catheter when a new drug 
concentration has been placed into the reser-
voir22,23, which usually takes one to several days.
At the nuclear medicine department, 10 ml of 
the patient’s medication mixed with approx-
imately 20 MBq 111In-DTPA (in 0.3-0.5 ml) 
was prepared under aseptic conditions. Next, 
a nurse practitioner emptied and refilled the 
pump  reservoir with the prepared mixture us-
ing the standard refill technique. Subsequently, 
planar and SPECT-CT images were acquired at 
24, 48, 72, and - if needed - 96 h and/or 7 
days after pump filling using a Siemens Sym-
bia T16 SPECT-CT scanner (Siemens Health-
care, Erlangen, Germany). Planar images (256 
x 256 matrix, medium-energy limited purposes 
(MELP) collimator) were acquired from anterior 
and posterior of the pump/abdomen region, 
the thorax, and the head/neck region with an 
acquisition time of 10 minutes per view (and 
20 minutes at 7 days post-injection). After that, 
SPECT-CT was acquired for verification, atten-
uation correction and anatomical localization. 
SPECT parameters were 128 x 128 matrix, 60 
views/detector, 30-second time per view. Low-
dose CT parameters were: 110 kV, 40 mAs, a 
0.6-second tube rotation, 0.8 mm pitch, and a 
5-mm slice thickness. 
111In-DTPA scintigraphy evaluation
The goal of the evaluation was to assess the 
cause of ITTD treatment failure. Potential caus-
es could be pump malfunction, leakage at the 
pump-catheter connection or the connection of 
the two catheter segments or from the catheter 
itself, catheter occlusion, and/or CSF flow ob-
struction at the catheter tip or elsewhere in the 
spinal canal. The first two authors (ED, DvA) 
evaluated the planar images according to the 
conventional analysis (CA) which was distilled 
from six case studies in literature13-17 In these 
studies imaging is performed after 4 to 72 h14-
18. In some publications, progression time of 
tracer through the catheter was calculated, and 
- if needed - the time for imaging was custom-
ized.17,18 When the tracer progressed along the 
subcutaneous and intrathecal catheter part and 
the tracer was distributed14 evenly throughout 
the cerebral cisterns, without any signs of leak-
age, the examination was regarded as normal 
(Table 1).17 All previous studies were done with-
out a standardized pump flow rate, without 
SPECT-CT18 except in one study, and without 
a standardized stepwise imaging interpretation.
Thereafter they reanalyzed the images based 
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on the optimized 111In-DTPA scanning protocol 
(OP) and analysis with evaluation of SPECT-
CT images, taking into account a standardized 
pump flow rate and with a stepwise standard-
ized interpretation (Table 1).
Conventional analysis (CA)
- Planar imaging assessment
Optimized practice (OP)
- Planar imaging assessment
- SPECT-CT assessment
- Standardization pump flow rate
- Stepwise standard interpretation
The stepwise and standardized interpretation of 
the images included the following: 
• Step 1. Is the pump flow rate standardized?
•  Step 2. Is access to patient’s file and previous 
other imaging procedures available?
•  Step 3. Is the pump visibility, is tracer activity 
around the pump visible, and has the tracer 
activity a normal shape?  
•  Step 4. Are the abdominal horizontal cathe-
ter segments visible, is normal tracer spread 
in the subcutaneous part of the catheter from 
anterior to posterior present?
•  Step 5. Is the tracer activity at the horizon-
tal/vertical catheter transition, normal or en-
hanced?
•  Step 6. Is caudal spread of tracer activity vis-
ible, if yes, is the tracer activity normal, en-
hanced or broadened? When visible, is tracer 
activity already present at the catheter tip?
•  Step 7.  Is tracer activity present in kidneys/
bladder/elsewhere in abdomen? When vis-
ible, is tracer activity already present at the 
catheter tip?
•  Step 8. Is the distribution of tracer activity 
spread in the lumbar and thoracic catheter 
segment in the spinal canal, normal? Is the 
intensity of tracer activity increased or has it 
a broader aspect? Is increased tracer activity 
accumulation present at catheter tip?
•  Step 9. Is tracer activity visible in the spinal ca-
nal above the level of the catheter tip, and in 
the cerebral cisterns. Has the tracer activity a 
normal intensity? Do we have relative differ- 
ences in tracer activity?
 Data analysis 
The sensitivity and specificity were calculated, 
comparing the results of the imaging assess-
ment (conventional analysis and optimized 
analysis) as the index test and the final diag-
nosis after three months as the reference test, 
which was based on all relevant imaging and 
clinical and surgical information. 
A true positive result was thereby defined when 
an abnormality could be demonstrated with the 
index test and the reference test revealed in-
deed a cause of ITDD failure, a true negative 
when an abnormality was not found with the 
index test and the reference test, a false posi-
tive when an estimated abnormality could not 
be confirmed by the reference test, and a false 
negative when the abnormality was missed. 
The accuracy of the conventional analysis and 
the optimized 111In-DTPA procedure were com-




Thirty-six 111In-DTPA planar and SPECT-CT ex-
aminations were performed in 27 patients. In 7 
patients, the examination was performed two 
times and three times in one patient. Patient 
characteristics are summarized in Table 2. In all 
drug delivery standardization procedures with 
the bridge bolus and in all scintigraphy exam-
inations no adverse events were encountered.
The reference standard (Table 2) was the results 
obtained with the optimized procedure analysis 
(n=17), including optimized planar (n=16) and 
SPECT-CT (n=1) or findings during intervention 
(n=19). With the conventional analysis 11 of 36 
Table 1. CA versus OP.
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Figure 1. Examples of planar images from 9 examinations with a standardized pump flow rate of the abdo-
men, thorax and head region (resp. lower, middle and upper row). 
Upper row: normal (A, B, C) and reduced (D–I) tracer activity at the cerebral cisterns. 
Middle row: enhanced tracer activity at catheter tip (F, white arrow), renal tracer activity (H, gray arrows).
Lower row: enhanced tracer activity at the lumbar horizontal-vertical transition (A-C,E,F,I, yellow arrows), 
invisible first catheter segment (A-F, red arrows), caudal tracer activity (B-D, blue arrows), only pump visible 
(G,H), renal activity (H, gray arrows), abnormal pump shape (I, dark gray arrow), enhanced tracer activity at 
catheter tip (F, white arrow).
examinations revealed a suspected pump-cath-
eter related cause of ITDD failure including 
leakage (n=1), catheter obstruction (n=4), CSF 
flow obstruction (n=4), and a visible pump only 
(n=2). With the optimized 111In-DTPA proto-
col and analysis 22 abnormalities were found 
in 21 examinations: leakage (n=7), catheter 
obstruction (n=7), and CSF flow obstruction 
(n=8). In one examination, two abnormalities 
were found: catheter obstruction and leakage 
at the pump-catheter connection (Figs. 1E, 2). 
Fifteen examinations did not reveal the cause of 
ITDD treatment failure. In 19 of these 21 exam-
inations, interventions confirmed the cause of 
ITDD failure, while after 1 positive examination 
no surgical intervention was performed. In one 
examination the diagnosis of CSF flow obstruc-
tion based on limited rostral tracer distribution 
turned out to be a false positive finding at fol-
low-up. In the 15 normal examinations one 































































































































































































































































































































































































































































   
   
   
   
   







   
   
   
   
   


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Seven examinations revealed leakage. Only 
two were clearly recognized on planar images, 
which showed only tracer activity In the pump 
or an abnormal pump shape (n=1, Fig.1I, dark 
gray arrow), and additional SPECT-CT con-
firmed the presence of tracer activity outside the 
pump in the pump pocket. The remaining cases 
of leakage were found with SPECT-CT (n=5): 
leakage in the pump pocket (n=1) caused by 
a sheared catheter located in the pump pocket 
(Fig.2G-J), retrograde  leakage via a retained 
extrathecal-intrathecal catheter segment (n=1, 
Fig.1C), increased dorsal lumbar subcutaneous 
tracer accumulation due to dura leakage (n=3), 
in one of them the dorsal leakage was also as-
sociated with tracer activity in the pump pock-
et, probably caused by CSF passing backwards 
alongside the subcutaneous part of the cathe-
ter into the pump pocket. One false negative 
finding was encountered when due to the per-
sistent ITB failure, a catheter replacement was 
performed, whereby minor catheter damage of 
the intrathecal catheter part was found. 
Figure 2. Sheared catheter and leakage in the pump pocket in a 59-year-old male with spasticity with a spinal 
cord lesion at T5. Dorsal tracer accumulation in the drug delivery system parts (A, green arrow) including 
needle-shaped catheter-catheter connector (B,C, blue arrows), anchor (B,C, black arrow) and retained old-
type anchor (B,C, white arrow). Enhanced tracer activity at the abdominal/lumbar transition (A, lower row) 
with limited tracer activity in the cerebral cisterns (A, upper row) was suspicious for catheter obstruction. 
SPECT-CT fusion images show enlargement of the pump shape (D, red arrow) and some fluid outside the 
pump pocket (F-I, gray arrows). At surgery fluid in the pump pocket was identified (J, gray arrow) caused by 
a sheared catheter. Also, at surgery a catheter obstruction was found.  Post-explantation image of the system 
showed a catheter-pump connector distortion (K, orange arrow) and a sheared catheter (K,L, purple arrow).
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Figure 3. A 54-year-old woman with pain caused by failed back surgery, in which a readout of the pump 
revealed a normal pump delivery rate. Planar image (A) revealing a normally shaped pump, with subtle 
tracer activity in the kidneys (A, gray arrows), and no tracer activity in the catheter segments. SPECT-CT 
(B-D) confirmed tracer activity in the kidneys (B, gray arrows) and in the bladder (C, yellow arrow), and no 
signs of tracer activity around the pump in the pump pocket (D, red arrow).  The subtle tracer activity outside 
the pump (in kidneys and bladder) means that the tracer passed the inner pump tubing and has reached 
the pump access port, which excluded a pump device failure. The normal pump shape and lack of tracer 
activity around the pump in the pump pocket (A, D) makes leakage at the pump catheter-connector also very 
unlikely. A subtotal catheter obstruction was therefore considered, alt-hough the lack of tracer activity in the 
catheter segments could not be fully explained. MRI revealed a granuloma at the tip of the catheter which 
was confirmed at surgery.
Catheter obstructions
Seven catheter obstructions were found. Five 
were recognized at planar imaging with con-
ventional analysis with augmented tracer ac-
tivity at the catheter tip with a minimal rostral 
spread (n=3, Fig.1F), increased tracer activity at 
the abdominal horizontal-vertical lumbar cath-
eter transition (n=1, Fig.1E) , and with tracer 
activity in the pump only (n=1, Fig. 1G), and 
associated with tracer activity in the kidneys 
and bladder (n=1,Fig.1H,3A-C). In the latter 
patient a granuloma at the catheter tip was de-
tected during surgery. Two examinations were 
considered normal with conventional analysis, 
but optimal analysis interpreted increased activ-
ity at the abdominal horizontal-vertical lumbar 
catheter transition as obstruction (n=2, Fig.1E). 
CSF flow obstruction
In eight examinations CSF flow obstruction was 
diagnosed and one of them was a false positive 
finding. Four of the remaining seven diagnoses 
could be based on planar imaging with conven-
tional analysis. Planar and SPECT-CT images of 
the optimized protocol and analysis indicated 
CSF flow obstructions (n=8). One of them was 
a false positive finding. The remaining sev-
en showed lumbar broadening and extended 
caudal activity in combination with invisible or 
limited visible cerebral cisterns (n=5, Fig.1D,4), 
gradually increasing caudal activity in combina-
tion with reduced rostral flow (n=1, Fig. 5), or 
only limited rostral flow (n=1).
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Figure 4. CSF flow obstruction in a 47-year-old female with spasticity with a spinal cord lesion at T10. 
Planar imaging at 48 h (A), 72 h (B) and 7 days after injection (C) revealed increased lumbar-caudal tracer 
activity (yellow and blue arrows) and tapering of tracer activity with reduced rostral tracer activity spread 
(green arrows) without tracer activity at the cerebral cisterns. SPECT-CT images (D,E) also showed increased 
tracer activity at the lumbar-caudal level (blue arrow) and tapering of tracer activity (green arrow). The 3D 
reconstruction image (F) clearly shows pronounced lumbar tracer activity (yellow arrow) and tapering of 
tracer activity (green arrow) more rostrally.
Figure 5. CSF flow obstruction in a 46-year-old 
male with spasticity with a spinal cord lesion at C5. 
Planar images at 48 h (A), 72 h (B) and 7 days after 
tracer injection (C) show increasing caudal tracer 
activity (blue arrows) over time, pronounced tracer 
activity at lumbar level (yellow arrows), a thoracic 
gradient above the catheter and insufficient rostral 
tracer distribution with reduced tracer activity at 
the cerebral cisterns (green arrows). Images are 
suspicious for a CSF flow obstruction.
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Accuracy of conventional and optimized 
analysis
The conventional analysis data showed true 
positives (n=11), false positives (n=0), true 
negatives (n=15), and false negatives (n=10). 
The calculated sensitivity was 52% (11/21) 
and the specificity 100% (15/15). The results 
of the optimized 111In-DTPA SPECT-CT proce-
dure revealed true positives (n=20), false pos-
itives (n=1), true negatives (n=14) and false 
negatives (n=1). The calculated sensitivity was 
95% (20/21) and the specificity 93% (14/15). 
A significant difference (p<0.001) was found 
between the accuracy of the conventional anal-
ysis and optimized analysis. 
Discussion
Based on the analysis of this retrospective study 
on observational routinely collected data, we 
confirmed the importance of our optimized 
111In-DTPA SPECT-CT examination. Moreover, 
it was found that optimized 111In-DTPA SPECT-
CT scintigraphy is a powerful diagnostic tool 
in ITDD failure when conventional diagnostic 
modalities do not reveal the cause. In most of 
the examinations with the optimized analysis, 
we were able to correctly diagnose the cause of 
ITTD failure, which was an improvement com-
pared to the conventional analysis. Our study 
indicate that planar imaging combined with 
SPECT-CT is an adequate technique to identify 
and localize functional alterations resulting in 
a correct diagnosis. In chronic ITTD treatment, 
the penetration of tracer activity into surround-
ing tissue can be hindered by a fibrotic layer 
around the pump, which impedes the diagnosis 
of leakage. The very intense tracer activity in 
the implanted pump itself could be an obstacle 
for the detection of aberrant fluid around the 
pump, however, image scaling of both planar 
and SPECT-CT images could facilitate separa-
tion of fluid inside the pump reservoir and in 
the surrounding pump pocket. 
To be certain that imaging is performed af-
ter tracer activity reaches the catheter tip and 
preventing potential misinterpretations, we 
implemented a standardized pump flow rate 
and changed the timing of scanning to 48 h, 
96 h, and seven days after pump filling. With-
out the standardization of the pump flow rate, 
the timing of tracer activity to reach the tip is 
unclear. As a result, the diagnosis of a partial 
obstruction characterized by a delayed and/or 
reduced rostral visibility will be missed. There-
fore, the published statement that the presence 
of any amount of tracer activity in the intrathe-
cal space14 and the cerebral cisterns17 indicates 
absence of an abnormality is not justified. 
Also, imaging should not be limited to a single 
time point, as leakage and partial obstruction 
can become more and more apparent over 
time. Increased tracer activity at the horizontal 
and vertical catheter transit position should be 
evaluated for possible overprojection of cathe-
ter parts, connector and/or fixation anchor. An-
other concern is visible tracer activity below the 
level of the tip of the catheter when the tracer 
has already reached the cisterns. We experi-
enced that in the majority of the normal cases 
intrathecal tracer activity is not found below 
the level of the tip. This could be related to the 
extremely low-volume pump infusions in con-
trast to large volume of contrast material bolus 
injections in radiographic examinations. When 
caudal tracer activity is present, the distinction 
between a normal variant and an abnormality 
cannot easily be made. From a clinical perspec-
tive, caudal tracer activity accumulation could 
be relevant in ITDD failure.24 The catheter tip 
in this reported case was positioned at level L5 
for surgical reasons. Scintigraphy showed stag-
nation of the tracer activity at that low lumbar 
level and did not transit upwards, which was 
interpreted as the cause of the ITDD failure.
To identify stagnation in the drug delivery, it is 
crucial to observe the amount of tracer activity 
in the cerebral cisterns. A blockage of the ros-
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tral tracer distribution with broad caudal, lum-
bar, and thoracic tracer activity is suspect for 
an obstruction in rostral CSF flow. The analysis 
demonstrates that with the optimized proce-
dure, we could not only estimate normal func-
tioning or a malfunction of the delivery system, 
but with the standardized pump flow rate we 
could easier diagnose an obstructed intrathecal 
rostral CSF flow. With SPECT-CT, we were able 
to confirm the suspected problems as revealed 
on the planar images, and we could also local-
ize the problem. 
Study limitations
Routinely collected data are frequently used to 
improve patient care and health care efficiency. 
In our study, we intended to evaluate the diag-
nostic role of 111In-scintigraphy in ITDD failure 
and to improve the procedure and the evalu-
ation of its results. However, the retrospective 
nature of the study hampers the application of 
reporting guidelines such as STrengthening the 
Reporting of OBservational studies in Epide-
miology (STROBE).25 Although, to our knowl-
edge, the analysis is the most extensive the 
sample size is small. In addition, a chronology 
bias26 is presented by the retrospective charac-
ter of the study, and this might have influenced 
our conclusions must be considered. We reas-
sessed all images to reduce a misclassification 
bias. However, the most critical limitation is the 
unstructured approach to data collection, which 
resulted in the absence of a harmonized refer-
ence standard to determine the real cause of 
ITDD failure. Instead, we composed the refer-
ence based on all available data, including the 
index test, additional imaging modalities, sur-
gery, and clinical information such as the result 
of dose adaptations, and follow-up. Despite the 
bias in the design of this study, the data suggest 
that the optimized 111In-DTPA SPECT-CT proce-
dure is an indispensable step in determining the 
causes of ITDD treatment failure.
Conclusion
The results of this study indicate that an op-
timized 111In-DTPA SPECT-CT procedure and 
analysis is a powerful diagnostic tool in cases 
of ITDD failure when previous conventional ex-
aminations do not reveal the cause for failure. 
The method is crucial not only for determining 
suspected infusion system malfunction but also 
for examining possible hindrance in the rostral 
intrathecal distribution of medication. Sizable, 
prospective, multicenter cohort studies are 
needed to develop consensus criteria for the 
role of isotopic scintigraphy in ITDD trouble-
shooting.
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 Isotopic scintigraphy in intrathecal drug delivery failure
Several paroxysmal baclofen withdrawal events. Plain radiography revealed a curled catheter just after the 
catheter fixation anchor (yellow arrow). CAP myelography revealed a normal myelogram. Based on this 
patient was considered ITB-tolerant. 111Indium-DTPA scintigraphy performed at the referral for a second 




Normal pattern of activity spread on planar (upper row) and SPECT CT images (lower row) 48 h after injecting 
111Indium-DTPA in the pump reservoir with standardized pump flow rate of reaching the catheter tip at 24 h.
Planar image revealed visible pump (A), no activity in catheter (B) and cerebral cisterns (C, red arrow). The 





In this case, planar image revealed activity in pump (A) and in kidneys (A,B, gray arrows), no activity in 
catheter (B), and cerebral cisterns (C, red arrow). Possible cause could be disconnection of pump/catheter or 
leakage of pump/catheter. A pump failure is not likely. 
A B C
A B C
 In vivo images during surgery (D), revealed fluid in 
pump pocket (green arrow), and activity in catheter 
access port funnel (E, blue arrow), which explained 
the abnormal shape (A, yellow arrow). Causes could 
be leakage somewhere in the drug delivery system or 
at dura insertion of catheter.
Planar images (left) revealed abnormal pump shape (A, yellow arrow), activity in catheter and thoracic 
subarachnoid space, and limited activity in cerebral cisterns (C, orange arrow).
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SPECT-CT images revealed remarkably increased pump activity (A–C, red arrow) and gradually increasing 
activity outside the pump (A–C, gray arrow). In vivo image during surgery (D, blue arrow) revealed fluid 
in pump pocket, which was caused by sheared Ascenda catheter (E,F, green arrow), and distortion pump–
catheter connection (E, yellow arrow).
In vivo images during surgery revealed old type 
sutured pump–catheter connector (A, red arrow), 
and by suture sheared catheter (B, yellow arrow) 




A B SPECT-CT revealed leakage at dorsal connector of 
the catheter segments (A,B, yellow arrow). Fluid 
passed along catheter to the pump pocket resulted 
in deformed pump shape (B, red arrow). At physical 
examination (C), in deeply implanted pumps, fluid 
in the pump pocket often cannot be recognized, 
whereas in other cases, it can be found easily (red 
arrow). In this particular case, the migration of a 
previously implanted intrathecal catheter resulted  in 
dura  leakage. A repeated homolog epidural blood 
patch solved the problem (Page 134).
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SPECT CT images (D–F) revealed a normal pattern, probably with minimal caudal activity. Clinically, signs of 
post-spinal headache were not present, and an explanation of treatment failure was not found. 
Planar images (A–C) revealed normal activity in pump, catheter, thoracic space, and cerebral cisterns. There 
was limited caudal activity (A, green arrow), which could be normal or limited CSF leakage.
D E F
A B C
Planar images (A–C) revealed normal activity in pump, catheter, thoracic space, and cerebral cisterns. 
Question: increased caudal activity (A, yellow arrow)?
A B C
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SPECT CT images (D–G) revealed intrathecal activity spread (green arrow) 
and remarkable increasing caudal activity (yellow arrows). Diagnostic 
dilemma: Normal or abnormal caudal activity spread? The initial conclusion 
was a normal variant; however, because of persistent treatment failure, 
revision of the intrathecal catheter segment was performed, whereby an 
intrathecal catheter leak was found.
D E F G
Plain X-ray (D), and artist rendering (E, blue line and blue arrow) revealed 
a retained catheter. SPECT-CT images (F,G) revealed remarkable increasing 
caudal activity (yellow arrows), caused by backflow via retained catheter 
segment (E, blue arrow).
Planar images (A–C) revealed normal 
activity in pump, catheter, thoracic 
space, and cerebral cisterns. Limited 





Planar images (A–C) revealed normal activity in pump and catheter, and stagnation of activity at the level 
of the catheter tip (B, blue arrow), with very limited activity cranial of the catheter tip in the thoracic/
cervical space, and in the cerebral cisterns (C) (red arrow). SPECT-CT (D) and MIP-SPECT (E) images revealed 
stagnation of activity at catheter tip level (blue arrow), which created suspicions of a granuloma.
D E
A B C
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Plain radiography (A) + magnification (B) revealed a dorsal coiled catheter (green arrows). SPECT-CT 
showed abnormal dorsal tracer activity accumulation (C, green arrow) with limited intrathecal tracer activity 
distribution suspect for a catheter obstruction. Planar scintigraphic images (E-G) revealed activity in pump 
and catheter, with remarkably intense tracer activity at the level of the abdominal/lumbar transition (green 
arrow), and limited tracer activity distribution in the spinal canal. In vivo (D, green arrow) showed a dorsal 
coiled catheter as the cause of the obstruction.
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SPECT-CT images (D–G) revealed stagnation of 
activity at the T10 spinal cord injury level (E, yellow 
arrow), minimal activity at high thoracic/cervical 
level (F, red arrow), and no activity in cerebral 
cisterns (G), which was caused by subarachnoid 
obstruction.
Planar images revealed remarkably wide aspect of activity at lumbar and thoracic level, also remarkable 
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Learning objectives
By reading this article, you should be able to:
•  Describe the consequences of failure of an intrathecal drug delivery system
•  Explain the choice of diagnostic procedures available to determine the cause of failure 
•  Describe the management of intrathecal drug delivery system failure
Key points
•  Device failures and human errors related to intrathecal drug delivery systems can lead to 
fatal complications as a result of withdrawal or overdose.
•  Health professionals often fail to recognise complications of intrathecal drug delivery failure 
because of lack of awareness.
•  Opioid-induced intrathecal granulomas can cause spinal cord compression and radicular 
symptoms.
•  Non-pathogenic microorganisms can cause meningitis with minor clinical symptoms.
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Intrathecal drug delivery is an invasive treat-
ment for the management of therapy-resis-
tant pain, spasticity, and dystonia that is not 
controlled by oral administration. This form of 
delivery is based on the premise that effective 
treatment can be achieved by administering a 
low volume of drugs near the site of action, 
thus reducing the incidence and severity of 
adverse effects. High systemic doses of drugs 
are required to achieve the same concentra-
tions. On-label drugs used include morphine, 
baclofen, and ziconotide, but the use of off-la-
bel drugs such as hydromorphone, clonidine, 
fentanyl, and mixtures of different drugs are 
used frequently. Errors and treatment failures 
can have life-threatening consequences. Health 
professionals are often unaware of potential 
complications of intrathecal drug delivery and 
their management due to a lack of exposure to 
these systems. This article aims to provide an 
overview of the management of complications 
and diagnostic procedures for troubleshooting 
drug delivery devices.  
Drug delivery device-related complica-
tions
Device-related complications can be caused by 
malfunction of the pump or catheter, which will 
lead to therapy failure.
Intrathecal catheter-related complications
Problems associated with intrathecal catheters 
are migration, laceration, occlusion, or dis-
connection.1 The Ascenda intrathecal catheter 
(Medtronic Inc., Minneapolis, MN, USA) seems 
to perform significantly better than earlier mod-
els.2 
Pump-related complications
Pump failure is uncommon despite the high im-
plantation rate.3 Failures of the Synchromed II 
(Medtronic Inc., Minneapolis, MN, USA) pump 
are rare. Pump stall caused by rotor corrosion 
can occur in earlier pump generations that are 
still in use. Programmable pumps have an elec-
tric power source, the failure of which can result 
in pump failure. Low battery life can result in 
pump failure, but this is indicated by the pro-
grammer device. 
Magnetic resonance imaging-related compli-
cations
Programmable pumps can fail temporarily 
during use of MRI because of rotor stall in-
duced by the magnetic fields. A pump should 
automatically restart after the termination 
of the scan, but it can sometimes take a few 
hours to do so. A reboot can be attempted by 
programming a bolus delivery; an emergency 
pump replacement must be performed should 
this process fail. 
The use of MRI in patients with the program-
mable Prometra pump system (Flowonix Medi-
cal Inc., Mount Olive, NJ, USA) is complicated. 
The device is MRI-compatible after its medica-
tion reservoir has been entirely emptied and re-
filled with a 0.9% NaCl solution and the system 
programmed at a zero-flow rate. These steps 
are required because the magnetic field opens 
the pump valves, which results in an immediate 
discharge of the contents of the drug reservoir, 
the inner tubing, and the catheter into the pa-
tient, thus causing an overdose. Removing the 
medication from the entire system is not easy 
and can only be entrusted to experienced clini-
cians, who may not be always accessible. Fixed-
rate delivery devices operate mechanically and 
are powered by a gas pressure chamber sur-
rounding a flexible inner reservoir, both made 
of titanium. An increase in temperature induced 
by MRI temporarily increases the delivery rate. 
In our view, the potential complications of ter-
mination of therapy outweigh the risk posed by 
the transient increase in delivery rate, particu-
larly in patients receiving intrathecal baclofen 
(ITB) therapy.
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Human factors
Human factors include refill schedule mistakes, 
miscalculations of the dead space of the inner 
pump tubing or catheter content, programming 
mistakes, and incorrect refill and access port 
procedures. Such errors can be mitigated by 
creating a prescription system in advance and 
adhering to it. Drug admixtures and pump pro-
gram prescriptions should be double-checked 
by competent clinicians. Refill procedures 
should only be performed by clinicians who are 
familiar with the technique required, and aware 
of the symptoms and signs of overdose or fail-
ure of therapy and the significance of neuro-
logical signs and symptoms. Suitable arrange-
ments must be in place for 24/7 medical cover 
because of the risk of life-threating complica-
tions. For reasons of safety, dose changes in an 
outpatient setting should not exceed more than 
10–15% of the daily dose. 
Complications
Early referral to a specialist centre is essential as 
treatment options in a non-specialist setting are 
limited to supportive measures.4
Overdose 
An overdose is usually the result of incorrect 
pump programming, pump failure, or, in the 
case of the Prometra pump, failure to empty 
the reservoir prior to MRI. Rarely is an overdose 
a consequence of an error related to prepara-
tion of the drug solution. 
Intrathecal baclofen overdose
Intrathecal baclofen overdose is characterised by 
ascending hypotonia, hypotension, hypothermia, 
nausea, vomiting, respiratory depression, sei-
zures, and decreased conscious level from som-
nolence to coma.5 Intrathecal analgesic overdose 
of opioids can present with nausea, vomiting, 
hyperalgesia, double vision, nystagmus, itching, 
myoclonus, respiratory depression, seizures, and 
somnolence to coma, and even death.6 
Intrathecal clonidine overdose
Overdose of clonidine can present as severe 
hypertension, confusion, unconsciousness, pro-
fuse sweating, dysarthria, and respiratory de-
pression.7 
Intrathecal ziconotide overdose
Overdose with intrathecal ziconotide is rel-
atively common, even during dose titration, 
due to its narrow therapeutic window and the 
delayed onset and offset of analgesia.8 The 
drug is cleared from the CSF relatively quick-
ly but remains bound within tissues.9 Adverse 
effects include dizziness, confusion, memory 
impairment, ataxia, abnormal gait, somno-
lence, asthenia, headache, nausea, vomiting, 
and diarrhoea. Less frequent adverse effects in-
clude postural hypotension, impaired vertebral 
expression, abnormal thought processes, dry 
mouth, anxiety, peripheral edema, nystagmus, 
and elevated creatine phosphokinase.9 The 
adverse outcomes of ziconotide are reversible 
within 4 days10 to two weeks.9
Management
The management of an overdose includes sup-
portive treatment with close monitoring. In se-
vere cases, lumbar puncture with the aspiration 
of 30 ml of CSF and reinjection of the same 
volume of saline should be considered. Intrave-
nous naloxone is required for the management 
of an opioid overdose.6 To prevent damage 
to the pump, a programmable pump that has 
been stopped should be restarted within 48 h. 
Reducing the flow rate may not be adequate to 
manage symptoms of overdose. In such cases, 
the reservoir should be emptied and rinsed sev-
eral times with saline to ensure that it is entirely 
free of the highly concentrated drug. The next 
step is to fill the reservoir with the medication 
at a lower concentration. The refill is followed 
by emptying the catheter via a catheter access 
port (CAP) puncture, programming for a bolus 
volume of the calculated catheter content and 
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repeat aspiration of the catheter. If the aspirat-
ed content is less than the inner pump tubing 
volume, the programming and the aspiration 
will have to be repeated. As the final step, the 
inner tubing and catheter should be filled by 
bolus pump programming. In a fixed flow de-
vice, emptying the internal tubing is impossible. 
The only solution is then several CAP punctures 
with aspiration for 24 h.
Withdrawal 
Sudden termination of intrathecal drug delivery 
as a consequence of catheter issues, pump is-
sues, or human factors such as programming 
errors or manipulation of pump by the patient 
can result in withdrawal phenomena. Within 
several to 48 h, abrupt interruption can present 
varied symptoms, which can result in misdiag-
nosis and life-threatening delay in treatment. 
Ziconotide can be discontinued abruptly with-
out withdrawal effects.9
Intrathecal baclofen withdrawal
Abrupt ITB interruption presents within sev-
eral hours or up to 2 days with mild exacer-
bation of spasticity, fever, excessive sweating, 
and pruritus.1 Diagnosis of withdrawal may not 
be suspected by clinicians unfamiliar with this 
condition. Neuropsychiatric symptoms such 
as hallucinations, disorientation and psychosis 
can occur. Hypotension, tachycardia, and sei-
zures may develop. In the most severe cases, 
hyperthermia, rhabdomyolysis, disseminated 
intravascular coagulation, and potentially fatal 
multi-organ system failure can occur.11 
Intrathecal opioid withdrawal
Symptoms of intrathecal opioid withdrawal 
symptoms include lacrimation or rhinorrhea, 
piloerection (‘goose flesh’), myalgia, diarrhoea, 
nausea/vomiting, anxiety, pupillary dilation and 
photophobia, insomnia, autonomic hyperactivity 
(yawning, tachypnea, hyperreflexia, tachycardia, 
sweating, hypertension), and hyperthermia.12 
Intrathecal clonidine withdrawal
Intrathecal clonidine withdrawal, which has 
also been reported in ITB,13 manifests in the 
form of hypertension and leads to rapid onset 
of a sympathomimetic crisis with associated 
Takotsubo-type cardiomyopathy.14 In the ab-
sence of obstructive coronary artery lesions, 
this syndrome, also known as left ventricular 
apical ballooning syndrome and stress-induced 
cardiomyopathy, is typically characterised by 
transient systolic dysfunction of the apical and 
mid-segments of the left ventricle. Patients of-
ten present with symptoms and signs of acute 
coronary syndrome. 
Management 
Supportive treatment with close monitoring is 
required. Oral baclofen in combination with in-
travenous benzodiazepines is required for man-
agement of ITB withdrawal.4,11
Intravenous supplementation may be required 
in patients with opioid and clonidine with-
drawal. Externalised intrathecal catheters can 
be used if supplementation therapy is not suf-
ficient. The disadvantage of this approach is 
that a larger volume needs to be delivered by 
an external device. In patients with pump ex-
plantation caused by infection, withdrawal can 
be overcome by the temporary use of the ex-
planted pump as an external device, whereby 
the original spinal catheter is externalised with 
replacement of the proximal catheter part.15 
 
Cerebrospinal fluid leak
Cerebrospinal fluid leaks can be caused by per-
sistent dural opening at the catheter insertion 
site, catheter-pump disconnection, a dam-
aged catheter-pump connector, a perforated 
or sheared catheter, or an interruption of the 
catheter-catheter connector. Older catheter 
systems that are still in use have a sutured cath-
eter-pump fixation. The suture can cut the con-
nector, leading to CSF leak. 
A severe CSF leak can result in withdrawal syn-
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drome, but this outcome is unusual with a mi-
nor leak. Limited leakage is detected based on 
treatment failure, spinal headache, or inadver-
tently during the percutaneous refill procedure 
(Fig. 1).
More pronounced leaks lead to local CSF accu-
mulation outside the spinal canal and are rec-
ognised by dorsal swelling, ventral swelling, or 
both, but visible swelling may be absent.
In some cases, the passage of CSF along the 
catheter to the pump pocket leads to abdomi-
nal swelling (Fig. 2). This swelling, which should 
be differentiated from a seroma, hematoma, or 
abscess. Cerebrospinal fluid can be confirmed 
by puncturing the distention, followed by ex-
amination of the fluid for beta-2-transferrin. 
A severe CSF leak is associated with intracranial 
hypovolemia, which can cause a subdural he-
matoma. Typically, a CSF leak is characterised 
by postural headache, but this is often absent. 
Nevertheless, a severe CSF leak should be con-
sidered an emergency. The origin of a leak is 




The treatment for leakage is to identify the 
cause and, if it is device-related, to perform a 
surgical restoration. In contrast to dural leaks as 
result of lumbar puncture, treatment with bed 
rest only is frequently insufficient when a leak-
age is related to inserted intrathecal catheters. 
In such cases, one or more homologous blood 
patches and bed rest are then the treatment of 
choice. Cerebrospinal fluid accumulation in the 
pump pocket being passed through along the 
catheter is treated by percutaneous fluid aspira-
tion. The needle is introduced above the pump 
and remains in contact with it to prevent acci-
dental catheter puncture.
Figure 1. Overlying catheter above the refill 
membrane.




Figure 3. A granuloma (A, blue arrow). Tremendous in vivo ingrowth with an abnormal black colouring (B, 
yellow arrow). The patient complained of exacerbation of pain in his legs without neurological signs. The 
causes can easily be overlooked when MRI is limited to the lumbar area. 
Granuloma formation
Granuloma formation at the thoracic catheter 
tip is an uncommon complication of intrathecal 
opioid administration16 and is rare with ITB.17 An 
association between granuloma and the dose 
of the intrathecal medication remains unclear.18 
Opioid-induced granulomas can cause spinal 
cord compression and radicular pain in the tho-
racic or lumbar regions. There is exacerbation of 
pain despite dose increments, as drugs are un-
able to reach the target neural tissue. Diagnosis 
is based on MRI showing an abnormal tissue 
formation at the catheter tip (Fig. 3). 
Management
Catheter replacement at another level or ter-
mination of the infusion with monitoring may 
be appropriate, as the mass could resolve on 
its own.16 Surgical removal of the granuloma 
is indicated in cases that involve neurological 
deficits.
Obstruction of cerebral spinal fluid flow 
Cerebrospinal fluid flow obstruction can be 
caused by focal arachnoiditis with fibroconnec-
tive adhesions, which will result in accumula-
tion of the infused medication. The accumu-
lation gives rise to a high local concentration, 
which can lead to a vicious cycle of chronic 
arachnoiditis.
Management
In cases of limited CSF flow obstruction, cath-
eter replacement can be attempted. However, 
multiple revisions are not indicated. Preliminary 
results show that restoration of the CSF flow 
by microsurgical adhesiolysis or percutaneous 
balloon fenestration appears to solve the prob-
lem.19
Infection
Implantable device infections can be attribut-
ed to the surgical procedure or the refilling of 
the percutaneous pump reservoir. They can be 
caused indirectly via hematogenous seeding 
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from a distant source. The clinical manifesta-
tions of local infection include localised pain, 
protrusion, erythema, and fever. In a progres-
sive infection with pus formation, the swelling 
is more pronounced, and the skin has a shiny 
appearance. A striking observation is that a 
device infection is not invariably accompanied 
by fever. The causative microorganisms can be 
identified on cultures of the local pus, blood, 
and CSF. 
Pump pocket infection can spread to the central 
nervous system, leading to meningitis.20 Isolat-
ed meningitis can occur even should the pump 
pocket appear to be normal. The clinical symp-
toms of meningitis are highly dependent on the 
causative microorganism. Symptoms such as fe-
ver, headache, stiff neck, vomiting, and change 
in consciousness occur inconsistently. There is 
a risk of missing the diagnosis of meningitis. 
Staphylococcus aureus meningitis presents with 
high-grade fever. In contrast, Staphylococcus 
capitis meningitis can be missed, as it does not 
present with high grade fever.    
Treatment
Superficial infection is treated with oral antibi-
otics.21 In more severe infections, explantation 
of the implanted device is necessary to mitigate 
the risk of meningitis.20 In ITB and intrathecal 
clonidine, the dose should be reduced gradually 
over 5 days, as sudden termination can lead to 
a potentially life-threatening withdrawal syn-
drome. Patients with cerebral damage or a spi-
nal cord injury at the T6 level or higher who are 
implanted with an ITB device are at risk of au-
tonomic dysreflexia upon sudden withdrawal. 
Broad-spectrum antibiotics such as meropenem 
and vancomycin should be administered until 
the causative microorganism is identified. 
Anecdotal information suggests that pump 
explantation may not always be necessary.22-24 
System salvage should be considered in infec-
tion with a non-pathogenic microorganism, mi-
nor clinical symptoms, and in patients at high 
risk of sympathetic crisis.22,24 Antibiotic treat-
ment with meropenem and vancomycin deliv-
ered intravenously combined with vancomycin 
in the pump24 and oral rifampicin is an option. 
Successful pump salvage by wrapping the 
pump in two gentamicin-impregnated colla-
gen sheets has been described in a patient with 
S. aureus infection of the pocket site.23 The pa-
tient had previously experienced life-threaten-
ing autonomic dysreflexia after ITB termination, 
which precluded temporary discontinuation of 
ITB. Major concerns of this method are the po-
tential for the developing antibiotic resistance 
with long-term gentamicin administration and 
the risk of recurrence. 
Diagnosis of intrathecal drug delivery 
system failure
We used an algorithm in our institution to de-
termine the cause of intrathecal drug delivery 
failure (Fig. 4). The primary diagnostic steps are 
estimating the amount of fluid in the pump res-
ervoir and a low-dose single-energy CT (SECT) 
scan.25
Computed tomography with post-processing 
two-dimensial (2-D) and (3-D) reconstructions 
allows visualisation of the entire drug delivery 
pathway as opposed to plain radiography (Fig. 
5). Catheter access port myelography can be 
used should CT fail to determine the cause. 
Fluid should be aspirated from the CAP before 
injection of contrast material to prevent over-
dose, as the catheter is filled with a high con-
centration of drugs. The highly viscous contrast 
material should then be flushed with normal 
saline. The catheter should subsequently be re-
filled with a precisely calculated amount equal-
ing to the catheter volume by either pump bo-
lus or manual injection. 
Information concerning a catheter’s diameter 
and length is essential in calculating its vol-
ume. This information should be recorded in 
the clinical records and in the memory of the 



















Readout pump (programmable device)
Empty pump reservoir
Low-dose SECT 2D/3D reconstructions
Catheter Access Port (CAP) puncture
combining CAP myelography with CT and 2- 
and 3-D reconstructions, failures associated 
with drug delivery can be identified. It is crucial 
to not limit the CT field of view to the spine 
but rather to extend it to the abdominal region 
where the pump is implanted. Contrast materi-
al should not be injected if it is not possible to 
aspirate fluid via the CAP, as there will be a risk 
of overdose. Non-contrast CT can be used to 
identify an abnormal catheter position. In addi-
tion, lumbar puncture CT myelography can be 
considered if in doubt. 111In-DTPA scintigraphy 
can be useful when CAP CT myelography fails 
to identify the cause of failure, and when fluid 
cannot be aspirated via the CAP or if dynamic 
Figure 5. Improved catheter visualization. Plain radiography indicated a possible kinked catheter (red arrow). 
DECT with 3D volume rendering revealed a regular curved catheter (yellow arrow) with no obstruction.
Figure 4. Overview (aetiology, diagnostic algorithm) 
of intrathecal drug delivery troubleshooting
CSF = cerebrospinal fluid; SECT = single-energy 
computed tomography; DECT = twin-beam dual-
energy computed tomography; 111In-DTPA SPECT 
= 111Indium-diethylene-triamine-penta-acetic-acid 
single-photon emission computed tomography.
Intrathecal drug delivery system failure
126
information regarding catheter flow and the 
spread of intrathecal medications is required. 
It can also help to identify minor leakages. 
111In-DTPA scintigraphy can be enhanced by 
adding single photon emission CT (SPECT) and 
by standardising the flow rate in programmable 
pump devices. Magnetic resonance imaging is 
of limited value in intrathecal drug delivery sys-
tem failure and is used to exclude granuloma, 
syringomyelia, or intrathecal obstructions.
Summary
Although intrathecal drug administration using 
an implanted pump system has been used in 
clinical practice for many decades, awareness 
of its applications, complications associated 
with its use and management of complications 
remains limited. Early diagnosis and manage-
ment of withdrawal and overdose is essential 
as they can be potentially life-threatening. Ear-
ly involvement of clinicians with experience in 
managing these devices is essential. 
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Multiple choice question 1
A 45-year-old woman with therapy-resistant lower back pain was treated with intrathecal mor-
phine for 5 years. She experienced an exacerbation of her pain without other clinical signs. Plain 
radiography revealed a sheared spinal catheter. The appropriate next step would be the following:
a) Removal of the complete catheter via a laminectomy
b)  Surgical disconnection of the catheter parts from the connector and removal of the extra-verte-
bral broken part, leaving the rest of the catheter in place
c) Non-contrast computed tomography with three-dimensional (3D) volume rendering reconstruction
d) Lumbar puncture CT myelography 
e) Scintigraphy, with the pump filled with 111Indium-diethylenetriamine penta-acetic acid (111In-DTPA)
Answers
a)  False. Complete removal of the catheter is justified when the retained catheter segment causes 
leakage of cerebrospinal fluid (CSF) via the extradural end of the sheared catheter. Plain radiog-
raphy cannot provide information concerning CSF leakage. 
b)  False. This approach is appropriate in the absence of CSF leakage via the extradural end of the 
sheared catheter. Information about leakage is not present. The correct approach is to leave the 
retained catheter in place if it can be determined that CSF leak is absent. 
c)  False. Non-contrast CT with 2D/3D volume rendering reconstruction can provide clear visualisa-
tion of the catheter to determine if the sheared catheter is intradural or extradural. It does not, 
however, provide information on any potential CSF leak. 
d)  True. With lumbar puncture CT myelography, CSF leakage can be identified by backflow of the 
contrast material via the sheared intra-extradural catheter part. 
e)  False. Pump scintigraphy is unhelpful, as the catheter is completely disrupted, and intra-extra-
dural CSF leakage can therefore not be identified.
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Multiple choice question 2
A 52-year-old patient presented with protrusion of the abdominal wall and mild postural headache 
about 24 hours after implantation of an intrathecal morphine drug delivery system. No other clini-
cal features were present. A puncture of the swollen pump pocket revealed 40 ml of a transparent 




d) Cerebrospinal fluid accumulation
e) Allergic reaction to the pump
Answers
a)  False. Although seroma can be yellow in colour, it is not transparent. The accumulation of 40 
ml in a day is unlikely. 
b)  False. Infection within 24 hrs with the accumulation of a large volume of exudate is unlikely. 
Secondary infection of accumulated fluid is a possibility, but it is unlikely to manifest within a 
day. Fever should be expected with an on-going infection.
c) False. Haematomas can occur after implantation, but the aspirate is not transparent light yellow. 
d)  True. Cerebrospinal fluid leakage can manifest within one day as a result of: 
• a sheared catheter segment in the pocket 
• disconnection or sheared pump–catheter connection 
• dural leakage with CSF advancing along the catheter to the pocket.  
The postural spinal headache is associated with the CSF leakage. Cerebrospinal fluid mixed 
with local wound fluid causes the light yellow colour. 
e) False. An allergic reaction to the pump will not result in 40 ml of fluid accumulation in the pocket.
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Multiple choice question 3
A 52-year-old man with a cervical spinal cord lesion was treated with intrathecal baclofen for 
25 years. He developed Staphylococcus aureus cellulitis at the orifice of the suprapubic catheter, 
which was successfully treated with an antibiotic medication. He subsequently developed superfi-
cial infection of the pump pocket without fever. The appropriate treatment includes the following:
a) Oral antibiotic trial(s) 
b) Dose reduction and an intravenous antibiotic treatment 
c) Immediate wound drainage
d) Immediate removal of the drug delivery system
e) Explantation of the drug delivery system after a dose reduction
Answers
a)  False. The superficial infection of the pump pocket is likely the result of progression of cellulitis. 
An oral antibiotic treatment trial would not be appropriate.
b)  True. Immediate explantation is not indicated, as the infection is superficial, and systemic symp-
toms such as fever are absent. The drug dose should be reduced in increments to prevent 
withdrawal. Intravenous antibiotic treatment should be initiated to prevent the development 
of meningitis. 
c) False. Immediate wound drainage is not indicated at this stage.
d) False. Immediate removal of the drug delivery system is not indicated at this stage. 
e)  True. The preferred treatment is the removal of the entire drug delivery system as soon as 
the intrathecal medication has been terminated. Biofilm formation on the surface of the drug 
delivery system makes eradication with antibiotics difficult.   
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Multiple choice question 4
A 45-year-old patient with an implanted device for ITB 3 months earlier for the management of 
spasticity presented with mild muscle weakness and mild fever for 4 weeks. No other clinical symp-
toms were present. The possible diagnosis includes the following: 
a) Condition unrelated to the drug delivery device
b) Staphylococcus aureus meningitis
c) Staphylococcus epidermidis meningitis
d) Intrathecal baclofen overdose
e) Mild intrathecal baclofen withdrawal syndrome
Answers
a) True. There is no reason to consider a relation with the drug delivery device. 
b) False. Staphylococcus aureus meningitis presents with a high-grade fever. 
c)  True. Staphylococcus epidermidis can result in treacherous, meningitis that can easily be over-
looked 
d) False. The mild elevation in temperature with muscle weakness makes an overdose unlikely. 
e)  False. Intrathecal baclofen withdrawal syndrome is associated with muscle hypertonia, not with 
muscle weakness. 





















































































































eFigure 2. Temporary external use of an explanted pump.
eFigure 3. Epidural spread. 111In-DTPA scintigraphy (A, red arrow) revealed dorsal dura leakage. The 20ml 
injected blood marked with 99mTechnetium (B, green arrow; C, yellow arrow) showed an epidural spread up 
to the high thoracic region (C). 
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We describe five traumatic spinal cord injury (SCI) patients with an intrathecal baclofen administration (ITB) 
failure caused by a rostral CSF flow obstruction referred to our expert center between January 2014 and Jan-
uary 2019. We discuss the diagnostic workup, rostral CSF flow obstruction as the cause of the ITB failure and 
treatment. 
Methods
When we could not determine the cause of the ITB failure through the patient’s history, physical spasticity 
examination, pump readout, absence of fluid in the pump reservoir during aspiration, or plain radiography, we 
performed pump catheter access port (computed tomography [CT]) myelography. When CT myelography did 
not reveal the diagnosis, we used scintigraphy. In an obstruction, we aimed for CSF flow restoration. In three 
cases, we conducted a laminectomy with microsurgical adhesiolysis. In two of these patients, we could not 
achieve CSF flow restoration; thus, we placed an intradural catheter bypass. Recently, in three patients, we 
applied a less invasive technique of percutaneous fenestration of the obstruction.
Results
In one case, we performed a successful catheter replacement. In another case using surgical adhesiolysis, spas-
ticity control was complete. In two cases, we could obtain improvement with an additional intradural bypass, 
followed by a percutaneous fenestration of the obstruction, resulting in further improved CSF flow restoration. 
In one case, percutaneous fenestration was the first line of treatment. In all cases with percutaneous fenestra-
tion, we experienced spasticity control.
Conclusion
Preliminary results showed that the restoration of rostral CSF flow might result in an effective ITB treatment in 
patients with an intrathecal obstruction.
Keywords
CSF flow, obstruction, neurosurgery, balloon dilatation, restoration
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Introduction
Following a spinal cord injury (SCI), 62% to 
88% of the patients develop spasticity.1-4 None-
theless, the resulting muscle tone might have 
advantages, such as advantages during trans-
fers or as a clinical indicator of noxious stimuli.5 
In generalized spasticity, the GABA-B receptor 
agonist baclofen is the most frequently used 
drug. Since 1984, intrathecal baclofen (ITB) has 
become an often used therapy in intractable 
cases.6 A rostral cerebrospinal fluid (CSF) flow 
obstruction is a rare cause of long-term ITB fail-
ure. In this paper, we describe five adult SCI pa-
tients with an ITB failure caused by a rostral CSF 
flow obstruction. After CSF flow restoration 
either by microsurgical adhesiolysis, intradu-
ral bypass,7,8 or percutaneous fenestration, we 
evaluated the ITB treatment effect. CSF flow 
restoration was attempted based on the fol-
lowing observations: a successful clinical treat-
ment with an intradural shunt in a patient with 
a CSF flow obstruction (not published); cere- 
bral cistern visualization with 111Indium-dieth-
ylene-triamine-penta-acetic acid scintigraphy 
137
(111In-DTPA) in normal cases; the lack of treat-
ment effect when the catheter tip was placed 
above an obstruction; and cerebral symptom-
atology, which occurred upon an ITB overdose. 
Based on these observations, we hypothesized 
that besides the regional effect of ITB, rostral 
CSF flow is also needed for effective ITB treat-
ment, and that the restoration of rostral CSF 
flow in obstructions could be a useful therapy 
in the case of ITB failure.  
Methods
The five patients were referred to our expert 
center for ITB troubleshooting between Janu-
ary 2014 and January 2019. In four of the five 
patients, catheter revision(s) had not resolved 
the ITB failure. All patients used a SynchroMed 
II delivery system (Medtronic Inc., Minneapo-
lis, MN, USA). Five were treated with baclofen 
only, and one with a combination of baclofen 
and hydromorphone. During the diagnostic 
workup, the rostral CSF flow obstruction was 
demonstrated and treated via the restoration 
of the rostral CSF flow. For this retrospective 
study, we received approval from the medical 
ethics committee of the Erasmus Medical Cen-
ter (MEC-2017-326), and the requirement to 
obtain informed consent was waived.
Diagnostic workup
When we could not determine the cause of ITB 
failure through the patient’s history, physical 
examination of the spasticity, pump readout, 
absence of fluid during aspiration of the pump 
reservoir, plain radiography, or low-dose CT, we 
performed pump catheter access port (CAP) 
computed tomography (CT) myelography.9 Via 
the CAP, we injected 10 ml of contrast materi-
al (iohexol, Omnipaque™ 320, GE Healthcare 
B.V., Eindhoven, The Netherlands), followed 
by fluoroscopy and CT. Occasionally, we in-
jected contrast material via a lumbar puncture 
when we could not perform CAP myelography 
(Cases 3, 5). To demonstrate the presence or 
absence of the rostral spread of the injected 
contrast material, we used the Trendelenburg 
position immediately after the contrast material 
injection. The images were evaluated for an in-
homogeneous or reduced contrast material dis-
tribution. To be informed about the length of 
the intrathecal obstruction, we added cervical 
CT myelography to the diagnostic algorithm9 
(Cases 3, 4). When in doubt of an obstruction, 
we additionally performed 111In-DTPA (Cases 1, 
2, 3). We mixed the medication in the pump 
reservoir with 20 MBq of 111In-DTPA and stan-
dardized the pump flow rate for each patient in 
such a manner that after 24 h the catheter tip 
would be reached in the case of normal flow. To 
maintain the same dose, we adapted the drug 
concentration in advance. A previous radioiso-
tope study showed that the tracer reaches the 
cerebral basal cisterns from the lowest caudal 
level in 2–2.5 h.10 Therefore, basal cisterns 
should be clearly visible at 111In-DTPA within 
48 h. We assumed stagnation in drug delivery 
due to a rostral CSF flow obstruction when the 
tracer appearance in the basal cisterns was later 
than 48 h, limited, or not present (Fig. 1). 
Summary of Cases
We summarized the patient’s history, the used 
diagnostic procedures exhibiting a partial or 
complete CSF obstruction, and the treatment 
in Table 1. 
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Case 1 Case 2 Case 3 Case 4 Case 5
Gender male male female male male
Age 44 64 47 60 38
Level of SCI C5 T12 T10 T2 C6
Treatment somewhere else
Dose adjustments yes yes yes yes yes
Improvement none none none none none
Catheter revision N = 1 N = 3 N = 18





Spasticity severe severe severe severe severe
Pain severe
Years of successful ITB 4 3 12 19 <1
Baclofen dose (mcg/24h) 502 1,374 498 483 2,216
Opioid dose (mg/24h) Hydromorphone 2.2
Our diagnostics
Plain radiography normal normal normal normal normal
Catheter tip T7–8 T9–10 T11 T7 T9
Aspiration fluid CAP yes yes yes yes no
CAP myelography obstruction partial T7 partial T11 complete T10–11 complete T5–7
CAP CT myelography obstruction partial T7 partial T11 complete T10–11 complete T5–7
111Indium scintigraphy obstruction partial T7 partial T11 complete T9–10 complete T9
LP CT myelography obstruction complete T8–9 extradural 
catheter
CP CT myelography obstruction complete T10
Our treatment
None




Microsurgical adhesiolysis + yes yes
Intradural bypass T8–L2 T6-10
Improvement some some
Percutaneous fenestration yes yes yes
Improvement good excellent good




A 44-year-old man who experienced a trau-
matic SCI American Spinal Injury Association 
(ASIA)-A at the C5 level eight years ago devel-
oped disabling intractable spasticity of the low-
er and upper extremities. After a successful ITB 
bolus injection test two years later, the patient 
was successfully treated with ITB for four years. 
However, the spasticity reoccurred gradually 
despite a daily dose of 502 mcg. Several higher 
doses did not result in an improvement, and the 
patient was referred to our center. At the time 
of referral, the patient had severe spasticity of 
the lower and upper extremities (a Modified 
Ashworth Scale [MAS] score of 3). CAP (CT) 
myelography was suspicious of an obstruc-
tion at the T10 level (Fig. 2A, 2B), which was 
confirmed by 111In-DTPA (Fig. 2C). Because no 
catheter revisions were performed previously, 
we first replaced the intrathecal catheter, which 
resulted in a clinically significant decrease of 
the spastic symptoms (MAS 1) for, currently, 15 
months.
 











































A 64-year-old man experienced a traumatic 
SCI ASIA-A at the T9–10 level 24 years ago. 
Over the years, the patient developed disabling 
therapy-resistant generalized spasticity of the 
lower extremities, which could be managed by 
oral spasmolytic medication. Nevertheless, after 
20 years, his spasticity could no longer be con-
trolled by this medication. After a positive ITB 
bolus injection test, the patient was successfully 
treated with ITB for three years. Gradually, his 
spasticity worsened, which could be reduced to 
MAS 3 by increasing to an extremely high daily 
dose of 1,374 mcg. CAP CT myelography (Fig. 
3A) and 111In-DTPA, including Single Photon 
Emission Computed Tomography (SPECT-CT) 
(Fig. 3B) and planar images (Fig. 3C), were sus-
picious of an obstructed spread of contrast ma-
terial and tracer material, respectively. We per-
formed a laminectomy at T9–10 with a midline 
dura opening. With a microscope, we observed 
severe adhesions and crystalloid drug accu-
mulation in several loculations. We conducted 
adhesiolysis of the fibrotic leptomeninges and 
removed the crystalloids, which resulted in CSF 
flow restoration. After finishing the surgery, the 
ITB dose was reduced arbitrarily by 50%. The 
next day, the patient was slightly sedated, with 
completely flaccid legs. We cut the dose further 
to 550 mcg, which was sufficient to control the 
patient’s spasticity (MAS 0) for two years.
Figure 2. Catheter access port (CAP) myelography (A) showed stagnation of contrast material (black arrow). 
The catheter tip is located above the contrast material (gray arrow). CAP CT myelography (B) with 4 
consecutive sagittal reconstructions revealed a caudal flow of the contrast material (white arrow). Planar 
111Indium-DTPA scintigraphy 7 days (C) showed a limited rostral tracer spread, increased lumbar/thoracic 




A 47-year-old woman experienced a traumatic 
SCI ASIA-B at the T10 level 18 years ago. The 
patient’s rehabilitation was hindered by severe 
lumbar and low thoracic pain and disabling 
generalized spasticity of the lower extremities, 
leading to a bedridden situation for about 18 
months. After a positive ITB bolus injection 
test, the patient was successfully treated with 
ITB for 12 years. Gradually, the patient experi-
enced exacerbation of her spasticity and pain. 
Despite dose adaptations of both baclofen 
and morphine, and later hydromorphone, her 
complaints were persistent. A catheter revi-
sion did not relieve the pain and spasticity. For 
troubleshooting, the patient was referred to 
our center. At the time of referral, the patient 
had severe spasticity of the lower extremities 
(MAS 3) with a daily ITB dose of 683 mcg, and 
high pain scores (a Visual Analogue Scale [VAS] 
score of 8) in the lumbar region with a daily 
hydromorphone dose of 4.5 mg. We evaluated 
her pain and performed local anesthetic lum-
bar blocks, which did not reveal improvement. 
CAP (CT) myelography indicated an inhomoge-
neous stagnation of contrast material just be-
low the SCI level. 111In-DTPA after 48 h showed 
an abnormal widening of the tracer spread at 
the lumbar/low-thoracic transition, a narrowed 
thoracic region, and no tracer activity in the cis-
terns, suggesting an obstruction (Fig. 4B). 
Figure 3. CAP CT myelography (A) with 5 consecutive sagittal reconstructions revealed narrowed contrast 
material column (red arrow), suspicious for contrast material stagnation.  111In-DTPA SPECT CT at 48 h 
(B) showed obstruction at the level of the spinal cord lesion (red arrow). 111In-DTPA planar (C) revealed a 
lumbar/thoracic gradient (red arrow), limited cerebral cistern tracer spread (orange arrow). In vivo microscopic 
view with opened dura showed intrathecal catheter tip (yellow arrow), forceps (blue arrow), and baclofen 
medication crystallization (green arrow).
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We performed a laminectomy at the T10–11 
level. Under microscopic vision, we performed 
an extensive local adhesiolysis of the fibrotic 
leptomeninges, but we could not restore the 
CSF flow. We decided not to enlarge the lam-
inectomy, but to place an intradural catheter 
bypass7, 8 from T9 to L2. After surgery, the spas-
ticity was under control (MAS 0) with a daily 
ITB dose of 460 mcg, but the pain remained 
unchanged despite a daily dose of 3.2 mg of 
hydromorphone. In the three years following 
the intervention, severe spasticity with a daily 
ITB dose of 505 mcg reappeared (MAS 3). The 
patient underwent several pain treatments else-
where, but despite these treatments and a daily 
intrathecal hydromorphone dose of 3.5 mg, the 
patient had a high VAS score of 8 at the referral. 
111In-DTPA including SPECT found identical pla-
nar images as before the surgical intervention, 
consistent with a nonfunctional intrathecal by-
pass (Fig. 5A). 
Based on our experience at the previous lam-
inectomy where we were not aware of the 
length of the intradural obstruction, we wanted 
to be informed about the magnitude of the ob-
struction in advance. Therefore, we performed 
lumbar dual-energy CT (DECT) myelography 
with 3D reconstructions (Fig. 5B, 5C), and, 
in a second session, cervical CT myelography 
(Fig. 5D, 5E). With the Seldinger technique,11 
we performed a percutaneous fenestration of 
the obstruction with balloon dilatation. With 
the patient in the prone position with 5 ml of 
lidocaine 1% local infiltration, a midline lumbar 
puncture was performed with an 18G Tuohy 
needle (B Braun Medical B.V., Oss, The Neth-
erlands). We inserted an Angled Guidewire 
0.035 (Terumo Benelux N.V., Leuven, Belgium) 
into the intrathecal space, and advanced a 5F 
Brite Tip introduction sheath over the guide-
wire (Cordis Cardinal Health B.V., Amsterdam, 
The Netherlands). Via the sheath, we perforat-
ed the obstruction with the guidewire. In the 
next step, we advanced a 5x120 mm 0.038 
Admiral Xtreme balloon (Medtronic Trading NL 
B.V., Eindhoven, The Netherlands) and gradu-
ally inflated the balloon until reaching the pain 
threshold. We deflated and repeated inflation 
several times to achieve, if possible, optimal 
balloon expansion at a nominal pressure of 8 
bar. We controlled the dilatation results with 
cervical myelography through the injection of 
10 ml of iohexol 300 via the inserted sheet. 
After each contrast material administration, we 
aspirated 10 ml of fluid to maintain intrathecal 
normovolemia. We repeated the balloon in-
flation and deflation procedure on two lower 
levels. Immediately after successful dilatation, 
the patient experienced severe nausea with 
vomiting, which we explained by the sudden 
rostral spread of the baclofen/hydromorphone 
medication. As therapy for this intoxication, we 
aspirated 30 ml of CSF and injected 1 mg of 
granisetron intravenously. Within a couple of 
minutes, the patient’s spasticity (MAS 0) and 
Figure 4. Planar 111In-DTPA at 48 h (A, B). A patient 
without CSF flow obstruction with normal lumbar, 
thoracic, and cerebral cistern tracer spread (A). Case 
4 with widened tracer activity caudal and at lumbar/
low-thoracic transition (B, black arrow), thoracic 
gradient (B, gray arrow), and no cisternal tracer 
spread (B, white arrow).
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pain (VAS 0) disappeared entirely and have 
remained absent for, currently, a period of six 
months with a daily ITB dose of 505 mcg and 
an intrathecal hydromorphone dose of 3.5 mg.
Case 4
A 64-year-old man experienced a traumatic 
SCI ASIA-A at the T2 level 25 years ago. The 
patient developed disabling therapy-resistant 
spasticity of the lower limbs and the abdominal 
and thoracic region, which was complicated by 
autonomic dysreflexia (AD) several times a day, 
and which could insufficiently be controlled by 
oral medication. Two years later, after a positive 
ITB bolus injection test, the patient’s spastici-
ty, as well as his AD, was successfully treated 
with ITB for 15 years. At the time of a pump 
replacement because of the end of the battery 
life, the patient’s treating physician also decid-
ed to replace the intrathecal catheter. From that 
time onward, the severe spasticity with fre-
quent daily periods of AD could no longer be 
managed by ITB. To overcome the ITB failure, 
the patient underwent three catheter revisions 
without any result. At the time of referral, the 
MAS score was 2. Nevertheless, the patient had 
severe spontaneous and intentional spasms of 
the lower extremities and the abdominal and 
thoracic region, and AD every hour. CAP CT 
myelography (Fig. 6A) and cervical CT myelog-
raphy (Fig. 6B) revealed contrast material stag-
nation at the SCI level. 
With the same percutaneous fenestration pro-
cedure (Fig. 6D–6J) as in Case 3, we could 
restore the rostral CSF flow (Fig. 6C). Immedi-
ately after the successful dilatation, the patient 
experienced nausea and a headache, probably 
as a result of the sudden rostral spread of the 
baclofen medication. We drained 30 ml of CSF 
and injected 1 mg of granisetron intravenously. 
Within a couple of minutes, his spasticity dis-
Figure 5. 111In-SPECT CT with stagnation of tracer (white arrow), non-functional intradural shunt (A, E, green 
arrow), and no tracer activity above the tip of the shunt (A). Lumbar CT (3D) myelography with stagnation 
of contrast material at Th11 (B, C, white arrow), and with cervical CT (3D) at Th10 (D, E, yellow arrow). 
Intrathecal catheter (red arrow).
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Figure 6. CAP myelography (A) and cervical CT myelography (B) with inhomogeneous stagnation (white 
arrow). Cervical CT myelography after percutaneous balloon fenestration (C) with restoration of contrast 
material spread (white arrow). Fluoroscopy during the procedure with inserted balloon (D, gray arrow). 
Cervical contrast material injection to evaluate the effect of balloon dilatation (black arrow): starting situation 
(E), some widening on the same level (F, G), and the result of the fenestration (I–J).
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appeared entirely. After that, the ITB dose was 
titrated to 157 mcg, which was sufficient to 
control his spasticity and AD, and the additional 
140 mg of daily oral baclofen medication could 
be stopped permanently. At this moment, the 
result has lasted for six months.
Case 5
A 38-year-old man experienced a traumatic 
SCI ASIA-B at the C6 level 19 years ago. The 
patient developed disabling therapy-resistant 
spasticity of the lower extremities, abdominal 
region, trunk, and right hand, which could in-
sufficiently be managed by oral spasmolytic 
medication. After a positive ITB bolus injection 
test two years later, the patient was successfully 
treated with ITB for less than one year. In par-
ticular, spasticity of the abdomen, trunk, and 
right hand was problematic. Over 14 years, the 
patient underwent 18 surgical interventions to 
improve the ITB treatment, but all these proce-
dures did not lessen his complaints. The patient 
was referred to our center for troubleshooting. 
At the time of referral, the patient had severe 
generalized spasticity of the lower extremities 
and right hand, and severe spontaneous and 
intentional spasms of the abdominal region 
and trunk several times a day, despite an ex-
treme ITB daily dose of 2,216 mcg. During CAP 
myelography, we could not aspirate CSF and, 
therefore, contrast material was not injected, 
and we terminated the procedure. 111In-DTPA 
SPECT at 72 h and seven days via the pump 
demonstrated tracer accumulation at the lum-
bar–low thoracic transition, a stagnation of 
the tracer at T2, and no activity in the cerebral 
cisterns. CT myelography via L3–4 showed 
an extradural catheter position. We inserted a 
new intrathecal catheter with the tip on T10. 
Postoperatively, with a daily ITB dose of 360 
mcg, the spasticity of his lower extremities was 
under control, but the spasticity of his abdo-
men, trunk, and right hand was not. Dose in-
crements up to 1,109 mcg did not improve the 
situation. With magnetic resonance imaging 
(MRI), a granuloma was excluded. Because of 
the persistent complaints two months later, an 
111In-DTPA was performed, and a tracer stop 
at the catheter tip and minimal activity in the 
cerebral cisterns were found, consistent with 
an obstruction at the catheter tip level. We 
performed a laminectomy at the T10–11 level 
and found an intact intrathecal catheter. With a 
microscope, we observed severe adhesions and 
crystalloid drug accumulation in several locula-
tions. We conducted extensive local adhesioly-
sis, but we could not restore the CSF flow. We 
decided not to extend the laminectomy, but to 
place an intradural catheter bypass7,8 from T10 
to C6. Following the surgery, the spasticity 
improved, but the trunk and upper extremity 
remained problematic, despite the high daily 
ITB dose of 1,109 mcg. Two years later, we 
performed a percutaneous fenestration of the 
obstruction. During a lumbar puncture at the 
L2–3 level, minimal spontaneous CSF flow was 
observed. We experienced a hindrance advan- 
cing the guidewire at several thoracic levels. 
By moving the guidewire back and forth, we 
could overcome the problem. We advanced 
the sheath over the guidewire and inserted the 
balloon. With repeated balloon inflation and 
deflation on the low thoracic level, we could 
manage several obstructions. When reaching 
level C7, we observed a massive obstruction. 
At this moment, the patient was complaining of 
a severe headache, mild autonomic dysreflexia 
(only transpiration and piloerection), and exac-
erbation of the abdominal spasticity. We termi-
nated the procedure, reduced the daily dose to 
500 mcg, and treated the headache with parac-
etamol. After removing the balloon out of the 
sheath, we observed spontaneous CSF flow, al-
though less than normal. The CT scan immedi-
ately after the procedure revealed improvement 
of the CSF flow; but at the lumbar and cervical 
levels — and less at the thoracic level — some 
obstructions were still present. The next day, 
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his spasticity considerably improved to MAS 1, 
and the paroxysmal spasms almost completely 




This small case series showed that rostral CSF 
flow restoration could solve ITB failure in SCI 
patients with an intrathecal flow obstruction. 
All patients had a previous successful ITB bolus 
injection test and were, therefore, suitable can-
didates for long-term ITB. As a consequence, 
the short benefit duration in one patient was 
unexpected, while the other four patients had 
successful ITB for years. 
Adhesions
In line with the literature,8 we identified perop-
eratively severe adhesions in three patients and, 
in two, even crystalloid drug accumulation in 
several loculations. We observed a rostral CSF 
flow obstruction as the cause of ITB failure only 
in traumatic SCI patients, and not in other ITB 
patients. There probably may be a relationship 
with the original trauma or the previous post-
traumatic neurosurgical intervention. It could 
be assumed that the obstruction existed already 
at the start of the ITB treatment. However, the 
experience of excellent treatment for years, 
which is also reported in the literature,8 more 
likely suggests a CSF flow hindrance during 
the course of the ITB treatment. We had no 
information about the preexisting arachnoid-
itis in the referred patients. In our opinion, it is 
not common practice to evaluate arachnoiditis 
before starting ITB. Even when arachnoiditis, 
known or unknown, is present, patients will be 
treated with ITB after a positive diagnostic ITB 
bolus test. The observed loculations may devel-
op after focal arachnoiditis resulting in fibro-
connective adhesions,12 whereby the leptome-
ninges will give rise to loculation formation.13 
This may lead to accumulation of the infused 
medication, which is what we found (Fig. 3D). 
The accumulation of drugs will give rise to a 
high local concentration, which in turn can lead 
to a vicious cycle of chronic arachnoiditis. It is 
assumed that the longer the exposure, the high-
er the probability that a toxic response to the 
drug will occur.14 In chronic intrathecal infusion 
of morphine and hydromorphone, arachnoiditis 
may result in the formation of space-occupying 
masses (granuloma) in the intrathecal space.15,16 
This phenomenon was recently supported by a 
relationship between granuloma formation and 
local mast cell degeneration in intrathecally 
administered drugs.17 Such an association was 
found for morphine and hydromorphone, but 
not for baclofen.17 The difference between the 
mentioned opioids and baclofen is in accor-
dance with clinical experience, in which gran-
uloma formation is a well-known complication 
of intrathecally administered opioids,15,16 but 
rare when using intrathecal baclofen.18–20 The 
extremely low incidence of the reported clinical 
granuloma formation in chronic ITB and the ab-
sence of factors of granuloma development in 
animals and mast cell cultures17 make the etiol-
ogy of obstruction in SCI patients treated with 
ITB unclear. 
Imaging
To be certain of a CSF flow obstruction, the 
Trendelenburg position is crucial in CAP (CT) or 
conventional lumbar CT myelography. When in 
doubt if an obstruction is present, the dynamic 
111In-DTPA often revealed the cause of the ITB 
failure. In a complete obstruction, the observed 
tracer widening and caudal tracer collection on 
the images are probably the result of a back-
flow. 
Interventions
After the success of the first case, we also in-
tended to perform an operative adhesiolysis in 
two other patients. However, despite extensive 
local adhesiolysis, we could not restore the CSF 
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flow. We decided not to extend the laminecto-
my, but to apply an intradural catheter shunt. 
With the shunt, we could obtain improvement 
in both cases, although not in the trunk and the 
right-hand spasticity in one patient. Based on 
our recent experience with promising results, 
we now prefer the less invasive percutaneous 
fenestration as the first step in rostral CSF flow 
restoration. To prevent a multi-segmental lam-
inectomy, the percutaneous technique also has 
the advantage in a more extended length ob-
struction. The method has a potential risk of 
damage in ASIA-B patients in particular (Case 
3). We regarded this as a calculated risk in a 
severely suffering patient after an insufficient 
result from visual microsurgical adhesiolysis. 
This risk was extensively discussed in advance 
with the patient. During the procedure, we in-
flated the small diameter dilatation balloon in 
several steps in such a way that compression 
on the spinal cord was minimal. All the proce-
dures were performed with a continuous awake 
monitoring of the patient to recognize potential 
damage. Before the procedure, we extensively 
discussed the pros and cons of the treatment. 
Another issue could be that in the future, epi-
dural stimulation could be of benefit. Traumatic 
adhesiolysis may interfere with epidural stimu-
lation, as this is reliant on viable axons remain-
ing at the site of the injury. For the moment, we 
will be confronted with ITB failures with, be-
sides adhesiolysis, no other treatment options. 
A larger group of patients and basic research 
are needed for the full elucidation of the effect 
of the restoration. When the balloon inflation 
will not meet our expectations, we will consider 
surgical adhesiolysis with or without a bypass. 
Needed rostral CSF flow
We hypothesized that rostral CSF flow is also 
needed for ITB administration to be effective. 
This is in contradiction to the current view of 
a solely local segmental ITB effect.21–23 With 
rostral CSF flow restoration either by surgical 
adhesiolysis, intradural bypass, or percutaneous 
balloon fenestration, we could obtain improve-
ment in the five treated patients. These pre-
liminary results supported our hypothesis and 
implied that an intervention to restore the flow 
could solve an ITB failure caused by a CSF flow 
obstruction. A recently published case report8 
of the successful use of a subarachnoid-sub-
arachnoid shunt seems to support our results. 
Autonomic dysreflexia control
From our own clinical experience with various 
ITB failures, we know that an ITB failure will not 
only lead to the reoccurrence of severe intrac-
table spasticity, but in high SCI levels, also to 
the lack of autonomic dysreflexia control (Case 
4),24,25 a syndrome that can even be life-threat-
ening.26–29 These features justify extended diag-
nostic procedures and attempts to find a solu-
tion for ITB failure, and not merely to accept ITB 
tolerance as an exacerbation of the underlying 
disorder. 
Duration of the clinical effect
How long the achieved result will last and 
whether we can repeat the procedure in the 
case of recurrent failure are uncertain. A larger 
group of patients and basic research are needed 
for the full elucidation of the effect of the resto-
ration of CSF flow. 
Conclusion
Preliminary results showed that the restoration 
of the rostral CSF flow might result in an effec-
tive ITB treatment in patients with an intrathe-
cal obstruction.  
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Episodic attacks of autonomic dysreflexia (AD) are regularly experienced by patients with a spinal cord injury 
(SCI) on T6 or higher levels. The episodes can result in a pounding headache, flushing, blurred vision, anxiety, 
a stroke, posturing, hyperthermia, retinal bleeding, seizures, myocardial ischemia, cardiac arrhythmias, and 
death. The observed associated bradycardia is explained as a baroreceptor reflex response to the high blood 
pressure. Intrathecal baclofen (ITB) has been used to treat chronic AD. This case highlights the occurrence of 
intractable AD after removal of the ITB delivery system because of a pump pocket infection. We describe the 
benefit of ITB as an emergency treatment for intractable AD. 
Findings
A 53-year-old male suffered from spasticity and AD after a C5 ASI B SCI in 2002 was successfully treated with 
ITB for 14 years. He developed Staphylococcus aureus and Pseudomonas aeruginosa cellulitis at the orifice of 
his suprapubic catheter, which caused an abscess in the pump pocket. To prevent a withdrawal syndrome, the 
medication was reduced in three steps of 25%, and the pump was explanted. Postoperatively, he experienced 
severe AD and was treated with clonazepam, clonidine, and urapidil. The next day, the severely fluctuating 
blood pressure and pulse rate were no longer controllable with the medication. At L2-3, a temporary external 
intrathecal catheter for reinitiating ITB was inserted. With this treatment, the AD and the spasticity symptoms 
could be controlled.
Conclusion/Clinical Relevance
The case demonstrated that refractory AD could be managed with ITB in an emergency.
Keywords




Episodic attacks of autonomic dysreflexia (AD) 
(“sympathetic storm”) are regularly experi-
enced by patients with a spinal cord injury (SCI) 
on T6 or higher levels (above the outflow to the 
splanchnic and renal vascular beds).1-5 Noxious 
or innocuous visceral or somatic stimuli below 
the SCI lesion such as bladder and bowel irrita-
tion1,3,6 can lead to a sudden excessive sympa-
thetic response. Spasticity, pain, sexual activity, 
pregnancy, delivery, pressure sores, and iatro-
genic medical procedures are also known to 
trigger AD.1,3,7 Loss of descending inhibition re-
sults in higher levels of norepinephrine release, 
which is responsible for cold, pale skin vaso-
constriction below the level of injury.3,8 The ob-
served associated bradycardia is explained as a 
baroreceptor reflex response to the high blood 
pressure.2,3,6 The AD syndrome varies from 
silent, mild forms with diaphoresis above the 
lesion and piloerection to a severe, life-threat-
ening situation.2,7 These attacks can happen up 
to 40 times a day.4 The episodes can result in 
a pounding headache, flushing, blurred vision, 
anxiety, a stroke, posturing, hyperthermia, ret-
inal bleeding, seizures, myocardial ischemia, 
cardiac arrhythmias, and death.1-3 Intrathecal 
baclofen (ITB) has been used to treat chronic 
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AD.9,10 We report the application of ITB in an 
emergency case of acute intractable sympa-
thetic storm. After the approval of the medical 
ethics committee of Erasmus Medical Center 
(MEC-2017-326), we retrospectively studied 
the case. The requirement to obtain informed 
consent was waived.  
Presentation of the case
A 53-year-old male suffered from spasticity 
and AD after a C5 ASI B SCI in 2002. Initial-
ly this complaint was controlled with oral ba-
clofen. Due to progression of spasticity, ITB 
was administered after two years. For fourteen 
years, the patient was treated with ITB using 
an implanted infusion system (SynchroMed 
II, Medtronic Inc., Minneapolis, MN, USA). 
During that time, a neuropathic pain developed 
below the level of the SCI and morphine was 
added to the ITB. Complaints were again under 
control with intrathecal morphine of 1.2 mg/
day and ITB of 192 mcg/day. More recently, 
the patient developed a cellulitis at the orifice 
of his suprapubic catheter. Initially, we started 
with flucloxacillin 4 g/day. After the bacterio-
logical culture revealed both Staphylococcus 
aureus and a Pseudomonas aeruginosa, the 
antibiotic treatment was changed to piperacil-
lin/tazobactam 16/2 g/day, and vancomycin 2 
g/day. The local infection quickly subsided with 
the antibiotic treatment, but the development 
of erythema and swelling around the pump in 
the left abdominal wall indicated that the infec-
tion had spread to the device. We feared that 
the abscess would force the infection to spread 
along the catheter to the epidural and intrathe-
cal space in a matter of days. 
Explantation of the pump was thus deemed 
necessary. To prevent a withdrawal syndrome, 
we reduced the medication in three steps by 
25%. Concomitantly, as a cross titration we 
started with oral baclofen and transdermal fen-
tanyl (50 mcg). As intrathecal baclofen was still 
administered, we started with a low oral ba-
Figure 1. Autonomic Dysreflexia: Severe fluctuations in blood pressure (black arrow) and pulse rate (gray 
arrow).
Intrathecal baclofen as emergency treatment alleviates severe intractable autonomic dysreflexia in cervical 
spinal cord injury
Figure 2. The treatment approach of a secondarily infected pump pocket (red arrow). The original infection 
was cellulitis at the orifice of a suprapubic urine catheter (yellow arrow). The implanted port system (white 
arrow) is connected with a hardly visible Ascenda intrathecal catheter. The port system is percutaneously 
punctured with a 90° Huber needle (green arrow).
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clofen dose of 40 mg, which was increased to 
80 mg while concomitantly reducing the intra-
thecal administration. At day four we removed 
the entire device. We did not find any sign of an 
infection dorsally at the catheter insertion site, 
but we identified an abscess in the abdominal 
pump pocket. The day thereafter, the patient 
developed episodic a severe headache, exces-
sive perspiration and piloerection in the upper 
part of the body, and severely varying blood 
pressures (BP), and pulse rates (PR), without 
pain, fever, respiratory insufficiency, and with 
except for a C-reactive protein of 73 mg/ml 
and an alkaline phosphatase of 135 U/l all lab-
oratory values were normal and remained un-
changed in the following days (Fig. 1). Thereby 
was his spasticity under control with oral ba-
clofen and intravenous clonazepam.
With a diagnosis of AD, related with a with-
drawal syndrome, the patient was admitted to 
the ICU and initially was successfully treated 
with a mixture of clonazepam, clonidine and 
urapidil. However, the next day the clinical 
situation was complicated by the patient’s di-
minished consciousness, later diagnosed as a 
posterior reversible encephalopathy syndrome 
(PRES).11 The severely fluctuating BP and PR 
returned, and the maximum tolerable oral and 
intravenous substitution was insufficient to 
compensate for the prior highly efficient route 
of administration of his baclofen.
A distinct subarachnoid hemorrhage (SAH) in 
the left frontal lobe was identified with MRI 
(Fig. 2). To alleviate the AD, we inserted at 
L2-3 a temporary external catheter (Perifix 
19G, B. Braun, Oss, The Netherlands) 30 cm 
intrathecal for reinitiating ITB (Fig. 2). After a 
positive 50 mcg single bolus, we titrated ITB 
up to 240 mcg/day using a standard syringe 
pump. With this treatment, we could manage 
the AD and the spasticity symptoms. After one 
week, we removed the temporarily external 
catheter and replaced it with a definite intra-
thecal Ascenda catheter (Medtronic Inc., Min-
neapolis, MN, USA). In order to bridge the time 
until the pump pocket infection was cured, we 
temporarily connected the catheter to a sub-
cutaneously implanted portal system (Porthales 
4000, Tricumed Medizintechnik GmbH, Kiel, 
Germany) at the opposite site (costal 10–11 
level). After a dose titration ITB up to 384 mcg/
day using a CADD-Solis external pump (Smiths 
Medical ASD, Inc., St. Paul, MN, USA), we 
discharged the patient from the hospital. Ten 
weeks later, we removed the portal system and 
connected the catheter to a new pump in the 
lower right abdominal quadrant. The patient 
gradually recovered from the PRES. His spas-
ticity and AD were brought under control with 
ITB of 384 mcg/day, and his pain by intrathecal 
morphine of 1.2 mg/day. 
Discussion
To our review, emergency resumption of ITB as 
treatment of life-threatening withdrawal syn-
drome with AD that has not been reported be-
fore. The cyclic character, the excessive regional 
perspiration, piloerection in the absence of pain 
and missing symptom control by an additional 
administrated opioid, we assumed opioid with-
drawal was not likely. To preempt or minimize 
a withdrawal syndrome,12 we performed a 
cross titration initially with only oral baclofen, 
and later with the addition of clonazepam; 
furthermore, to prevent an opioid withdrawal, 
we used transdermal fentanyl. In our practice, 
we wean the intrathecal medication arbitrarily 
in steps of 25% while concomitantly starting 
oral and transdermal treatment. This manner of 
weaning is the compromise to prevent a with-
drawal syndrome versus the potential for devel-
opment of meningitis. Based on our experience, 
we assume the same clinical aggravation would 
have emerged after a slower weaning protocol. 
Thereby, it should be taken into consideration 
that the fear the abscess would force the infec-
tion to spread along the catheter to the epidur-
al and intrathecal space in a matter of days is 
Chapter 9
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the reason for other physicians deciding upon 
the immediate removal of the implanted infu-
sion system, thus preferring to take the risk of 
a withdrawal syndrome instead of the devel-
opment of severe meningitis. The symptom-
atology, in this case, differed from the regular 
ITB withdrawal syndrome, as his spasticity was 
under control with no signs without fever, respi-
ratory insufficiency, or a multiorgan failure. Our 
patient was previously diagnosed with severe 
AD that was successfully suppressed with ITB. 
The patient exhibited intractable sympathet-
ic storms as a result of a spasticity exacerba-
tion. Possible confounding factors could be 
the cessation of intrathecal morphine and the 
presence of an infection, which itself could 
lead to an autonomic disturbance. However, 
AD did not occur in the previous cellulitis at 
the orifice of the suprapubic catheter period, 
but developed several days later. Per protocol, 
we explored the common causes of an auto-
nomic disturbance, including bowel, bladder, 
and skin problems. Also, a physical examina-
tion and computed tomography did not reveal 
additional treatable disorders to remove the 
triggers. Also, to our best knowledge a relation 
between the presence of morphine in the ITB 
pump and the development of AD is unknown. 
A primary concern is the paucity of knowledge 
of the syndrome AD among caregivers8 and 
additionally the limited knowledge of ITB, in 
particular its value in preventing AD.9,10 We ob-
served a protracted duration of the syndrome 
over hours, which is consistent with prior stud-
ies.13,14 The patient revealed an excessive fluc-
tuating BP and PR. the patient’s varying sys-
tolic BP of 90 to 155 mmHg exceeds the norm 
of 150 mmHg5,7 as well as the sudden 20–40 
mmHg elevation7,15 and should therefore also 
be considered excessive. Moreover, the associ-
ated HR of 149/min was extreme. Because we 
could not control the clinical situation with the 
applied medication, we were forced to reiniti-
ate ITB. With no sign of a local dorsal infection, 
clear CSF, and a CSF Gram examination that 
had not revealed microorganisms at the remov-
al of the implanted device, we decided upon 
a catheter insertion, although we were at that 
time not informed about the bacterial culture. 
We regarded the insertion of a foreign body 
such as the temporary intrathecal catheter into 
a potentially infected area as a calculated risk 
for the introduction of meningitis. We consid-
ered the development of PRES and SAH as a 
direct complication of the frequently repeated 
hypertensive crises. 
Based on this case, we propose that ITB in-
fusion using a temporary intrathecal catheter 
during emergency situations could be possible 
in every hospital. In our experience, the higher 
ITB dose at the end after a catheter replace-
ment is not uncommon. We are not aware 
of a clear explanation. A different intrathecal 
catheter tip level or other ventral/lateral/dorsal 
position could be an option. Also, it is not ex-
cluded that the clinical situation has worsened 
the spasticity and AD complication, resulting in 
the need for a higher dose. A limitation of this 
study is the retrospective design and the expe-
rience in only one patient. 
 
Conclusion/Clinical relevance
The premise of the case is the rapid reintro-
duction of ITB (as opposed to iv and oral anti-
spasmodics) in the setting of ITB withdrawal in 
particular when associated with AD to prevent 
complications (in this case, PRES, SAH). Further 
in-depth study is necessary to validate our ob-
servation.
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The knowledge of many physicians about ITB is 
limited as ITB is a treatment with low volume. 
This problem is exacerbated by the lack of con-
centration ITB therapy in a limited number of 
treatment centers and the need for involvement 
of many medical specialists including neurolo-
gists, rehabilitation physicians, nursing home 
physicians, neurosurgeons, interventional an-
esthesiologists, emergency physicians, radiolo-
gists, and nuclear physicians. The restricted ap-
plication of ITB treatment and resulted limited 
expertise has led to incorrect referrals and in-
sufficient diagnostic and treatment procedures, 
a lack of awareness of potentially lifethreaten-
ing situations, and a lack of around-the-clock 
availability of professionals with expertise of 
ITB. This situation is at odds with the critical 
nature of the assessment of the indication for 
ITB, the logistical requirements involved in pa-
tient selection, the surgical intervention, ITB af-
tercare, and ITB troubleshooting. It is therefore 
not surprising that incorrect assessment of drug 
tolerance and unjustified conclusions regarding 
the exacerbation of the underlying disorder are 
common. The abovementioned issues were 
the main reason for the studies in this thesis, 
aiming to improve 1) ITB aftercare, 2) the di-
agnosis of ITB related complications and 3) the 
treatment of ITB treatment failure. 
The specific objectives of the thesis 
Objective 1: To evaluate the safety and 
 efficiency of a home-based ambulant clinic 
for aftercare (Chapter 2)
In the study that focused on the development 
and evaluation of the home-based Ambulant 
Care Clinic, the efficiency and safety of high-
level standard aftercare with intrathecal ba-
clofen on location were proven. 
For safety management, the Dutch Technical 
Agreement 8009 “Safety management system 
for hospitals and organizations which adminis-
ter hospital care was followed. For risks man-
agement of the near incidents, the “Healthcare 
Failure Mode and Effect Analysis (HFMEA) of 
the “National Center for Patient Safety (NCPS) 
was applied. In case of a high risk of frequen-
cy and severity of consequences, an extensive 
PRISMA Medical analysis (Prevention Recovery 
Information System for Monitoring and Analy-
sis) to manage structural human errors in prac-
tice was made. A quality and safety certifica-
tion procedure were performed annually by an 
independent professional inspection institute 
(KIWA, Rijswijk, the Netherlands). With the 
approach of the home-based Ambulant Care 
Clinic, transport to the hospital or center, which 
is often a burden for severely handicapped pa-
tients, was significantly reduced. This approach 
paves the way for further applications of ITB 
therapy in severely handicapped spastic pa-
tients and therefore has the potential to ad-
dress ITB undertreatment.
To improve ITB troubleshooting, an expert 
center that engages in close cooperation with 
a home-based Ambulant Care Clinic was es-
tablished. In addition to addressing the im-
portance of daily care, the partnership was 
used to provide a solution to the problem of 
realizing around-the-clock availability of ex-
perienced caregivers. The center also features 
a double-check facility, i.e. a real-time con-
trol by two persons. This control check is cru-
cial for protecting not only the standard “five 
rights”1 (right person, right drug, right dose, 
right route of administration, and right time) 
but also for the appropriate concentration of 
the medication and the appropriate complex 
pump programming. With the support of the 
nurse practitioners of the home-base Ambu-
lant Care Clinic in our center, a unique infra-
structure required for around-the-clock ITB 
troubleshooting was realized. Currently, in the 
Netherlands, the home-based Ambulant Care 
Clinic is responsible for the aftercare of 40% of 




aftercare approach does not exist, which is 
tremendously problematic in severely handi-
capped spastic patients. Missing the aftercare 
structure will result in frequent visits of the 
patients to the neuromodulation center, which 
seems to be an important factor of the world-
wide ITB undertreatment. (See comments of 
the reviewers Chapt.2) In some countries the 
drug device company technicians take care for 
the refills and reprogramming in severely hand-
icapped patients, which does not meet the 
current requirements of patient care (Personal 
communication).
Objective 2: To describe the various causes of 
ITB failure (Chapter 3,6,7) 
The majority of the different diagnostic pro-
cedures were performed in patients referred 
from other centers with the diagnosis of ITB 
drug delivery failure, in which the underlying 
cause could not be found. The patients were 
referred with the diagnosis: “tolerance for the 
treatment” or “an exacerbation of the under-
ly-ing disorder”. This conclusion could have an 
enormous impact on the quality of life of pa-
tients with intractable spasticity. We performed 
an extensive diagnostic imaging workup which 
could include multiple diagnostic modalities. As 
described in the thesis we could find the cause 
of the failure in a substantial number of pa-
tients, followed by successful treatment. In cas-
es where we could not identify an abnormality, 
extensive attempts with dose adaptations were 
undertaken to obtain again a positive effect 
of the ITB treatment. With dose adaption we 
were also successful in a substantial number of 
cases.
Reported drug delivery device-related adverse 
events are2-26: pump failure, hypermobility of 
the pump, skin irritation with wound dehis-
cence, infection, and catheter related prob-
lems. However, most of the adverse events are 
caused by intrathecal catheter failure.2-26 The 
main reasons for this are migration, lacerations, 
occlusion, and disconnection of the cathe- 
ter.  Although the performance of the current 
Ascenda catheter felt to be improved,27 a defi-
nite conclusion about its superiority over the 
old catheters cannot be made yet. Besides its 
potential improvement, a significant problem 
arose after its introduction caused by a reduced 
opacity on plain radiography, which hinders 
the diagnosis of catheter-related problems. 
Our study is hampered by a bias of a highly 
selected patient population. The majority of 
the patients with catheter-related problems 
were not referred but were already treated in 
the original center. As a result, we were deal-
ing with referred patients of intractable ITB 
failure in a subacute or chronic situation. The 
identified causes after our diagnostic workup 
were mainly catheter problems like occlusion, 
catheter leakage, epidural and subdural posi-
tion, dura leakages, and CSF flow obstructions. 
Pump-related problems were not found.
CSF flow obstruction resulting in inadequate 
distribution of the medication has not been 
described in the literature as a relevant com-
ponent in ITB failure. The studies on intrathecal 
drug delivery are concentrated on the applied 
infusion device and not on the rostral distri-
bution of the medication in the subarachnoid 
space. This is probably caused by previous re-
ports in which only the segmental effects of in-
trathecally delivered baclofen medication was 
described.28,29 Based on the results of success-
ful treatment of the underlying causes of ITB 
failure, which were detected after extensive 
diagnostic procedures in our studies, we con-
cluded that in ITB failure, a final diagnosis of 
“tolerance” or “an exacerbation of the under-
lying disorder” is only justified after extensive 
diagnostic procedures.
Objective 3: To assess the role of radiological 
and nuclear imaging techniques in identifying 
the cause of ITB failure (Chapter 3,5,6)
The advanced radiological and nuclear imag-
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ing techniques performed in the studies have 
played a crucial role in identifying the cause 
of ITB failure, which was not found in the re-
ferral centers. In about half of radiological and 
two-thirds of nuclear medicine procedures, we 
could identify the cause of ITB failure.
Plain radiological imaging is currently the cor-
nerstone for the diagnosis of catheter-related 
adverse events in ITB. Catheter-pump or cathe-
ter-catheter segment disconnections, dislodge-
ment, shearing, and pump displacements are 
crucial issues related to the sudden termination 
of ITB infusion. However, with plain radiogra-
phy, only the metal catheter tip, unfolded fix-
ation anchor, and needlelike catheter–catheter 
segment of the currently standard Ascenda 
intrathecal catheter are visible; as such, pivot-
al information regarding the catheter course 
and its connections may be missed. Although 
earlier models of catheters that are still in use 
exhibit better opacity, their visibility can also be 
problematic. 
We implemented and optimized as advanced 
imaging procedure pump catheter access port 
(CAP) myelography and CAP-CT myelography. 
These procedures allow the evaluation of the 
catheter over its full length and improved the 
diagnosis of disconnection, catheter leakage, 
dural leakage and malposition. In addition, 
we applied 111In-DTPA scintigraphy when we 
could not aspire CSF via the CAP, or when the 
CAP-procedures did not reveal the diagnosis, 
or when we were uncertain about it. We also 
optimized the procedure and assessed the ac-
curacy of the modification of its use in ITB fail-
ure. With 111In-DTPA scintigraphy functional 
information about the temporal distribution of 
medications was helpful in detecting CSF flow 
obstruction as the cause of ITB failure. In some 
patients, we have used MRI to identify an in-
trathecal process.
Despite an optimal diagnostic approach, an 
additional problem is the restricted applica-
tion of ITB treatment, which has the conse-
quence that, for many radiologists, imaging 
assessments may be hindered by insufficient 
knowledge of the structure of the drug delivery 
system. Missing a standardized assessment of 
interpretation, a 14-step interpretation check-
list for systematic assessment of plain radiogra-
phy was developed based on an analysis of the 
procedures performed in our clinic. The same 
checklist could be used in case plain radiogra-
phy will be replaced by low dose CT scan. 
Another problem is the lack of awareness of 
emergency issues related to abnormal radio-
logical findings indication potential failure in 
drug administration. A sudden termination of 
ITB ad-ministration may cause a progressive 
and potentially life-threatening withdrawal 
syndrome. The multidisciplinary discussion of 
patients and diagnostic exams in our center 
has increased the awareness of reporting ra-
diologists.
Objective 4: To investigate the optimization of 
radiological and nuclear imaging techniques 
(Chapter 3-5)
The appropriateness of existing algorithms in 
troubleshooting and the involved diagnostic 
procedures is under debate. Of particular con-
cern is the use of CAP myelography. Based on 
the results of our study, we agree with Saulino 
et al.30 that CAP (CT) myelography should be 
included in the algorithm of ITDD failure. As a 
new approach, we optimized the CAP CT my-
elography with 1) the addition of dualenergy 
CT, 2) with 2D/3D reconstructions and volume 
ren-dered images, 3) with image reconstruc-
tion with a large field of view. With dual-en-
ergy CT beamhardening artifacts around the 
implanted titanium pump could be reduced. 
2D/3D reconstructions and volume-rendering 
provide optimal visualization of the pump and 
catheter structures. A large field of view visu-
alizes not only the vertebral column but also 
the pump and the extra-vertebral path of the 
catheter, which allows the detection of cathe-
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ter leakage, catheter obstruction, or abnormal 
rostral spread of injected contrast material. 
111In-DTPA scintigraphy was optimized by 
1) standardizing the pump flow rate, 2) the 
addition of SPECT-CT and 3) a stepwise and 
standardized interpretation of images. With 
this improved procedure, the cause of delivery 
failure could be correctly identified in more pa-
tients, which resulted in a diagnostic improve-
ment compared to the conventional approach 
in 111In-DTPA scintigraphy. With the standard-
ized pump flow rate, intrathecal tracer transit 
time to the cerebral cisterns could be assessed. 
We demonstrated that the tracer transit time 
and the related magnitude of the tracer activity 
in the cerebral cisterns are pivotal for correct 
imaging interpretation. Delayed tracer transit 
time and reduced tracer in the cerebral cisterns 
is an indication for hindered transport in the 
catheter or intrathecal space caused by partial 
obstruction. 
Based on our studies we disagree with the 
statement in the literature that presence of 
tracer activity in the intrathecal space31 or the 
cerebral cisterns32 excludes an abnormality. 
The studies indicated also that the addition of 
SPECT-CT33 improves the localization of tracer 
accumulation caused by structural or functional 
disorders.
Objective 5: To investigate the role of low-dose 
single-energy computed tomography as a re-
placement for plain radiography (Chapter 4,5,7)
The currently used standard intrathecal cath-
eter imaging with plain radiography is ham-
pered by inferior catheter opacity. For this rea-
son, there is an urgent need for improvement 
of the limited opacity of the applied catheters. 
We investigated the use of low-dose CT as a 
replacement of conventional plain radiogra-
phy as the first line of diagnostic evaluation. 
CT with 2D/3D post-processing reconstruc-
tions based on maximum intensity projection, 
multiplanar reformation, and volume rendering 
techniques could provide optimal visualization 
of the entire catheter pathway. However, the 
rather high radiation exposure associated with 
standard high-resolution CT imaging limits its 
use for routine imaging. To examine the possi-
bility of obtaining high-resolution imaging with 
a reduced dose, a phantom study focusing on 
a low-dose single-energy 2D/3D CT scan was 
conducted. Scans were performed with various 
acquisition and image reconstruction settings 
to evaluate the trade-offs among the catheter 
visibility, the pump beam-hardening artifacts, 
and the radiation dose. A clinical protocol us-
ing Sn100 kVp with 2D/3D single-energy CT 
reconstruction as a substitute for routine ob-
servational plain radiography was defined. We 
expect that in the future, plain radiography for 
postoperative documentation and for exclusion 
of catheter-related problems in the emergency 
setting will be replaced by low-dose single en-
ergy CT with 2D/3D reconstructions.
Objective 6: To evaluate the appropriateness 
of cerebrospinal fluid (CSF) flow restoration in 
case of spinal canal obstruction (Chapter 8)
ITB treatment failure in patients with spinal 
cord lesion can have specific causes related 
to CSF flow obstruction. In case of ITB failure 
catheter replacement will not solve the clini-
cal problem. These patients normally will be 
considered to be tolerant to the treatment. In 
several of these patients, who were ultimate-
ly referred to our center, we were able to di-
agnose intrathecal CSF flow obstruction. The 
obstruction could be identified with a catheter 
access port CT myelography or scintigraphy. 
Occasionally lumbar CT myelography was per-
formed. Before adhesiolysis, information about 
the length of the obstruction in the spinal canal 
is crucial. Cervical retrograde CT myelography 
can be performed to assess the upper limit. The 
catheter access port or lumbar CT myelography 
can be used for estimation of the lower limit.
We hypothesized that the intrathecal obstruc-
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tion was probably related to chronic arachnoid-
itis, that chronic arachnoiditis hampers rostral 
flow of CSF and baclofen and that rostral CSF 
flow is a prerequisite for successful ITB treat-
ment. Based on this hypothesis, CSF flow in 
these patients was restored with either micro-
surgical repair or percutaneous balloon adhe-
siolysis, which resulted in a solution for ITB 
failure. Remarkably, with the exception of one 
case, the ITB treatment proved successful for 
many years. Scarce information is present in 
the scientific literature. Only one patient with 
a subarachnoid-to-subarachnoid shunt treat-
ment has been reported.34 How long the per-
formed adhesiolysis will last is unclear, and the 
clinical results should be followed.
Objective 7: To report about emergency ITB 
treatment in severe, intractable autonomic 
dysreflexia as result of an ITB withdrawal 
syndrome (Chapter 9)
In addition to the baclofen withdrawal syn-
drome that can be caused by the sudden termi-
nation of ITB, severe sympathetic hyperactivity 
in patients with a spinal cord lesion above T6 
or a cerebral lesion can occur. The associated 
extreme fluctuations in blood pressure can give 
rise to stroke, posturing, hyperthermia, retinal 
bleeding, seizures, myocardial ischemia, cardi-
ac arrhythmias, and death.35-39 In one of our 
patients the ITB delivery device had to be ex-
planted due to infection. Discontinuation of ITB 
resulted in a therapy-resistant life-threatening 
sympathetic storm which occurred as a result of 
autonomic dysreflexia. To continue ITB, it was 
decided to use a temporary intrathecal catheter 
and infusion with an external pump device as 
an emergency treatment. The results indicate 
that a life-threatening sympathetic storm can 
successfully be treated with ITB. It seems that 
ITB not only prevents severe autonomic dysre-
flexia, as stated in some case reports,39 but is 
also of value as an emergency treatment. 
Strength and limitations 
•  The concept of aftercare on location (Chap-
ter 2) is an innovative and patient-friendly 
initiative. Despite the retrospective nature of 
the study included a large number of patients 
and was able to demonstrate its efficacy and 
safety.
•  The proposal for a systematic analysis of plain 
radiography in patients treated with intrathe-
cal drug delivery using an implantable pump 
device (Chapter 3) is the most extensive de-
scription of potential problems that can be 
detected. The study has significant education 
and clinical aspects for radiologists who lack 
knowledge about the used implanted drug 
delivery device and the consequences of an 
abrupt cession of the intrathecal drug deliv-
ery. In addition to this, systematic assessment 
of plain radiography has also clinical implica-
tions for treating physicians.
•  Phantom studies were performed to evaluate 
the optimal acquisition and reconstruction 
parameters of a low-dose CT with a side-
by-side evaluation with plain radiography 
(Chapter 4). This technological approach 
guarantees that a new imaging approach en-
ters the clinical domain arena after adequate 
evaluation and optimization. The results are 
promising with important clinical implications 
as it solves the problem of poorly visible in-
trathecal catheter structures on routine ob-
servational plain radiography.
•  The study of the catheter access port (com-
puted tomography) in the intrathecal drug 
delivery study (Chapter 5) is a unique anal-
ysis with a significant educational and clinical 
implication of the optimized procedure.
•  Reports on application of 111In-DPTA SPECT-
CT is limited to 11 procedures in 9 patients.33, 
40 Our study reporting on 36 examinations in 
27 patients is therefore extensively increasing 
the number of reported cases. The multiple 
image acquisitions per patient allowed us to 
study temporal distribution of medication 
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and to detect CSF flow alterations. This was 
only possible after optimizing and standardiz-
ing the imaging procedure (Chapter 6). 
•  As a next step after the detection of CSF flow 
obstruction we hypothesized that rostral CSF 
flow is needed for an effective ITB treatment. 
This hypothesis was leading in the develop-
ment and implementation of a surgical or 
minimal invasive restoration of rostral cere-
brospinal fluid flow in patients with a proven 
obstruction. The preliminary results showed 
indeed that the restoration of the rostral CSF 
flow might result in an effective ITB treat-
ment in patients with a spinal cord lesion 
complicated with an intrathecal obstruction 
(Chapter 8).
However, the studies also have several limita-
tions:
•  Although, the different studies in this thesis 
included the largest number of patients com-
pared to previous studies, the sample sizes 
are too small to draw firm conclusions. The 
number of patients per year treated in the 
Netherlands is approximately 1000, with an 
incidence of new treatments of 100 per year. 
We have focused on problem solving in in-
tractable ITB failure which has restricted the 
number of patients that could be included in 
our studies.
•  This thesis is a retrospective analysis based 
on available data. This has resulted in a het-
erogenous data set as clinical work up and 
data collection was unstructured. The ob-
servational routinely collected data analysis 
could not be addressed with existing report-
ing guidelines such as Strengthening the 
Reporting of Observational in Epidemiology 
(STROBE).41 
•  As we included patients referred from other 
hospitals with intractable ITB failure we have 
studied a highly selective group of patients. 
This could be result in an overestimation of 
the diagnostic accuracy of the evaluated ad-
vanced imaging techniques.
•  In all studies we were faced with the absence 
of a standardized reference test. In most 
studies the reference test was based on a 
composite of all available data. Ideally all pa-
tients should have undergone an intervention 
to find out what the real cause was of ITB 
failure. This was considered to be unneeded 
and unethical in those patients in whom the 
diagnostic procedure was normal. However, 
even not all patients with image abnormali-
ties underwent an intervention. On the oth-
er hand, one may argue that the best prove 
for a good diagnosis is not the interventional 
confirmation, but improvement of symptoms 
after treatment focused on the potential 
cause of ITB failure
Implications for clinical practice
The results of the thesis indicate possibilities 
for  improvements in the diagnosis and treat-
ment of ITB failures. More precisely, the impli-
cations for clinical practice are:
•  The radiologist must be informed about the 
systematic medication delivery path assess-
ment, starting at the pump and ending at the 
catheter tip or the cerebral cisterns.
•  The radiologist must be informed about the 
emergency of a radiological examination, 
and their interpretations in ITB withdrawal 
syndrome and (s)he must immediately inform 
the involved clinician about potential causes 
of ITB failure.
•  Plain radiography can be replaced by low-
dose energy CT with 2D/3D reconstructions.
•  With the optimized catheter access port, 
dual-energy CT myelography with 2D/3D 
reconstructions, precise information about 
the delivery system can be obtained with a 
reduction of beam-hardening artifacts. 
•  With the optimized 111Indium-DTPA SPECT-
CT, more correct diagnoses can be made.
•  The nuclear medicine physician is aware of 
the systematic assessment of the drug deliv-
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ery path, starting at the pump to the cerebral 
cisterns taken into consideration the pivotal 
tracer transit time.
•  The involved ITB-treating physician is in-
formed about the importance of advanced 
diagnostic image procedures. Both catheter 
access port (CT) myelography and scintig-
raphy have their role in the diagnostic algo-
rithm.
•  Percutaneous balloon fenestration for ad-
he-siolysis in the spinal canal in spinal cord 
le-sion patients with ITB failure seems to be 
promising. However, the definite conclusion 
about its clinical value has to be evaluated.
•  ITB can be used as an emergency treatment 
in life-threatening autonomic dysreflexia in 
high level spinal cord patients.
Future research
Following the completion of this thesis, several 
questions remain unanswered; in addition, im-
proving the treatment presents new challeng-




Randomized controlled trials (RCT’s) of intra-
thecal baclofen bolus injections, and a study of 
three months continuous infusion42 have pro-
vided significant evidence that ITB reduces in-
tractable generalized spasticity.26,42-46 The latter 
study of three months duration in patients with 
a spinal origin of spasticity42 has not a blinded 
evaluation of the out-come because all patients 
have undergone a lumbar baclofen bolus in-
jection test in advance and  as reported in the 
study all patients have experienced a positive 
result of this bolus. Repeating the study and 
omitting the lumbar baclofen test bolus is un-
justified in RCT’s in which patients with a spinal 
origin of spasticity are included. However, RCT’s 
on patients with spasticity of supraspinal origin 
are lacking and randomization between three 
months treatment versus placebo is possible in 
certain circumstances. In addition, advanced 
clinical insight has revealed that in particular in 
this specific group not all patients respond to 
a lumbar baclofen bolus test. It might well be 
that patients with a negative test lumbar bolus 
injection will respond to long-term continuous 
infusion with an intrathecal catheter tip posi-
tion based on the clinical manifestation of the 
spastic syndrome. This means that patients with 
a negative lumbar test bolus injection, placebo 
controlled RCT with cervical or low thoracic 
catheter tip position for respectively lower and 
upper extremity spasticity could be performed. 
Since RCT’s for long-term applications are un-
ethical, the justification for chronic ITB and in-
sights into the side effects and complications 
thereof must be derived from prospective ob-
servational studies. 
Prospective studies could be carried out in our 
setting of a University Medical Center (Erasmus 
MC) with the integrated ambulant care clinic 
(Care4homecare). The standardized visits on 
location offer unique possibilities of reducing 
the known complications of noncompliance 
and missing outcomes.
The results of long-term application and in-
sights into the side effects, complications and 
costs can be derived from certain observational 
studies. Such research must provide greater in-
sight into dose escalations, dose tolerance, the 
possible relationship between dose escalations 
and the development of intrathecal obstruc-
tions, the optimal catheter tip position, and 
the diagnostic value of dose escalation for the 
development of failure. The study could also 
include a long-term evaluation of the CSF res-
toration treatment in cases involving CSF flow 
obstructions and increased sympathetic activity 
in spinal cord injury and cerebral lesion patients. 
Finally, this study will also provide data which is 





Peroperative contrast material injection 
followed by low-dose 2D/3D single-energy 
computed tomography
Reliable assessment of CT myelography in cas-
es of intrathecal drug delivery failure is diffi-
cult, as normal reference images are lacking. 
To  improve the detection of abnormalities as a 
cause of ITB failure postoperative CT myelog-
raphy could be performed after  peroperative 
injection of contrast material via the catheter. 
The obtained CT myelography could be prove 
the optimal positioning of the catheter and the 
baseline images could be used for comparison 
with follow-up studies in the case of drug de-
livery failure.
Computed tomography myelography before 
intrathecal baclofen treatment in spinal cord 
lesion patients 
The rostral CSF flow obstruction observed 
in spinal cord lesion patients treated with ITB 
could be a reason to perform CT myelography 
prior to ITB treatment. The goal is to obtain in-
formation regarding the presence of obstructive 
arachnoiditis and to acquire a baseline image 
for comparing when treatment failure occurs. A 
topic for further study is whether an identified 
CSF flow obstruction should be treated before 
the start of ITB treatment or when ITB treat-
ment failed to relieve symptoms immediately 
after the start of treatment or during follow-up.
The measurement of cerebrospinal fluid pres-
sure as a diagnostic tool for obstruction
A partial or complete obstruction within either 
the drug delivery system or in the spinal canal 
with reduced CSF flow is difficult to identify. 
Flow measurement at the catheter tip is not 
possible with the SynchroMed II drug delivery 
system. Pressure measurement via an inserted 
needle in the pump CAP47 has been recently 
proposed.
Normal catheter visible (A), some fibrotic reactions around the catheter (B), severe fibrosis around the catheter 
(C), normal intrathecal image (D), partial obstruction (E), and complete obstruction (F).
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Spinaloscopy
Further research could explore the use of spi-
naloscopy to evaluate normal imaging find-
ings and as a tool to support the treatment of 
(partial) intrathecal obstruction. The advantage 
would be obtaining information about obstruc-
tions in the intrathecal space and the ability to 
compare the results with those of radiological 
and nuclear scintigraphy examinations. The 
disadvantages are the interventional nature of 
the procedure and the vulnerability of the ap-
plied fiber optic scope device.
Intrathecal drug distribution
Numerous factors influence intrathecal drug 
distribution, including anatomical abnormal-
ities, patient posture, infused medication, in-
fusion baricity and rate, catheter diameter, 
lumbosacral CSF volume, CSF density and pres-
sure.48 Intrathecal infusions can therefore lead 
to high interpatient variability in drug distribu-
tion, even with the same dosage and under 
controlled settings.49 Recently, it has been hy-
pothesized that variations in CSF pulsatility (in 
terms of frequency and stroke volume) might 
lead to inter- and intrapatient variability in drug 
distribution.48 A cine phase-contrast MRI with a 
computer model50,51 a 4D phase-contrast flow 
analysis52 would likely yield more insights into 
baclofen distribution in different patient pop-
ulations. Such a study could also help to iden-
tify the ideal catheter tip position and volume 
of administered ITB. When 4D phase-contrast 
flow analysis revealed to be a suitable tool to 
determine CSF flow disturbances, it might be 
used in the initial onset and the later phase of 
the upper motor neuron syndrome as a result 
of a spinal cord lesion. If present or worsening 
CSF flow will be identified an RCT on the value 
of restoration of the flow with balloon fenes-
tration could be considered.
Needle and template improvements
In CAP myelography, we found substantial 
problems with needle insertion in the CAP fun-
nel. We found that the thin, vulnerable 24G 
Huber needle exhibited a tendency to bend and 
distort, particularly when inserted into a more 
deeply positioned pump or in the presence of 
rigid fibrotic scar tissue, which results in the 
procedure being challenging. We thus suggest 
the application of a conical 20G–24G needle. 
Another proposal is modifying the template of 
the CAP kit to include a partial open ring.
Remote control
Patients with an implanted SynchroMed II 
drug delivery system face potentially signif-
icant danger should they undergo an MRI 
examination in a hospital that does not have 
expertise in ITB and therefore does not have 
a means of restarting the pump. Although 
the pump generally restarts automatically 
after the MRI procedure, it is possible that 
this restart will not take place, which could 
potentially lead to a severe withdrawal syn-
drome. Remotely controlling of the pump is 
probably a potential solution when an MRI is 
performed. A further step could be minor re-
mote dose adaptations, which would relieve 
disabled patients of the burden of traveling to 
the treatment center or eliminate the need for 
a home visit by the aftercare organization.
Conclusion
As a last available therapy of spasticity for the 
patient, the consequences of ITB failure are 
high, which deserves appropriate attention 
from all caregivers involved. The studies in this 
thesis demonstrate that advanced diagnostic 
and therapeutic procedures in ITB-failure are 
crucial for the restoration of the therapy. The 
results provide insight into the current possi-
bilities of advanced diagnostic procedures. Ap-
plying the proposed systematic assessment of 
plain radiological imaging will probably reduce 
the number of missed diagnoses. The applica-
tion of low-dose CT scan instead of plain radi-
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ography could solve the problem of poorly visi-
ble intrathecal catheter structures, which seems 
to be an important clinical improvement. With 
catheter access port (CAP) CT myelography us-
ing dual-energy CT scanner with metal artifact 
reduction algorithm and 2D/3D reconstruc-
tions, we could demonstrate that CAP CT my-
elography is an essential step in the diagnos-
tic algorithm for cases involving ITDD failure. 
Also, the application of 111In-DTPA SPECT-CT 
is crucial when fluid cannot be aspirated for the 
CAP procedure or when CAP-CT myelography 
does not reveal the cause of the ITDD failure, 
or when information on the CSF fluid dynam-
ics is needed for the correct diagnosis. When 
the studied diagnostic possibilities are applied, 
unjustified conclusions of “tolerance” or “ex-
acerbation of the underlying disorder” can be 
reduced. A successful diagnosis followed by 
adequate treatment and complementary in-
volvement of different medical specialists is an 
important prerequisite for a good outcome. 
The preliminary results of the restoration of 
rostral cerebrospinal fluid flow might lead to 
the development of an effective ITB treatment 
in spinal cord lesion patients with an intrathecal 
obstruction. 
The thesis suggests a need for improvement of 
communication and close cooperation of dif-
ferent medical specialists. Although out of the 
scope of the studies the niche character and 
the fragmentation of the available care could 
be a hindrance for the implementation of an in-
terdisciplinary approach. In a non-acute situa-
tion of ITB failure, the required cooperation can 
probably be reached with increased knowledge 
of available structures. A significant concern is 
the appropriate approach to ITB failure in an 
emergency. For adequate troubleshooting, 24 
hours per day, seven days per week, availabili-
ty of expertise on pump analysis and program-
ming, an infrastructure for “double-check” of 
highly concentrated medication, advanced ra-
diological diagnostics, and an operating room 
and intensive care are required. These require-
ments are not easy to reach. The close collabo-
ration between an expert center and an expe-
rienced ambulant clinic, allowing a permanent 
availability of the needed expertise might solve 
this problem.
This thesis gives answers on questions, but a 
substantial number of unanswered questions 
remain, which will continue to challenge the 
caregivers performing ITB.
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In the introduction, spasticity syndrome was 
briefly described. Spasticity is an important 
symptom of upper motor neuron syndrome. 
This syndrome results from damage to the 
descending cortical-reticulospinal motor path-
ways at the cortical, brainstem, or spinal cord 
level. Baclofen, a vigorous and selective GA-
BA-B receptor agonist in the central nervous 
system, is usually used for drug therapy. How-
ever, due to the blood-brain barrier, relatively 
low CSF concentrations are realized after oral 
administration, which makes the treatment of 
moderate to severe spasticity insufficient. With 
higher oral doses, many side effects can occur. 
Intrathecal administration allows for signifi-
cantly higher baclofen levels to be achieved at 
much lower doses and with fewer side-effects 
Intrathecal baclofen is indicated as a last-resort 
treatment for therapy-resistant disabling gen-
eralized spasticity of spinal or cerebral origin. 
The principle and the problems associated with 
intrathecal baclofen administration (ITB) were 
described. The relative rarity of ITB in the clini-
cal setting may lead to a lack of knowledge on 
the part of medical practitioners and a subse-
quent underutilization of this treatment. In the 
event of complications, diagnostic procedures 
seem to be too few, too limited, or performed 
too late. Surgical reinterventions are frequently 
conducted with only limited diagnostics or in 
the absence of any such procedures. Further-
more, the effects of sudden termination that 
were not recognized by caregivers in all cas-
es or was underestimated, which could prove 
life-threatening. These observations indicated 
a need for improved ITB failure treatment, 
which motivated this thesis.
For adequate troubleshooting of intrathecal 
drug delivery and to ensure around-the-clock 
availability of the expertise required for patient 
relief and pump analysis and programming, 
the ability to “double-check” highly concen-
trated medication and pump programming is 
required, as well as access to advanced radio-
logical diagnostics, an operating room, and 
intensive care facilities. However, in particular, 
achieving 24-hour availability for such a “dou-
ble-check” service would not be straightfor-
ward. Therefore, in order to offer around-the-
clock care, we decided to cooperate with the 
home-based Ambulant Care Clinic.
Chapter 2 
Efficiency and safety of ITB aftercare on loca-
tion  
Regular outpatient follow-up care is required 
when treating therapy-resistant spasticity with 
ITB. Logistically, however, this can be challeng-
ing. A solution could be to perform treatment 
at home. In the Netherlands, the Dutch Health-
care Authority initiated a project intended to 
deliver ambulatory ITB-related services via a 
home-based Ambulant Care Clinic. Nurse prac-
titioners provide this aftercare with support 
from medical specialists. The study demon-
strated the efficiency and safety of ITB care for 
patients with severe disabling spasticity in their 
home settings.
     
Chapter 3 
Plain radiography in patients treated with 
intrathecal drug delivery using an implantable 
pump device
Adverse events related to the pump and cathe-
ter still occur. The majority of such events, such 
as migration, damage, disconnection, and oc-
clusion, are related to the spinal catheter. This 
overview aimed to update radiologists’ know-
ledge of how plain radiography of the implant-
ed ITB delivery system should be interpreted. 
A secondary goal was to increase awareness 
of the need for immediate multidisciplinary 
 troubleshooting. The interpretation of radio-
graphic images of catheter-related adverse 




stepwise interpretation of standard plain radio-
graphic images was drafted.
Chapter 4 
Low-dose computed tomography with two- 
and three-dimensional postprocessing as an 
alternative to plain radiography for intrathecal 
catheter visualization: a phantom pilot study
The inferior opacity of intrathecal catheters 
(in particular, the Ascenda) is problematic. 
For troubleshooting purposes, plain radiogra-
phy was extended with dual energy CT with 
2D/3D reconstructions. Using this approach, 
optimal visualization of the entire catheter 
pathway and a reduction in the beam-harden-
ing effects of the implanted titanium pump was 
achieved. However, clear catheter imaging is 
also required for routine plain radiography. In a 
phantom pilot study with a variety of different 
scanning protocols, high-resolution imaging 
with low- dose single-energy CT 2D/3D recon-
structions which resulted in limited radiation 
exposure was found to be optimal to substitute 
for plain radiography. Ultimately, a CT setting 
of Sn100 kVp was identified as the best trade-
off between visibility and reduction of artifacts.
Chapter 5 
Catheter access port myelography in intrathe-
cal drug delivery
In 53 adult patients, 70 CAP CT myelograms 
were performed on patients who underwent 
evaluation due to intrathecal drug delivery 
failure. In all cases, the cause could not have 
been identified through procedures that were 
previously routinely used.  Data concerning 
needle insertion into the CAP funnel were re-
trieved from 65 cases of 70 cases. Of these 
cases, 19 were associated with mild and 6 with 
severe needle distortion.  CAP fluid aspiration 
contrast medium injection was not possible 
(n=17). In one case contrast was injected in 
de the pump pocket unintentionally.  In the 
remaining fifty-two examination CAP myelog-
raphy was performed but had limited value 
for the diagnosis. CAP-CT myelography was 
performed in 50 cases and the examination re-
vealed 19 abnormal results: dorsal dural leak, 
subdural catheter position, limited rostral flow 
of contrast material, limited and abnormal con-
trast distribution, obstruction of rostral flow, a 
leak at the pump-catheter connection, and a 
sheared catheter localized in the pump pocket. 
A limited contrast distribution in two examina-
tions turned out to be false positive findings. 
CAP-CT myelography was normal in 31 pro-
cedures. Four normal CT-CAP myelographic 
procedures were false negative as the reference 
tests revealed a cause of ITDD failure. CAP-CT 
myelography had a sensitivity of 81% and in 
a specificity of 93%. With the use of CAP-CT 
myelography with 2D and 3D images, an im-
provement of imaging of the drug delivery sys-
tem was achieved which indicated the need for 
an essential step in the troubleshooting algo-
rithm used for intrathecal drug delivery failure. 
Chapter 6 
Diagnostic accuracy of optimized planar-
SPECT low-dose computed-tomography 
111In-DTPA examinations in intrathecal drug 
delivery failures
Thirty-six 111In-DTPA procedures were per-
formed in 27 patients who had experienced 
intrathecal drug delivery failure and the cause 
could not be identified via other diagnostic mo-
dalities. The diagnostic protocol was optimized 
through standardization of the pump flow rate, 
the stepwise and standardized interpretation of 
the images and the application of SPECT-CT. 
Using optimized scintigraphy, 22 abnormal cas-
es were detected (leakages, spinal catheter ob-
structions, and obstructions in the CSF flow). In 
addition, 14 cases were assessed as normal. In 
all 19 patients who underwent operations, we 
could confirm the scintigraphy diagnosis. It was 
found that the optimized 111In-DTPA SPECT-
CT scintigraphy is a powerful diagnostic tool 
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in ITDD failure when conventional diagnostic 
modalities do not reveal the cause. 
      
Chapter 7 
Complications associated with intrathecal 
drug delivery systems
An overview of our experience of the diagnosis 
and treatment of intrathecal drug delivery fail-
ures was presented. A particular focus was on 
the potential of abrupt withdrawal of intrathe-
cal drug administration to be life-threatening. 
Furthermore, the therapeutic dilemma posed 
by the development of meningitis or withdraw-
al syndrome as result of an infection of the drug 
delivery system was discussed. Attention was 
also paid to potentially treacherous non-patho-
genic bacterial meningitis with minor, or even 
absent, clinical symptomatology. An additional 
topic that was discussed was that dura leakage 
could result in CSF accumulation in the pump 
pocket.      
 
Chapter 8 
Restoration of cerebrospinal fluid flow to solve 
treatment failure caused by obstruction in 
long-term intrathecal baclofen administration
Six spinal cord lesion patients with an ITB fail-
ure caused by a CSF flow obstruction were 
described. The diagnostic workup treatment, 
and potential causes were described. When 
the cause of failure could not be identified 
by investigating a patient’s history, a physi-
cal spasticity examination, the pump readout, 
confirming the absence of medication fluid in 
the pump, or plain radiography or CAP (CT) 
myelography was performed. To obtain infor- 
mation concerning the obstruction length, ad- 
ditional cervical CT myelography was initiated. 
In three cases, a laminectomy with microscopic 
surgical adhesiolysis was carried out. In two 
of these cases, CSF flow restoration was not 
achieved. The laminectomy was not enlarged, 
but an intradural bypass was placed. Recent-
ly, a less invasive technique of percutaneous 
fenestration of the obstruction with balloon 
dilatation was applied in three cases, resulting 
in CSF flow restoration with spasticity control. 
Preliminary results show that in an intrathecal 
obstruction using restoration of CSF flow ap- 
pears to be an effective.
Chapter 9 
Case report: Intrathecal baclofen as emergency 
treatment alleviates severe intractable auto-
nomic dysreflexia in cervical spinal cord injury 
The episodic syndrome of severe overactive 
sympathetic discharge (“sympathetic storm”) 
is well-known in patients with a chronic spinal 
cord injury above the outflow to the splanch-
nic and renal vascular beds (T6 level). Noxious 
or innocuous visceral or somatic stimuli below 
the lesion, such as bladder or bowel irritation, 
can lead to a sudden excessive sympathetic 
response due to the loss of descending inhibi-
tion; this can occur up to 40 times a day. The 
effects of this syndrome can vary from silent, 
mild forms with flushing, diaphoresis above the 
lesion, and piloerection to a pounding head-
ache, blurred vision, anxiety, stroke, posturing, 
hyperthermia, retinal bleeding, seizures, myo-
cardial ischemia, cardiac arrhythmias, and even 
death. In chronic cases, ITB has been used to 
prevent the symptomatology. In the reported 
case, the therapy-resistant life-threatening au-
tonomic dysreflexia was successfully managed 
with emergency ITB treatment.
Chapter 10 
General discussion
In the general discussion presented in this chap-
ter the results of the studies were reviewed and 







In de introductie wordt kort het syndroom spas-
ticiteit beschreven. Spasticiteit is een belangrijk 
symptoom van het bovenste motorneuronsyn-
droom als gevolg van schade aan de dalende 
corticale-reticulospinale motorische banen op 
corticaal, hersenstam- of ruggenmergniveau 
met o.a. aanzienlijk variërende spasticiteit. Voor 
de medicamenteuze behandeling wordt meest-
al baclofen gebruikt — een krachtige en selec-
tieve GABA-B-receptoragonist in het centrale 
zenuwstelsel. Echter door de bloed-hersenbar-
rière ontstaan na orale toediening relatief lage 
liquorconcentraties, met vaak onvoldoende ef-
fect en bij hogere doseringen veel bijwerkingen. 
Veel hogere baclofenspiegels bij een veel lagere 
dosering met minder bijwerkingen worden be-
reikt bij de intrathecale toediening. ITB wordt 
toegepast, bij onvoldoende regulering van ge-
generaliseerde, matige tot ernstige spasticiteit 
met orale toediening. Het niche aspect van ITB 
kan leiden tot gebrek aan kennis en onvoldoen-
de behandeling.  Bij complicaties wordt diag-
nostiek vaak te weinig, te beperkt of te laat uit-
gevoerd en worden chirurgische re-interventies 
gedaan met beperkte, of zelfs zonder, diagnos-
tiek. Bovendien wordt een plotselinge ITB-be-
eindiging niet in alle gevallen herkend of onder-
schat — een situatie die levensbedreigend kan 
zijn. Deze observaties zijn de aanleiding voor 
onderzoek naar een verbetering van de ITB-be-
handeling, wat heeft geleid tot dit proefschrift. 
Voor adequate probleemoplossing, is 24 uur 
per dag expertise voor de patiëntenzorg, het 
uitvoeren en het dubbel kunnen controleren 
van de pompanalyse, programmering en medi-
catie, de mogelijkheid van geavanceerde radio-
logische diagnostiek, beschikbaarheid van een 
operatiekamer en intensieve zorg vereist. Met 
name de permanente mogelijkheid van dubbe-
le controle door gekwalificeerde professionals, 
is niet eenvoudig voor de ITB-behandeling te 
realiseren. Daarom werd besloten om samen 
te werken met de thuiskliniek voor ambulante 
zorg. De structuur van de samenwerking werd 
beschreven.
Hoofdstuk 2 
Efficiëntie en veiligheid van ITB-nazorg op 
locatie
Voor de behandeling van therapieresistente 
spasticiteit met ITB is regelmatige poliklinische 
nazorg nodig. Logistiek gezien kan dit pro-
blematisch zijn. Een oplossing kan zijn de be-
handeling thuis uit te voeren. Met financiering 
van de Nederlandse Zorgautoriteit, is daartoe 
een innovatieproject uitgevoerd om op locatie 
ITB-nazorg te leveren met een ambulante kli-
niek. Deze nazorg is uitgevoerd door verpleeg-
kundig specialisten met ondersteuning van een 
medisch specialist. Met de studie is de efficiën-
tie en veiligheid van ITB-nazorg in de thuisom-




Blanco radiologisch onderzoek bij patiënten die 
worden behandeld met intrathecale toedie-
ning van geneesmiddelen met behulp van een 
implanteerbaar toedieningssysteem
Complicaties bij de intrathecale medicatie met 
een geïmplanteerde pomp en spinale katheter 
komen regelmatig voor. De meeste, zoals mi- 
gratie, beschadiging, disconnectie en occlusie, 
houden verband met de katheter. Van de ana- 
lysegegevens van alle gemaakte Röntgenfoto’s 
werd een overzicht gemaakt, bedoeld om om 
de een kennisupdate te geven aan radiologen 
hoe blanco radiologisch onderzoek van het ge-
implanteerde ITB-toedieningssysteem dient te 
worden geïnterpreteerd. Daarnaast werd geat-
tendeerd op de noodzaak van een mogelijke 
onmiddellijke multidisciplinaire probleemop-
lossing. Van de analyse werd een protocol ver-






Lage dosis CT met 2D/3D bewerking als alter-
natief voor routine blanco röntgendiagnostiek 
voor visualisatie van intrathecale katheters: 
een fantoom-pilot-studie
De geringe opaciteit van intrathecale katheters, 
in het bijzonder de Ascenda, is problematisch. 
Bij complicaties is daarom de blanco röntgen- 
diagnostiek vervangen door een “dual-energy” 
CT met 2D/3D-reconstructies. Met deze aan- 
pak konden we een optimale visualisatie van 
het gehele kathetertraject bereiken en beeld- 
vervorming, veroorzaakt door het metaal van 
de geïmplanteerde pomp, verminderen.  Echter, 
voor routinecontrole van het toedienings- 
systeem is ook goede beeldvorming nodig. 
Met een fantoom-pilot-studie met verschillen-
de scanprotocollen, konden we hoge-resolu-
tie beeldvorming met een lage stralingsdosis 
 “single-energy” CT met 2D/3D-reconstructies 
als vervanging voor blanco röntgendiagnostiek 
bereiken. Uiteindelijk werd voor een Sn100 
kVp CT-instelling gekozen als beste keuze voor 
de zichtbaarheid en de reductie van artefacten.
 
Hoofdstuk 5 
Catheter access port (CAP )-CT myelografie bij 
intrathecale medicatietoediening
Bij 53 volwassen patiënten met een falen van 
intrathecale medicatie toediening werd 70 keer 
CAP-CT  myelografie verricht. In alle gevallen, 
kon de oorzaak niet worden vastgesteld met 
de gebruikelijke procedures. Zeventien keer 
kon geen vloeistof worden opgezogen uit de 
CAP. Eén keer werd abusievelijk het contrast-
middel in de pomppocket gespoten. In de res-
terende 52 gevallen  werd CAP-myelografie 
verricht, wat bleek van beperkte waarde te zijn 
voor het vaststellen van de diagnose. CAP-CT 
myelografie werd 50 keer uitgevoerd met 19 
afwijkingen als resultaat: dorsaal liquor lek, 
subdurale katheter positie. Verminderde rostra-
le verspreiding van het contrastmiddel, vermin-
derde rostrale, abnormale verspreiding van het 
contrastmiddel, obstructie van de rostrale ver-
spreiding, lekkage van de pomp-katheter con-
nectie, gescheurde katheter gelokaliseerd in de 
pomppocket.  Twee keer bleek de verminderde 
verspreiding van het contrastmiddel vals posi-
tief te zijn. CAP-CT myelografie was normaal 
in 31 gevallen. Vier als een normale CAP-CT 
myelografie beschouwd, werden op basis van 
de referentie test als vals negatief beoordeeld. 
CAP-CT myelografie had een sensitiviteit van 
81% en een specificiteit van 93%.  Vastgesteld 
werd dat de toepassing van de CT-myelogra-
fie met 2D/3D beeldbewerking een essentiële 
stap is in het algoritme voor het vaststellen van 
de oorzaak van het falen van de ITB therapie. 
Additioneel werd van de 65 beschikbare gege-
vens het inbrengen van de naald CAP geana-
lyseerd. Negentien keer werd bij het inbrengen 
de naald verbogen, met 6 keer een ernstige 
vervorming. Een voorstel werd gedaan voor 




Analyse van een geoptimaliseerd 111In-DTPA-
onderzoek (planair en SPECT) bij intrathecale 
medicatietoediening
Zesendertig keer in 27 patiënten werd een 
111In-DTPA-scintigrafie uitgevoerd bij patiën-
ten met een falen van de intrathecale medi-
catie-toediening, waarbij de oorzaak niet kon 
worden gevonden met andere diagnostische 
modaliteiten. Het protocol voor het nucleaire 
werd geoptimaliseerd door standaardisatie van 
de pompsnelheid en de stapsgewijze interpre-
tatie van de verkregen beelden met daarnaast 
de toepassing van SPECT-CT. Met de geopti-
maliseerde scintigrafie werden 22 afwijkingen 
gevonden, (lekkages, spinale katheterobstruc-
ties, obstructies in de liquorruimte). Daarnaast 
werden 14 als normaal beoordeeld. Bij alle 19 
geopereerde patiënten kon de scintigrafische 
diagnose worden bevestigd. Gebleken is dat de 
geoptimaliseerde 111In-DTPA-scintigrafie een 
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krachtig diagnostisch hulpmiddel is bij het falen 
van intrathecale medicatietoediening wanneer 
met conventionele onderzoeken de diagnose 
niet kan worden gesteld.   
    
Hoofdstuk 7 
Complicaties geassocieerd met intrathecale 
medicatie toedieningssystemen
Op invitatie werd een overzicht van onze er-
varing met de diagnose en behandeling van 
intrathecale medicatietoediening gepresen-
teerd. Bijzondere aandacht werd besteed aan 
potentieel levensbedreigend abrupte beëindi-
ging van de intrathecale medicatie toediening. 
Verder werd ingegaan op het therapeutisch 
dilemma, bij het ontstaan van een meningitis 
of een onttrekkingssyndroom bij een geïnfec-
teerd toedieningssysteem. Aandacht werd ook 
besteed aan de verraderlijke niet-pathogene 
bacteriële meningitis met geringe, of zelfs af-
wezige,  klinische symptomatologie. Ook werd 
besproken dat een dura-lekkage kan resulteren 
in liquorophoping in de pomppocket.  
    
Hoofdstuk 8 
Herstel van de liquorcirculatie bij het falen van 
de behandeling veroorzaakt door een obstruc-
tie bij langdurige intrathecale toediening van 
baclofen
Zes dwarslaesie patiënten met een falen van 
de ITB-therapie werden behandeld. De diag-
nostiek, behandelingen potentiele oorzaken 
werden beschreven. Wanneer de oorzaak van 
het falen niet kon worden gevonden uit de 
anamnese, het lichamelijk onderzoek, de pom-
puitlezing, controle van de juiste hoeveelheid 
aanwezige van medicatievloeistof in de pomp 
of blanco Röntgenfoto’s, werd CAP (CT) mye-
lografie uitgevoerd. Om informatie te verkrij-
gen over de lengte van de obstructie, werd een 
cervicale CT-myelografie verricht. In drie ge-
vallen werd als behandeling een laminectomie 
met microscopische chirurgische adhesiolyse 
uitgevoerd. Twee keer werd geen herstel van 
de liquorcirculatie bereikt. Besloten werd de 
laminectomie niet verder uit te breiden, maar 
een intradurale bypass geplaatst. Recent werd 
3 maal een minder invasieve techniek van per-
cutane fenestratie van de obstructie met ballon-
dilatatie toegepast, resulterend in  liquorstroom 
herstel met als resultaat weer controle over de 
spasticiteit. De voorlopige resultaten tonen aan 
dat herstel van liquorstroom bij een intratheca-
le obstructie een effectieve lijkt te zijn. 
Hoofdstuk 9 
Case report: Spoedbehandeling met intra-
thecaal toegediend baclofen als behandeling 
van een ernstige therapieresistente autonome 
dysreflexie bij een cervicale dwaerslaesie
Het paroxysmaal optredend syndroom van 
ernstige sympathische overactiviteit (“sympa-
thische storm”) is bekend bij patiënten met 
een dwarslaesie boven de uitstroom naar de 
 splanchnische- en niervaten (T6-niveau). Scha-
delijke of onschadelijke viscerale of somatische 
stimuli onder de laesie, zoals blaas- en dar-
mirritatie, kunnen dagelijks veelvuldig, tot 40 
keer per dag, leiden tot een plotselinge buiten-
sporige sympathische reactie op basis van een 
afgenomen remming. Het syndroom varieert 
van niet herkende, milde vormen met trans-
piratie boven de laesie, blozen en pilo-erec-
tie tot een beukende hoofdpijn, wazig zien, 
angst, beroerte, houdingsstoornis, hyperther-
mie, netvliesbloeding, epileptische aanvallen, 
myocardiale ischemie, hartritmestoornissen en 
overlijden. In chronische gevallen is ITB ge-
bruikt om de symptomatologie te voorkomen. 
In de beschreven casus van een geïnfecteerd 
toedieningssysteem waarbij de ITB-behande-
ling moest worden beëindigd, werd met een 
ITB-spoedbehandeling de therapieresistente, 






In de algemene discussie werden de resultaten 
van de studies beschreven en werden voorstel-





Eindelijk na veel wachten en niet verder kun-
nen, is dit proefschrift klaar; de kers op de taart 
na meer dan dertig jaar bezig te zijn geweest 
met de intrathecale toediening van baclofen 
(ITB). In de loop der jaren is van verschillende 
zijden getracht mij te overtuigen te promove-
ren op ITB. Nu aan het einde van mijn carrière 
heb ik de rust en tijd gevonden voor verdie-
ping en nader onderzoek, wat heeft geresul-
teerd in dit proefschrift.
Ik heb de ITB leren kennen als een geweldi-
ge therapie.  Na een beperkte toepassing van 
het Promedos implanteerbaar pompsysteem 
van Siemens ben ik overgegaan op het Syn-
chromed toedieningssysteem van Medtronic. 
De oorsprong daarvan ligt bij het bezoek van 
Pieter de Jonge, toenmalig medewerker van 
Medtronic. Het implanteerbare, program-
meerbare pompsysteem was toen nieuw en 
vanwege mijn ervaring met pompsystemen 
en de intrathecale toediening van opioïden 
bij pijn bij kanker kwam Pieter zich oriënteren 
omtrent toepassingsmogelijkheden van het 
Synchromed toedieningssysteem. In 1984 had 
Prof.Penn in de Lancet het succes van ITB bij 
therapieresistente spasticiteit gepubliceerd. Ik 
was ervan overtuigd dat dat de indicatie was 
voor de toepassing van het pompsysteem. 
Groot probleem was de financiering. Dankzij 
de financiële steun van het Sophia Zieken-
huis te Zwolle, de “paraplu”-constructie en 
een budget voor het maken van de videotape 
“Bending the Unbendable” door Jo Merkun, 
toenmalig directeur van Medtronic Nederland, 
konden we aan de slag. Na jaren van moeiza-
me strijd, met “case bij case” onderhandelen 
met zorgverzekeraars heeft uiteindelijk wijlen 
Prof.Dr.E.Borst, Minister van VWS, na een 
persoonlijke benadering, gezorgd voor een 
vergoedingssysteem. 
Aanvankelijk was de behandeling met ITB ge-
richt op de functionele verbetering (“cure”) 
van therapieresistente spasticiteit. In de loop 
der tijd werd duidelijk dat de therapie ook van 
groot waarde is voor verbetering van de zorg 
en kwaliteit van leven (“care”) bij zeer ernsti-
ge spastische patiënten. Eén van de problemen 
om bij deze categorie patiënten de behande-
ling te realiseren waren de belastende ambu-
lance- of rolstoeltransporten. Om hiervoor een 
oplossing te vinden, heb ik samen met Simone 
Goslinga de ambulante kliniek Care4homecare 
opgericht, waarbij gebruikmakend van video-
conferencing, patiënten zoveel mogelijk op 
locatie konden worden behandeld. Vervolgens 
heb ik Prof.Dr.F.J.P.M.Huygen benaderd met 
het voorstel om samen met Markus Wijffels, 
revalidatiearts van Rijndam Volwassenreva-
lidatie een ketenzorg ITB te ontwikkelen en 
deze zorg regionaal in Rotterdam Erasmus Me-
disch Centrum te concentreren. Hierbij werd 
steun verkregen van de Raad van Bestuur met 
als voorwaarde dat in 2018 de behandeling 
aantoonbaar academisch zou moeten zijn. Dit 
is dan ook mede de spin-off geweest voor dit 
proefschrift. Zonder hulp van velen zou dit 
proefschrift niet gerealiseerd. Ik tracht ieder-
een te bedanken, maar mogelijk zijn toch een 
aantal niet genoemd. Hiervoor mijn excuses.
Allereerst wil ik mijn promotor Prof.Dr.F.J.P.M. 
Huygen, anesthesioloog/pijnspecialist bedan-
ken. Beste Frank, bedankt voor je vertrouwen 
in mij om de ITB in het EMC te integreren en 
je rol als mijn promotor. Ik waardeer je inzet, 
de kritische beoordeling van het manuscript en 
de plezierige samenwerking. Zonder jouw in-
zet was de ITB in het EMC nooit van de grond 
gekomen. 
Ook mijn mede-promotor Prof.Dr.A.van der 
Lugt, neuroradioloog wil ik bedanken. Beste 
Aad, ik herinner mij ons eerste gesprek nog 
als de dag van gisteren. Ik heb toen aange-
geven dat ik geen verstand heb van neurora-
diologie, maar dat radiologen dat niet hebben 
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van het geïmplanteerde toedieningssysteem 
en van de soms levensbedreigende gevolgen 
van een acuut stagneren van de intrathecale 
medicatietoediening, maar dat als we samen 
zouden werken de “troubleshooting” bij ITB 
aanzienlijk zouden kunnen worden verbeterd; 
en dat het gelukt is, is wel duidelijk. Ik ben je 
zeer dankbaar voor onze geweldige discussies 
en de tijd die je eraan hebt besteed, ook toen 
nog niet duidelijk was dat jij mede-promotor 
zou zijn. Jij hebt mij gerelateerde delen van 
de neuroradiologie bij gebracht en mij, tot in 
detail, geleerd de bevindingen te beschrijven.  
Ook gaat mijn dank uit naar mijn co-promo-
tor Dr.B.S.Harhangi, neurochirurg. Beste San-
jay, ik mag mij gelukkig prijzen dat het hoofd 
van jouw afdeling Prof.Dr.C.M.F.Dirven mij 
met jou in contact heeft gebracht om jou als 
“spinale neurochirurg” te betrekken in de ITB 
behandeling. Altijd stond je klaar voor overleg, 
om gezamenlijk neurochirurgische interventies 
te verrichten, voor ondersteuning en het le-
zen van het manuscript; niets was daarbij je te 
veel. Hartelijke dank.
Prof.Dr.C.M.F.Dirven, neurochirurg. Beste Cle-
mens, dank voor de hulp bij onze eerste com-
plexe patiënt en de contacten daarna, die er 
uiteindelijk toe hebben geleid dat de neurochi-
rurgie intensief bij de ITB behandeling en dit 
proefschrift is betrokken.
Leden van de promotiecommissie, Prof.
Dr.P.A.E.Sillevis Smitt, Prof.Dr.H.J.Stam, Prof.
Dr.J.J.van Hilten. Dank voor het beoordelen 
van mijn proefschrift en de bereidheid zitting 
te nemen in de kleine commissie. Daarnaast 
dank ik Prof.Dr.R.J.Stolker, Prof.Dr.V.de Groot, 
Prof.Dr.M.Smits, voor de bereidheid zitting te 
nemen in de grote commissie en te opponeren 
bij mijn verdediging.
Prof.Dr.J.B.R.J Brouwers, ziekenhuisapotheker. 
Beste Koos, samen hebben we in het verre ver-
leden activiteiten omtrent intrathecale medi-
catie toediening opgezet; samen gepubliceerd 
en gepresenteerd op meerdere symposia. Was 
altijd een genoegen. Dank voor je bereidheid 
als externe deskundige in de Corona zitting te 
willen nemen.
Dr.S.Frankema, anesthesioloog/pijnspecialist. 
Beste Sander, dank voor je tijd bij de promotie 
besprekingen en je kritische benadering bij de 
behandelingen en het manuscript. 
Ook de collega’s van Pijngeneeskunde Emmy, 
Dirk, Salah, Heike, Maaike, Brigitte, Carola, 
Rob, Jessica, Judith, Krishna, Else, Katelijne, 
Feline, Rebecca, Astrid, Margreet, Corine, An-
neke en natuurlijk de grote steun en toeverlaat 
Anita hierbij bedanken voor de samenwerking.
Drs.A.Froberg, nucleair geneeskundige.  Beste 
Liedeke, jaren geleden hebben we samen in 
de Daniël den Hoed Kliniek aan de wieg ge-
staan van de toepassing van de 111Indium- 
DTPA-scintigrafie als diagnosticum bij ITB 
“troubleshooting” en dit hernieuwd voortge-
zet in het EMC. Dank voor de samenwerking 
en de tijd die je ervoor nam om telkens het 
resultaat van de scintigrafie te bespreken. Ik 
heb er veel van geleerd.
Dr.D.M.E.van Assema, nucleair geneeskundi-
ge. Beste Danielle, Fijn dat je bereid was de 
begeleiding van het scintigrafisch onderzoek 
over te nemen. Ik ben onder de indruk hoe 
minutieus je te werk gaat en de puntjes op de 
“i” weet te zetten. Dank voor je tijd en inzet 
als medeauteur en om de nucleaire diagnos-
tiek bij ITB falen te verbeteren.
Dr.A.van Es, Drs.P.J.van Doormaal, Drs.W.Din-
kelaar. Beste Ad, Pieter-Jan, Wouter, het was 
een geweldige ervaring om samen met jullie de 
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interventie van ballonfenestratie bij liquorob-
structies bij dwarslaesie patiënten te ontwikke-
len, uit te voeren, te mogen presenteren op het 
Europese Neuroradiologiecongres en uiteinde-
lijk te publiceren. Hiervoor mijn dank.
Marcel Dijkshoorn, Dank voor de prachtige 
2D/3D plaatjes die je wist te maken van het 
radiologische onderzoeken en voor je bereid-
heid je steeds ad hoc te willen in te zetten als 
we weer een plaatje van een individuele pati-
ent nodig hadden. Ook Dr.Marcel van Straten 
en Thomas de Man en Priscilla van Andel wil ik 
bedanken voor hun ondersteuning.
Prof.Dr.J.J.van Hilten. Beste Bob, wat hebben 
we jarenlang samengewerkt om ITB als the-
rapie van dystonie bij CRPS te doen slagen. 
Helaas heeft het niet geleid wat we ervan ver-
wacht hadden. Heel veel dank voor de plezie-
rige en leerzame contacten.
Beste Pieter de Jonge, zonder onze jarenlange 
intensieve samenwerking was ITB in Neder-
land nooit zover gekomen en was dit proef-
schrift nooit gerealiseerd. Wat hebben we wat 
lief en leed samen gedeeld; uiteindelijk gere-
sulteerd in een langdurige vriendschap met jou 
en Tineke. Hartelijk dank.
Beste Jo Merkun, Ongelofelijk, hoe je binnen 
Medtronic 30 jaar geleden je nek hebt uitge-
stoken voor de financiële ondersteuning om 
ITB in Nederland van de grond te krijgen, en 
dan in 2010 ons weer te steunen bij de ont-
wikkeling van Care4homecare. Ik heb je inzet 
geweldig gewaardeerd; dank hiervoor.
Beste Natasja, binnen de vele mensen van Med-
tronic, waarmee ik de loop der jaren mee heb sa-
mengewerkt, spring jij er toch wel uit. Je steeds 
maar niet aflatende ijver om de ITB in Nederland 
gestalte te geven, vind ik indrukwekkend. Dank 
voor de plezierige samenwerking.
Verder wil ik hierbij Henk Meertens, Kees 
Ruck, Willem Koenders, Bart Stulens, Renee 
Kraaiveld, Claire de Monte, Constance Swijg-
sen, Rik Buschman, en andere medewerkers 
van Medtronic betrokken bij ITB bedanken.
Zonder Mosadex en haar dochteronderne-
ming Care4homecare was er geen expertcen-
ter in het EMC, en dus ook niet dit proefschrift, 
gerealiseerd. Ik wil hen dan ook danken voor 
hun bijdrage.
Natasja en Eva, lieve meiden, dank voor de 
jarenlange intense geweldige samenwerking. 
Fijn dat jullie mijn paranimfen willen zijn. 
Marieke dank voor de poster en het mooie 
boekje wat je ervan hebt gemaakt. 
Lieve Elly, mijn mmmtje, dank voor alle geduld 
en onvoorwaardelijk steun om het proefschrift 
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Basiscursus klinisch onderzoekers (BROK) 2017     1.5
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Heimiddag Centrum voor Pijngeneeskunde 2014     0.2
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ITB treatment in severe spasticity, Nursing homecare physicians, Humanitas, Rotterdam 2015     0.5
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Troubleshooting in ITB, Anesthesiology Medicine Erasmus MC, Rotterdam 2015     1.0
Postoperative Pain Therapies, KOL Perspective, Gerson Lehrman Group., New York, USA 2015     0.2
Interventional Pain Devices, KOL Perspective, Gerson Lehrman Group, New York, USA 2015     0.2
New care delivery model: Care4homecare, Targeted drug delivery expert forum: 
Advancing spasticity and pain management, (faculty) (2days), Lisboa, Portugal 2015     1,5
ITB treatment in severe spasticity, Careyn, Brielle 2014     0.5
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ITB, No place like home, E-Health zorg op afstand, OLVG, Amsterdam 2014     1.0
No place like home, EBMT congress, (3days) Milan, Italy 2014     1.0
ITB treatment in severe spasticity, Symposium Multiple Sclerosis, Gouda 2014   0.5
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Development DBC ITB, NZA/DBC-Onderhoud/Care Assurance Companies, Utrecht 2015     1.5
Fase III Trial Arterial Hepatic Infusion (HIA), Erasmus MC, Rotterdam 2016     1.5
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